
<html lang="en"     class="pb-page"  data-request-id="6a31f6d7-c149-41d8-8a8b-23d661533370"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00812;issue:issue:10.1021/jmcmar.2018.61.issue-17;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites" /></meta><meta name="dc.Creator" content="Marie-Noëlle  Paludetto" /></meta><meta name="dc.Creator" content="Christian  Bijani" /></meta><meta name="dc.Creator" content="Florent  Puisset" /></meta><meta name="dc.Creator" content="Vania  Bernardes-Génisson" /></meta><meta name="dc.Creator" content="Cécile  Arellano" /></meta><meta name="dc.Creator" content="Anne  Robert" /></meta><meta name="dc.Description" content="Oxidation of two tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib, using a chemical catalytic system able to mimic the cytochrome P450 type oxidation, allowed us to prepare  putative react..." /></meta><meta name="Description" content="Oxidation of two tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib, using a chemical catalytic system able to mimic the cytochrome P450 type oxidation, allowed us to prepare  putative react..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 13, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00812" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00812" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00812" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00812" /></link>
        
    
    

<title>Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00812" /></meta><meta property="og:title" content="Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0009.jpeg" /></meta><meta property="og:description" content="Oxidation of two tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib, using a chemical catalytic system able to mimic the cytochrome P450 type oxidation, allowed us to prepare  putative reactive/toxic metabolites of these anticancer drugs. Among these metabolites, aromatic aldehyde derivatives were unambiguously characterized. Such biomimetic oxidation of TKI-type drugs was essential to facilitate the identification of low amounts of aldehydes generated from these TKIs when incubated with human liver microsomes (HLM), which are classical models of human hepatic metabolism. These TKI derivative aldehydes quickly react in vitro with amines. A similar reaction is expected to occur in vivo and may be at the origin of the potentially severe hepatotoxicity of these TKIs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00812"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00812">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00812&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00812&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00812&amp;href=/doi/10.1021/acs.jmedchem.8b00812" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7849-7860</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00791" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00817" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marie-Noëlle Paludetto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie-Noëlle Paludetto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</div><div class="loa-info-affiliations-info">Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse, Cedex 1, France</div><div class="loa-info-affiliations-info">Université Paul Sabatier, 31400 Toulouse, France</div><div class="loa-info-affiliations-info">Pharmacie, Institut Claudius Regaud, IUCT-O, 31037 Toulouse, Cedex 1, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie-No%C3%ABlle++Paludetto">Marie-Noëlle Paludetto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Bijani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Bijani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Bijani">Christian Bijani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florent Puisset</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florent Puisset</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse, Cedex 1, France</div><div class="loa-info-affiliations-info">Université Paul Sabatier, 31400 Toulouse, France</div><div class="loa-info-affiliations-info">Pharmacie, Institut Claudius Regaud, IUCT-O, 31037 Toulouse, Cedex 1, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florent++Puisset">Florent Puisset</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vania Bernardes-Génisson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vania Bernardes-Génisson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</div><div class="loa-info-affiliations-info">Université Paul Sabatier, 31400 Toulouse, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vania++Bernardes-G%C3%A9nisson">Vania Bernardes-Génisson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cécile Arellano</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cécile Arellano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse, Cedex 1, France</div><div class="loa-info-affiliations-info">Université Paul Sabatier, 31400 Toulouse, France</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#debdbbbdb7b2bbf0bfacbbb2b2bfb0b19eabb0b7a8f3aab2adbbedf0b8ac"><span class="__cf_email__" data-cfemail="284b4d4b41444d06495a4d4444494647685d46415e055c445b4d1b064e5a">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=C%C3%A9cile++Arellano">Cécile Arellano</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Anne Robert</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anne Robert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b2d3dcdcd79cc0ddd0d7c0c6f2ded1d19fc6ddc7deddc7c1d79cd4c0"><span class="__cf_email__" data-cfemail="c7a6a9a9a2e9b5a8a5a2b5b387aba4a4eab3a8b2aba8b2b4a2e9a1b5">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anne++Robert">Anne Robert</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9092-6776" title="Orcid link">http://orcid.org/0000-0002-9092-6776</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00812&amp;href=/doi/10.1021%2Facs.jmedchem.8b00812" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7849–7860</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 13, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 May 2018</li><li><span class="item_label"><b>Published</b> online</span>13 August 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 September 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00812" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00812</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7849%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMarie-No%25C3%25ABlle%2BPaludetto%252C%2BChristian%2BBijani%252C%2BFlorent%2BPuisset%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D17%26contentID%3Dacs.jmedchem.8b00812%26title%3DMetalloporphyrin-Catalyzed%2BOxidation%2Bof%2BSunitinib%2Band%2BPazopanib%252C%2BTwo%2BAnticancer%2BTyrosine%2BKinase%2BInhibitors%253A%2BEvidence%2Bfor%2BNew%2BPotentially%2BToxic%2BMetabolites%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7860%26publicationDate%3DSeptember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00812"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1111</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00812" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marie-Noëlle&quot;,&quot;last_name&quot;:&quot;Paludetto&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Bijani&quot;},{&quot;first_name&quot;:&quot;Florent&quot;,&quot;last_name&quot;:&quot;Puisset&quot;},{&quot;first_name&quot;:&quot;Vania&quot;,&quot;last_name&quot;:&quot;Bernardes-Génisson&quot;},{&quot;first_name&quot;:&quot;Cécile&quot;,&quot;last_name&quot;:&quot;Arellano&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;Robert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;7849-7860&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00812&quot;},&quot;abstract&quot;:&quot;Oxidation of two tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib, using a chemical catalytic system able to mimic the cytochrome P450 type oxidation, allowed us to prepare  putative reactive/toxic metabolites of these anticancer drugs. Among these metabolites, aromatic aldehyde derivatives were unambiguously characterized. Such biomimetic oxidation of TKI-type drugs was essential to facilitate the identification of low amounts of aldehydes generated from these TKIs when incubated with human liver microsomes (HLM), which are classical models of human hepatic metabolism. These TKI derivative aldehydes quickly react in vitro with amines. A similar reaction is expected to occur in vivo and may be at the origin of the potentially severe hepatotoxicity of these TKIs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00812&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00812" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00812&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00812" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00812&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00812" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00812&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00812&amp;href=/doi/10.1021/acs.jmedchem.8b00812" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00812" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00812" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00812%26sid%3Dliteratum%253Aachs%26pmid%3D30102538%26genre%3Darticle%26aulast%3DPaludetto%26date%3D2018%26atitle%3DMetalloporphyrin-Catalyzed%2BOxidation%2Bof%2BSunitinib%2Band%2BPazopanib%252C%2BTwo%2BAnticancer%2BTyrosine%2BKinase%2BInhibitors%253A%2BEvidence%2Bfor%2BNew%2BPotentially%2BToxic%2BMetabolites%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D17%26spage%3D7849%26epage%3D7860%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291490" title="Mass spectrometry">Mass spectrometry</a>,</li><li><a href="/action/doSearch?ConceptID=291091" title="Oxidation">Oxidation</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292236" title="Aldehydes">Aldehydes</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/jmcmar.2018.61.issue-17/20180913/jmcmar.2018.61.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Oxidation of two tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib, using a chemical catalytic system able to mimic the cytochrome P450 type oxidation, allowed us to prepare  putative reactive/toxic metabolites of these anticancer drugs. Among these metabolites, aromatic aldehyde derivatives were unambiguously characterized. Such biomimetic oxidation of TKI-type drugs was essential to facilitate the identification of low amounts of aldehydes generated from these TKIs when incubated with human liver microsomes (HLM), which are classical models of human hepatic metabolism. These TKI derivative aldehydes quickly react <i>in vitro</i> with amines. A similar reaction is expected to occur <i>in vivo</i> and may be at the origin of the potentially severe hepatotoxicity of these TKIs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Renal cell carcinoma (RCC) accounts for about 3% of adult malignancies and its incidence is increasing. RCC is inherently resistant to chemotherapy, radiation, or hormone therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For localized RCC, nephrectomy is therefore the cornerstone of therapy. However, 40–45% of patients have locally advanced or metastatic RCC at the time of diagnosis. In addition, 20–30% of patients undergoing surgery experience a local recurrence or subsequently develop metastatic disease. In these cases, a systemic therapy is required. For the past decade, tyrosine kinase inhibitors (TKIs) were considered as a very important class of anticancer medicines. TKIs are small chemical heterocyclic molecules with suitable chemical properties for oral administration, a real advantage in anticancer therapy. Among them, sunitinib and pazopanib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) target tumor angiogenesis by inhibition of the vascular endothelial growth factor receptor (VEGFR). These treatments have extended the median overall survival of patients with advanced RCC<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> and are commonly used as first-line treatments.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> However, these drugs are also responsible for a severe hepatotoxicity occurring during the course of therapy with rare fatal cases of hepatic failure,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> whose mechanisms are poorly understood. Hepatic oxidation of sunitinib and pazopanib is primarily mediated by CYP3A4,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> giving rise to hydroxylated and <i>N</i>-dealkylated metabolites<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> whose structures are not, at first glance, correlated to direct or indirect hepatotoxicity. Nevertheless, toxic species generated by drug metabolism likely have high reactivity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> It is therefore possible that, when generated <i>in vivo</i>, such reactive/toxic metabolites would not exist in sufficiently large amount to be detected, due to their fast reaction with macromolecule targets, thus escaping from their individual detection and characterization. This was recently proposed for another TKI, erlotinib.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In this context, the novel structural identification of the metabolites of sunitinib and pazopanib will help understand and manage the hepatotoxicity and drug–drug interactions induced by the TKI treatment.</div><div class="NLM_p">The biomimetic oxidation of drugs by redox-active metalloporphyrin catalysts associated with a single oxygen atom donor [such as lithium hypochlorite, potassium hydrogen persulfate (KHSO<sub>5</sub>), magnesium monoperphthalate (MMPP)] has been reported to efficiently mimic the biotransformation performed <i>in vivo</i> by cytochromes P450s or peroxidases. In fact, these catalytic systems can efficiently oxidize a variety of substrates either in aqueous or organic solutions and perform, among other transformations, hydroxylation of saturated structures, oxidation of aromatics, or N-demethylation of tertiary amines, with a certain degree of regioselectivity.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17">(13−17)</a> In these chemical catalytic conditions, it is possible to generate significant amounts of reactive metabolites that are not trapped by biological targets and, consequently, can be more easily detected and characterized. These “<i>in chimico</i> conditions” should be considered as a suitable tool for further <i>in vivo</i> investigations.</div><div class="NLM_p">In the present work, we investigated the biomimetic oxidation of sunitinib and pazopanib under various conditions, in order to identify potential reactive/toxic metabolites. This study allowed to isolate and characterize the aldehyde derivatives of sunitinib and pazopanib, which have not been identified up to now by NMR spectrometry. These metabolites are expected to readily react with endogenous amine functions and can be consequently considered as potentially toxic entities. Moreover, these reactive aldehyde derivatives of sunitinib and pazopanib were also identified when sunitinib and pazopanib were oxidized by incubation with human liver microsomes (HLM), a classical tool for cytochrome P450-mediated metabolism studies.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Our results indicate that P450-mediated oxidation of TKIs is expected to produce carboxaldehyde metabolites, which may escape detection in metabolism studies, due to their high reactivity, but should be considered as key intermediates to explain the hepatotoxicity of these drugs.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the tyrosine kinase inhibitors (TKIs) sunitinib <b>1</b> and pazopanib <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The choice of the different catalysts and oxidants was based on their known abilities to mimic the reactions mediated <i>in vivo</i> by cytochrome P450 enzymes. The activation of metal complexes of porphyrins by single oxygen atom donors involves a highly electrophilic metal-oxo as active species, which is reminiscent of cytochrome P450 active species generated in the presence of dioxygen associated with NADPH/P450 reductase.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> These metalloporphyrin-based systems can oxidize a great variety of substrates and provide similar oxidation products than those generated by P450/O<sub>2</sub>/P450 reductase. This biomimetic oxidation occurs in organic or aqueous solutions. In fact the active site of P450 enzymes is a highly hydrophobic pocket, and the P450 oxidation involving hydrophobic substrates is efficiently mimicked in organic solvents.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> So, the reaction can be tuned using different catalysts (different porphyrin ligands with manganese as redox active metal) and different single oxygen atom donors: <i>meta-</i>chloroperbenzoic acid (mCPBA), magnesium monoperoxyphthalate (MMPP), potassium hydrogen persulfate (KHSO<sub>5</sub>), lithium hypochlorite (LiOCl), and peracetic acid (PAA). In addition, the reaction can be carried out in a homogeneous organic medium or in a biphasic water/organic medium when the oxidant is water soluble (MMPP, KHSO<sub>5</sub>, LiOCl). In this latter case, a quaternary ammonium is added as a phase transfer catalyst to assist the transfer of the oxidant into the organic phase containing the catalyst and the substrate. In all cases, 4-<i>t</i>-butylpyridine was used as a co-catalyst.<a onclick="showRef(event, 'ref13 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref17">(13,17)</a> The general equation of the catalytic reactions and the metal complexes used as catalysts is depicted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General scheme of catalytic oxidations and metalloporphyrins used as catalysts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Catalytic Chemical Oxidation of Sunitinib</h3><div class="NLM_p">First of all, the oxidation of sunitinib carried out by KHSO<sub>5</sub>, MMPP, or <i>m</i>CPBA, in the absence of metal catalyst, either in organic (CH<sub>2</sub>Cl<sub>2</sub>) or in biphasic (CH<sub>2</sub>Cl<sub>2</sub>/water/R<sub>4</sub>N<sup>+</sup>Cl<sup>–</sup>) conditions, provided sunitinib-<i>N</i>-oxide (<b>1</b>-<i>N</i>-oxide, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This product was characterized by NMR. Upon oxidation of N18, the chemical shifts of H<sub>2</sub>C17 and H<sub>2</sub>C19 were drastically low field shifted with respect to the starting sunitinib base (Δδ<sub>H</sub> = +0.61–0.63 ppm, Δδ<sub>C</sub> = +10.45–11.20 ppm in methanol-<i>d</i><sub>4</sub>). The H<sub>2</sub>C16 and H<sub>3</sub>C20 were affected to a lower extent (Δδ<sub>H</sub> = +0.21–0.28 ppm, Δδ<sub>C</sub> = −2.72–2.74 ppm). The <sup>15</sup>N NMR signal of N18 was upfield shifted by ca. 80 ppm (δ<sub>N</sub> = −258.3 in sunitinib-<i>N</i>-oxide compared to −338.6 ppm in sunitinib base). On the basis of mass spectrometry studies, sunitinib-<i>N</i>-oxide was detected as a minor metabolite in urine or feces of treated rats or monkeys, but not in humans.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Noteworthy, as already reported, the olefinic C3–C8 bond was slowly isomerized when sunitinib or sunitinib derivatives were kept in solution under ambient light.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> After 2 weeks in methanol, the <i>Z</i>/<i>E</i> ratio of sunitinib was 85/15, as evidenced by NMR (δ<sub><i>H</i>3C–C13</sub> = 2.48 and 2.33 ppm for the <i>Z</i>- and <i>E</i>-isomers, respectively; δ<sub>C3</sub> = 115.50 and 119.57 ppm, δ<sub>C4</sub> = 104.87 and 108.70 ppm, δ<sub>C8</sub> = 123.90 and 125.05 ppm, δ<sub>C9</sub> = 130.16 and 128.16 ppm, δ<sub>C13</sub> = 126.13 and 123.90, for the <i>Z</i>- and <i>E</i>-isomers, respectively, in methanol-<i>d</i><sub>4</sub>). Since the <i>Z/E</i> isomerization complicates the assignment of NMR spectra, all sunitinib solutions and reaction mixtures were kept protected from light.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Catalytic oxidation of <b>1</b> in the presence of Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>, resulting in oxidation at methyl-C11 (<b>1</b>-CH<sub>2</sub>OH, <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>, and <b>1</b>-CHO were characterized by NMR and mass spectrometry, partial NMR data in pyridine-<i>d</i><sub>5</sub> are reported on the structures) and in N18-desethylation (<b>1</b>-NHEt was detected by UHPLC-MS). Noncatalytic oxidation of <b>1</b> provided <b>1</b>-<i>N</i>-oxide (given as comparison).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The catalytic oxidation of sunitinib was carried out using Mn<sup>III</sup>(Cl<sub>12</sub>TMP)Cl or Mn<sup>III</sup>(TDCPP)Cl associated with MMPP or KHSO<sub>5</sub>, at room temperature. TLC monitoring of the reactions showed that compounds more polar than the substrate were formed and that these four different catalytic systems provided mixtures with the same products.</div><div class="NLM_p">As an example, when Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub> was used (catalyst/oxidant/substrate mol ratio = 0.02/3/1), the reaction was quenched by addition of acetone after 1 h and purified over reverse phase C18 column. Despite chromatography did not allow to separate the different oxidation products, they were characterized as a mixture, by NMR in pyridine-<i>d</i><sub>5</sub>. Along with some remaining starting material (67 mol %, even with longer reaction times, the substrate was never completely consumed in these reactions, probably due to the low excess of oxidant with respect to the substrate), three main oxidation products were identified (15 mol %, 12 mol %, and 6 mol %). In all these products, the <sup>1</sup>H and <sup>13</sup>C NMR signals of the <i>H</i><sub>3</sub><i>C</i>–C11 (3.74/14.71 ppm in <b>1</b>) disappeared, indicating that oxidation occurred at this particular methyl group. The more abundant product (<b>1</b>-CHO, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, 15 mol %) exhibited a <sup>1</sup>H NMR signal at 11.70 ppm correlated with a <sup>13</sup>C NMR signal at 182.40 ppm, characteristic of a carboxaldehyde function. C11 was detected at 133.78 ppm, shielded by 4.67 ppm, with respect to <b>1</b> (138.45 ppm). The side chain of <b>1</b>-CHO was very similar to that of <b>1</b>, indicating that no oxidation occurred on the side chain (Δδ < 0.1 ppm for protons and <0.7 ppm for carbon atoms). In addition, a ROE correlation was detected between the aldehyde proton (11.70 ppm) and the <i>H</i>N15 detected at 9.86 ppm, thus confirming the structure of this aldehyde derivative of <b>1</b>.</div><div class="NLM_p">In the NMR spectrum of the second oxidation product (12 mol %), the methyl-C11 was replaced by a methylene entity detected at 6.52 ppm and at 59.11 ppm in <sup>1</sup>H and <sup>13</sup>C NMR spectra, respectively, and C11 was detected at 143.49 ppm (<b>1</b>-CH<sub>2</sub>OH, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compared to 138.45 ppm for <b>1</b>). Conversely, the <i>H</i><sub>3</sub><i>C</i>–C13 was detected at 3.83/12.33 ppm, very close to the corresponding chemical shifts of the substrate (3.78/12.10 ppm in <b>1</b>). NMR data for C13 were not significantly modified (127.97 ppm in <b>1</b> and 127.73 ppm in <b>1</b>-CH<sub>2</sub>OH), indicating that no reaction occurred at the methyl-C13 site. A ROE correlation was detected between the methylene at C11 (6.52 ppm) and the <i>H</i>N15 detected at 8.94 ppm. This feature is significant of the oxidation of the methyl-C11 to the alcohol HO–CH<sub>2</sub>–C11 (<b>1</b>-CH<sub>2</sub>OH, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In addition, NMR detection of the complete side chain (<i>H</i>N15 to <i>H</i><sub>3</sub><i>C</i>20) allowed to rule out oxidation of the side chain. This product is the expected intermediate of oxidation of <b>1</b> to <b>1</b>-CHO.</div><div class="NLM_p">The minor product detected by NMR (6 mol %) exhibited typical chemical shifts of a CH<sub>2</sub>–O–CH<sub>3</sub> function at C11 (6.09/68.50 ppm for the methylene, 4.52/59.40 ppm for the methyl, <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The <i>H</i><sub>3</sub><i>C</i>–C13 was detected at 3.75/11.45 ppm, very close to the corresponding signals of the starting sunitinib. This compound, detected at <i>m</i>/<i>z</i> 429.2 amu (MH<sup>+</sup>) in mass spectrometry analyses, is likely to be the result of the methylation of <b>1</b>-CH<sub>2</sub>OH in the experimental conditions. The mechanism of its formation was not investigated further.</div><div class="NLM_p">In the LC-MS analysis of the metabolite mixture, the major products were detected with retention time values in the range 4–5 min in our conditions (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace a). The unreacted sunitinib was detected at 4.62 min (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace b). The extracted ionic current (XIC) <i>m</i>/<i>z</i> = 415 amu, assigned to the introduction of an oxygen atom in the molecule (+16 amu), displayed peaks at three different retention times (4.16, 4.36, and 4.70 min, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace c). This mass can be assigned either to the N-oxidation of the aliphatic N18, to the hydroxylation on the aliphatic side chain (metabolites hydroxylated at C16 or C20 have been detected <i>in vivo</i>),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> or to a hydroxylation on the aromatic moiety. Oxidation on the side chain or on the aromatic scaffold could be differentiated by tandem mass spectrometry (MS/MS, MRM mode), using the transitions assigned to the cleavage of C17–N18 and C14–N15 bonds, respectively. The transitions 415 → 326 and 415 → 283, signatures of hydroxylation at C20 or N-oxidation at N18 on the side chain<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S1</a>), gave rise to ionic currents at 4.16 and 4.70 min and were not characterized further. The transitions 415 → 342 and 415 → 299, signatures of hydroxylation on the aromatic scaffold (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S1</a>), gave rise to a single ionic current at 4.36 min. This product was therefore identified as the alcohol metabolite <b>1</b>-CH<sub>2</sub>OH, which was characterized by NMR.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Catalytic oxidation of <b>1</b> by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>: UHPLC-MS of the reaction mixture. (a) Total ionic current (TIC, scanning mode). (b) XIC for <i>m</i>/<i>z</i> = 399, insert: mass spectrum at 4.62 min, assigned to <b>1</b>; (c) XIC for <i>m</i>/<i>z</i> = 415; (d) XIC for <i>m</i>/<i>z</i> = 413, insert: mass spectrum at 4.36 min, assigned to <b>1</b>-CHO; (e) XIC for <i>m</i>/<i>z</i> = 429, insert: mass spectrum at 4.56 min, assigned to <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>; (f) XIC for <i>m</i>/<i>z</i> = 371, insert: mass spectrum at 4.28 min, assigned to <b>1</b>-NHEt.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <b>1</b>-CHO (XIC for <i>m</i>/<i>z</i> = 413) co-migrated with <b>1</b>-CH<sub>2</sub>OH at 4.36 min (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace d). The molecular ion peak of the mass spectrum at 4.36 min (<i>m</i>/<i>z</i> = 413.14 amu) is consistent with oxidation of the methyl–C11 to an aldehyde function (+14 amu with respect to the spectrum of <b>1</b>, <i>m</i>/<i>z</i> = 399.13, trace d, insert). Tandem mass spectrometry spectra (MS/MS, MRM mode) for <i>m</i>/<i>z</i> = 413 produced main fragments at <i>m</i>/<i>z</i> = 340.1 and 297.1, assigned to the cleavage of C17–N18 and C14–N15 bonds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S1</a>), respectively, confirming that the introduction of the oxygen atom took place in the aromatic core and not at the amine side chain.</div><div class="NLM_p">Derivatization of the aldehyde function, carried out by addition of methoxylamine in the mixture of sunitinib metabolites, resulted in complete disappearance of the extracted ionic current at <i>m</i>/<i>z</i> = 413, while the oxime derivative <b>1</b>-CH═N–OCH<sub>3</sub> was detected at 4.77 and 5.09 min (<i>m</i>/<i>z</i> = 442.3, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S2</a>, trace a). The position of the oxime function was confirmed by the presence of peaks at the same retention time for 442 → 369 and 442 → 326 specific transitions in MRM MS/MS mode (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S2</a>, traces b and c, respectively). The detection of two chromatographic peaks for this derivative can be tentatively assigned to <i>Z</i>/<i>E</i> isomerism of the oxime function. This result confirms both the presence of the aldehyde function on the aromatic moiety of sunitinib and its ability to readily react with primary amines.</div><div class="NLM_p">The chromatogram of the extracted ion (XIC) of the methyl ether derivative <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace e) exhibited a similar profile than that of the parent alcohol, but with more retained peaks (<i>R</i><sub>t</sub> = 4.47, 4.56, and 4.70 min), all having a <i>m</i>/<i>z</i> value of 429.1 amu. By comparison with <b>1</b>-CH<sub>2</sub>OH, the product eluted at 4.56 min is probably the methyl ether at C11.</div><div class="NLM_p">Noteworthy, the mono-<i>N</i>-desethyl sunitinib metabolite, which is the main human metabolite detectable <i>in vivo</i>,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> was also detected, partly overlapped by <b>1</b>-CHO and <b>1</b>-CH<sub>2</sub>OH (4.28 min, <i>m</i>/<i>z</i> = 371.1, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, trace f). This result indicates that the oxidation of sunitinib catalyzed by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub> was able to provide the main human metabolite of sunitinib. This catalytic system should therefore be considered a reliable model of <i>in vivo</i> P450 reactivity.</div><div class="NLM_p last">Then, beside the oxidation of the amine side chain, the biomimetic oxidation of <b>1</b> using a metalloporphyrin catalyst was found to be regioselective at the α-pyrrolic position C11, the major oxidation products being the corresponding alcohol and aldehyde. Since aldehyde function is prone to react with amines <i>in vitro</i>, it is likely that, if the aldehyde is generated <i>in vivo</i> by P450 metabolism, it can further react with amine side chains of proteins and provide potentially toxic covalent sunitinib-protein adducts.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Human Liver Microsome-Induced Oxidation of Sunitinib</h3><div class="NLM_p">Having in hands the aldehyde <b>1</b>-CHO and the alcohol <b>1</b>-CH<sub>2</sub>OH obtained by biomimetic oxidation, we decided to investigate the microsomal oxidation of sunitinib to check if these two drug oxidation products might be generated in human metabolization conditions. The identification, in biological conditions (microsomes), of these potential unknown metabolites, might be much easier with the available reference compounds that we characterized here for the first time.</div><div class="NLM_p">The results of the chemical oxidation of sunitinib <b>1</b> were compared to that obtained after incubation of <b>1</b> with human liver microsomes. These P450-rich subcellular fractions are indeed considered reliable models of drug hepatic metabolism.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The supernatant of microsomal incubation media containing <b>1</b> were analyzed by UHPLC-MS. Results are reported in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Along with unreacted <b>1</b> (<i>R</i><sub>t</sub> = 4.60 min, <i>m</i>/<i>z</i> = 399.4, trace a), and the N18-monodesethylated derivative (<i>R</i><sub>t</sub> = 4.27 min, <i>m</i>/<i>z</i> = 371.1, trace b), extracted ionic currents with <i>m</i>/<i>z</i> molecular ion values of 415 and 413 were detected at the same retention time as <b>1</b>-CH<sub>2</sub>OH and <b>1</b>-CHO of the catalytic biomimetic oxidation mixture (<i>R</i><sub>t</sub> = 4.36 min, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, traces c and f for <b>1</b>-CHO and <b>1</b>-CH<sub>2</sub>OH, respectively). Characterization of the <b>1</b>-CHO was confirmed by the transitions 413 → 340 (trace d) and 413 → 268 (trace e) in MRM mode, corresponding to the cleavage of the C17–N18 and C12–C14 bonds, respectively, while characterization of <b>1</b>-CH<sub>2</sub>OH was assessed by the transitions 415 → 342 (trace g) and 415 → 299 (trace h), corresponding to the cleavage of the C17–N18 and C14–N15 bonds, respectively. This result formally confirmed the presence of the aldehyde derivative of <b>1</b> in the microsomal incubation media, along with the intermediate alcohol derivative. In addition, the MRM transitions 415 → 326 and 415 → 283 were detected at 4.15 and 4.69 min, indicating that incorporation of an oxygen atom in the amine aliphatic chain (hydroxylation or N-oxidation) also occurred upon incubation of <b>1</b> with human liver microsomes (data not shown). In addition, minor chromatographic peaks detected at 3.1 (<i>m</i>/<i>z</i> = 399.2) and 2.4 (<i>m</i>/<i>z</i> = 371.1) min were assigned to the <i>E</i>-stereoisomers of <b>1</b> and <b>1</b>-NHEt, resulting from isomerization of the C3–C8 double bond under the reaction conditions (data not shown).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Oxidation of <b>1</b> catalyzed by human liver microsomes: UHPLC-MS of the reaction mixture. (a) XIC for <i>m</i>/<i>z</i> = 399, assigned to <b>1</b>; (b) XIC for <i>m</i>/<i>z</i> = 371, assigned to <b>1</b>-NHEt; (c) XIC for <i>m</i>/<i>z</i> = 413, assigned to <b>1</b>-CHO, insert: mass spectrum at 4.36 min, assigned to the mixture of <b>1</b>-CHO + <b>1</b>-CH<sub>2</sub>OH; (d) 413 → 340 MRM MS/MS transition; (e) 413 → 268 MRM MS/MS transition; (f) XIC for <i>m</i>/<i>z</i> = 415, assigned to <b>1</b>-CH<sub>2</sub>OH, insert: mass spectrum at 4.36 min, assigned to the mixture of <b>1</b>-CH<sub>2</sub>OH + <b>1</b>-CHO; (g) 415 → 342 MRM MS/MS transition; (h) 415 → 299 MRM MS/MS transition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Derivatization of <b>1</b>-CHO produced by human liver microsomes was carried out by addition of methoxylamine in the incubation medium. This reaction resulted in the complete disappearance of the peak assigned to <b>1</b>-CHO (<i>m</i>/<i>z</i> = 413), while the oxime derivative <b>1</b>-CH═N–OCH<sub>3</sub> was detected at 4.74–4.77 min (<i>m</i>/<i>z</i> = 442, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S2</a>, traces d and e). This result confirms the oxidation of <b>1</b> to an aldehyde derivative by human liver microsomes and the ability of this metabolite to react in the presence of primary amines.</div><div class="NLM_p">In conclusion, thanks to the characterization of oxidative derivatives of <b>1</b> obtained by the biomimetic oxidation system, it has been possible to unambiguously detect the carboxaldehyde <b>1</b>-CHO after incubation of <b>1</b> with P450-rich human liver microsomes, a metabolite that has never been previously identified in animals or patients, probably because of its reactivity with primary amines. This aldehyde is therefore expected to be highly reactive with protein amines and consequently should be considered as a potentially toxic metabolite. Since it can be generated by P450 in hepatocytes, this characterized metabolite may take a large part in the sunitinib hepatotoxicity.</div><div class="NLM_p last">On the basis of mass spectrometry studies, hydroxylation of the aromatic core of sunitinib has previously been proposed as structure for a very minor fecal metabolite of <b>1</b> in humans.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, the regioselective hydroxylation at the α-pyrrolic position C11 was not reported.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Catalytic Oxidation of Pazopanib</h3><div class="NLM_p">To the best of our knowledge, the characterization of pazopanib <i>in vivo</i> metabolites has only been reported in a single publication.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> After administration of [<sup>14</sup>C]pazopanib to 10 patients, on the basis of HPLC-MS analyses, hydroxylations of the drug at C7 and C19 positions, along with N8-demethylation, have been proposed as P450-mediated phase I metabolism. <i>In vitro</i>, the drug was found stable under very drastic conditions: 3 M HCl, 3 M NaOH at 80 °C or 30% H<sub>2</sub>O<sub>2</sub> at room temperature for 2 days.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pazopanib was susceptible only to photolytic conditions (UV light for 3 days at 200 W·h/m<sup>2</sup>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In these conditions, the oxidation of <i>H</i><sub>3</sub><i>C</i>–C7 to an aldehyde function was proposed on the basis of UHPLC-MS fragmentation patterns. However, these studies, carried out very far from any biologically relevant conditions, do not allow to propose relevant <i>in vivo</i> metabolism of this drug.</div><div class="NLM_p">Pazopanib is commercially available as a hydrochloride salt form, which is practically insoluble in aqueous media at pH above 4 and in many solvents except in DMSO or DMF, which are not suitable for oxidation reactions. So, facing these limitations, we decided to use atypical solvents such as <i>N</i>-methylpyrrolidone and acetic acid. These solvents were able to solubilize pazopanib hydrochloride, a hydrosoluble oxidant, and an organosoluble catalyst. For example, catalytic oxidation of pazopanib was carried out in acetic acid, using Mn<sup>III</sup>(TDCPP)Cl as catalyst, 4-<i>t</i>-butylpyridine as co-catalyst, and MMPP as oxidant (catalyst/oxidant/substrate mol ratio = 0.02/3/1). The very poor solubility of the reaction products and of the drug did not allow separation of the oxidation products.</div><div class="NLM_p">A preliminary study allowed to identify by mass spectrometry (using a direct introduction) compounds with <i>m</i>/<i>z</i> values of 438.5 amu, assigned to the starting pazopanib, and 454.4 and 452.5 amu, corresponding to an alcohol (M + 16) and an aldehyde (M + 14) derivative, respectively. A series of products with specific isotopic patterns of chlorinated derivatives was also detected. In this series, the <i>m</i>/<i>z</i> values of 472.4, 506.4, 488.3, and 486.3 amu were assigned to chloro- (M + 34), dichloro- [M + (2 × 34)], chloroalcohol- (M + 16 + 34), and chloroaldehyde (M + 14 + 34) derivatives of pazopanib, respectively (data not shown). To go further into the characterization of these products, the mixture was then analyzed by NMR in pyridine-<i>d</i><sub>5</sub>. In these conditions, eight products have been characterized in the reaction mixture. Unreacted starting material accounted for 42 mol % of the mixture and was completely characterized by <sup>1</sup>H and <sup>13</sup>C NMR (compound <b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The major product, accounting for 27 mol %, was a derivative which had undergone oxidative chlorination at C14 (<b>2</b>-Cl, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). This feature has been evidenced by the disappearance of the aromatic H14 (at 7.09 ppm in <b>2</b>) and by a 9 ppm downfield shift of C14 (98.59 and 107.83 ppm in <b>2</b> and <b>2</b>-Cl, respectively), along with a 4.6 ppm upfield shift of C9. This reaction is typically a chloroperoxidase-type reaction. It has been reported to occur <i>in vivo</i> in the presence of a hemin derivative associated with chloride anions.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Catalytic oxidation of <b>2</b> in the presence of Mn<sup>III</sup>(TDCPP)Cl/MMPP, resulting in chlorination at C14 providing <b>2</b>-Cl, and oxidation at methyl-C7 providing <b>2</b>-CH<sub>2</sub>OH, <b>2</b>- CH<sub>2</sub>OCOCH<sub>3</sub> and <b>2</b>-CHO. These metabolites were characterized by NMR and mass spectrometry. The chlorinated derivatives of <b>2</b>-CH<sub>2</sub>OH, <b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>, and <b>2</b>-CHO were also characterized by NMR (partial NMR data in pyridine-<i>d</i><sub>5</sub> are reported on the structures). The “a” denotes detected only in NMR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In two other products accounting for 9 mol % each, the <i>H</i><sub>3</sub><i>C</i>–C7 disappeared and was unambiguously replaced by an aldehyde function, with the <i>C</i>O detected at 180.00 ppm and the <i>H</i>CO at 11.56 and 11.62 ppm (<b>2</b>-CHO, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The <i>H</i><sub>3</sub><i>C</i>–N1 was also significantly downfield shifted upon oxidation at C7 (Δδ = +0.44–0.52 ppm in proton and +3.09–3.19 ppm in carbon-13). Complete assignment of all protons/carbons of these two metabolites cannot be achieved due to signal overlapping. However, taking into account that chlorination of pazopanib at C14 was evidenced (<b>2</b>-Cl), one can reasonably consider that one of these aldehydes is chlorinated at C14 and the other is not. This proposal is consistent with the mass spectrometry data reported above.</div><div class="NLM_p">Two other products accounting for 6 mol % and 3 mol % were identified as alcohol derivatives resulting from the hydroxylation of <i>H</i><sub>3</sub><i>C</i>–C7, with a <i>CH</i><sub>2</sub>OH detected at 6.39/54.44 ppm and 6.33/54.50 ppm, respectively (<b>2</b>-CH<sub>2</sub>OH, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The C7 was downfield shifted with respect to <b>2</b> (Δδ = +3.8 ppm). The <i>H</i><sub>3</sub><i>C</i>–N1 was downfield shifted compared to <b>2</b> (Δδ = +0.28–0.33 ppm in proton and +0.80–0.89 ppm in carbon-13) but to a lower extent than in <b>2</b>-CHO. These alcohol derivatives are obviously intermediates in the oxidation of <b>2</b> to <b>2</b>-CHO, and, for the same reason as for the aldehyde derivatives, one of these alcohols is likely to be chlorinated at C14.</div><div class="NLM_p">In addition, the acetate esters of <b>2</b>-CH<sub>2</sub>OH were characterized as two minor products (<b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>), with the carbonyl function detected at 171.20 ppm (2 + 2 mol %). These compounds are likely the result of the side reaction of <b>2</b>-CH<sub>2</sub>OH (chlorinated or not at C14) with acetic acid used as solvent.</div><div class="NLM_p">Then, these products were characterized by UHPLC-MS. The XIC ionic currents of the expected <i>m</i>/<i>z</i> values are reported in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, along with the mass spectra. Under these conditions, pazopanib and its nonchlorinated metabolites were detected at 2.79, 2.56, and 2.82 min for <b>2</b>, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, with R = H, respectively (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, traces a–c). The monochlorinated series appeared at 3.55, 3.32, and 3.63 min for <b>2</b>-Cl, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, with R = Cl respectively (traces d–f), with mass isotope profiles confirming the presence of a chorine atom in these molecules (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> for the structures).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Catalytic oxidation of <b>2</b> by Mn<sup>III</sup>(TDCPP)Cl/MMPP: UHPLC-MS of the reaction mixture. Traces a–c: XIC for pazopanib <b>2</b>, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, respectively (R = H). Traces d–f: XIC for the chlorinated derivatives <b>2</b>-Cl, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, with R = Cl (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> for the structures). Inserts contain the mass spectra of the assigned chromatographic peaks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dichlorinated pazopanib was detected as a minor product (<i>m</i>/<i>z</i> = 506.2, co-eluted with <b>2</b>-CHO, R = Cl, <i>R</i><sub>t</sub> = 3.63 min, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, trace f).</div><div class="NLM_p">Derivatization of the aldehyde function, carried out by addition of methoxylamine in the mixture of pazopanib oxidation products, resulted in complete disappearance of the extracted ionic current at <i>m</i>/<i>z</i> = 452, while the oxime derivative <b>2</b>-CH═N–OCH<sub>3</sub> was detected at 2.96 and 3.11 min (<i>m</i>/<i>z</i> = 481.3, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S3</a>, trace a). As for sunitinib, the detection of two chromatographic peaks for this derivative is likely due to <i>Z</i>/<i>E</i> isomerism of the oxime function. The oxime fragmentation produced the 481 → 449 and 481 → 368 transitions in MRM MS/MS mode (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S3</a>, traces b and c, respectively). This result confirms both the presence of the aldehyde function on the aromatic moiety of pazopanib and its ability to react with primary amines.</div><div class="NLM_p last">Then, the regioselective oxidation at C7, leading to an alcohol, which was overoxidized to an aldehyde, was clearly evidenced using a biomimetic metalloporphyrin catalyst associated with a single oxygen atom donor. This result is consistent with the proposal of an alcohol at C7 as a pazopanib primary metabolite in humans.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> It is worth mentioning that the docking of pazopanib into the active cavity of CYP3A4 showed that the methyl group at C7 was in the close vicinity of the heme (the distance between the methyl hydrogen atom and the iron being 3.64 Å).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Human Liver Microsome-Induced Oxidation of Pazopanib</h3><div class="NLM_p">As reported above for sunitinib, we carried out pazopanib oxidation by human liver microsomes. After setting up suitable UHPLC-MS analysis conditions using the previously characterized oxidation products of pazopanib, the supernatant of the microsomal incubation medium was then compared to the chemical oxidation products.</div><div class="NLM_p">After incubation of pazopanib <b>2</b> with human liver microsomes, unreacted <b>2</b> (XIC <i>m</i>/<i>z</i> = 438 at 2.81 min) and the hydroxylation product <b>2</b>-CH<sub>2</sub>OH (XIC <i>m</i>/<i>z</i> = 454 and MRM transition 454 → 373 at 2.55 min) were detected in the supernatant of microsomal media (data not shown). More importantly, the aldehyde derivative <b>2</b>-CHO was also unambiguously detected in microsomal incubation supernatants. The ionic currents due to the specific transitions 452 → 371, 452 → 343 and 452 → 328 assigned to <b>2</b>-CHO (<i>R</i><sub>t</sub> = 2.84 min, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, traces a–c, respectively) were similar to that obtained with an authentic sample formerly prepared by Mn<sup>III</sup>(TDCPP)Cl/MMPP catalytic oxidation (<i>R</i><sub>t</sub> = 2.82 min). The characterization of the metabolite <b>2</b>-CHO was confirmed by addition of methoxylamine in the microsomal media. In these conditions, the MRM transition 481 → 449 assigned to the oxime derivative was detected at 3.09 min (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">Figure S3</a>, trace d).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of specific MS/MS transitions (MRM mode) of <b>2</b>-CHO (traces a–c) and <b>2</b>-Cl (traces d–f) in the mixture of oxidation products of pazopanib <b>2</b>, after oxidation by Mn<sup>III</sup>(TDCPP)Cl/MMPP or by human liver microsomes. R stands for the substituent at C14 (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The chlorinated derivative of pazopanib <b>2</b>-Cl was also detected by UHPLC-MS of microsomal media. The ionic currents due to the transitions 472 → 436, 472 → 391 and 472 → 355 assigned to <b>2</b>-Cl (<i>R</i><sub>t</sub> = 3.54–3.55 min) were fully consistent with the Mn<sup>III</sup>(TDCPP)Cl/MMPP biomimetic media (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, traces d–f, respectively). It should be noted that aromatic chlorination usually decreases solubility and increases the oxidative potential of the chlorinated fragment. These features may hinder further metabolism, thus preventing elimination of the drug and contributing to its toxicity.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using a biomimetic catalytic system, based on the association of a metalloporphyrin and a single oxygen atom donor, we prepared several oxidation products of sunitinib and pazopanib, which are predictive of the potential P450 metabolism of these tyrosine kinase inhibitors (TKIs) <i>in vivo</i>. Although pazopanib has been reported to be very recalcitrant to reaction, even under drastic chemical conditions, this biomimetic catalytic system allowed us to prepare, under mild conditions, and to characterize several oxidation and chlorination products of this drug. For both sunitinib and pazopanib, reactive aldehyde derivatives were characterized among other oxidation products.</div><div class="NLM_p">Then, with reference compounds in hand, the production of these reactive aldehydes was evidenced for both drugs upon human liver microsomes incubation, showing that metalloporphyrin-catalyzed oxidation can also be a reliable model of liver metabolism. Sunitinib and pazopanib oxidation to such reactive metabolites has not been experimentally documented yet, while aldehyde derivatives of several other TKIs have been proposed on the base of adduct derivatives identified in LC-MS.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The reactivity of these metabolites, especially toward amines, may be responsible for the hepatotoxicity of these drugs. Moreover, sunitinib and pazopanib have been reported to inhibit several P450 isoenzymes.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The putative reaction of carboxaldehyde metabolites of these drugs with the amine side chains of the P450 protein may be responsible for the mechanism-based inhibition of these enzymes.</div><div class="NLM_p">Finally, it should be emphasized that the parallel oxidation of drugs by metalloporphyrin-based biomimetic systems on one hand, and liver microsomes on the other hand, had not been reported yet. The identification of the same metabolites in both oxidation systems for both sunitinib and pazopanib gives solid evidence for the biological relevancy of the biomimetic system.</div><div class="NLM_p">In addition, the preliminary experiments using the biomimetic catalytic system were an essential tool to identify the metabolites produced in microsomal incubation media. Clearly, if we had not prepared and characterized these P450 relevant oxidation products by metalloporphyrin-catalyzed oxidation beforehand, the “fishing” of these reactive aldehyde in liver microsomal incubation media would not have gone so well. In addition, these studies strongly suggest that a way to reduce the hepatotoxicity of these two tyrosine kinase inhibitors, sunitinib and pazopanib, will be to change the oxidable methyl group at C11 or C7. A methyl substituent at C7 in pazopanib (and indazole analogues) exhibited good potency against all human VEGFR and also resulted in minimized CYP inhibition compared to other substituents.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In the sunitinib series, the C11 and C13-dimethyl pyrrole derivatives exhibited the highest activities.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">In these conditions, replacement of a CH<sub>3</sub> group by a CD<sub>3</sub> is a way to considerably slow down metabolic conversion by kinetic isotope effect of deuterium, with minimum modification of the structure (and, therefore, of the activity) of the parent drug. Noteworthy, the first deuterated drug was approved by FDA in 2017.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Materials and Instruments</h3><div class="NLM_p">Sunitinib <span class="smallcaps smallerCapital">l</span>-malate and pazopanib hydrochloride were purchased from Alsachim. All solvents and commercially available reagents were used without further purification. Sunitinib (free base, <b>1</b>) was prepared from sunitinib <span class="smallcaps smallerCapital">l</span>-malate. The manganese complexes of porphyrins were prepared as previously reported.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> TLC was performed on neutral aluminum oxide 150 F<sub>254</sub> plates (Merck). Reverse phase chromatography was carried out on Sep-PakC18 classic cartridges (Waters). Human liver microsomes and incubation buffers were purchased from Corning (ref 452161, 451220, 451200).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> NMR Spectroscopy</h4><div class="NLM_p last"><sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N, <sup>19</sup>F spectra were recorded at 293 K on a Bruker AV500 spectrometer that was equipped with a 5 mm broadband inverse triple-resonance probe with Z field gradients using methanol-<i>d</i><sub>4</sub> or pyridine-<i>d</i><sub>5</sub> as solvent. All chemical shifts were relative to tetramethylsilane for <sup>1</sup>H and <sup>13</sup>C, to NO<sub>3</sub><sup>–</sup> for <sup>15</sup>N, and to CCl<sub>3</sub>F for <sup>19</sup>F.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Mass Spectrometry</h4><div class="NLM_p last">Direct introduction mass spectrometry analyses were performed on Qtof Premier (Waters) or on QTRAP 2000 (AB Sciex) mass spectrometers, in the positive ionization mode (ESI<sup>+</sup>) in the range <i>m</i>/<i>z</i> 80–700 amu. After dilution in water, samples were directly injected in water in the mass spectrometer without liquid chromatography system. The cone voltage was 30 or 50 V (Qtof) or 80 V (QTRAP) for MS. For direct introduction MS/MS analyses performed on Qtof Premier, the cone voltage was 30 V and collision energies 15 or 30 eV.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> LC/MS Analyses</h4><div class="NLM_p last">LC/MS analyses were performed on an UHPLC Waters Acquity system equipped with a Waters TQ-S micro mass spectrometer (triple quadrupole detector), an electrospray ionization source (ESI), and MassLynx software. The Acquity UPLC BEH Shield RP18 (1.7 μm, 2.1 × 50 mm) column was used as a stationary phase. Eluent A was ammonium formate 5 mM pH 3.2, and eluent B was formic acid 0.1% (v/v) in acetonitrile. The flow rate was 0.4 mL/min, and the column temperature was 30 °C. Eluting conditions for sunitinib were a linear gradient of A and B as follows: The percentage of B, initially set at 5%, increased to reach 15% (<i>t</i> = 0.5 min), 30% (<i>t</i> = 3 min), 35% (<i>t</i> = 3.5 min), stayed at 35% until 5.5 min, then increased again to reach 95% (<i>t</i> = 6.5 min), stayed at 95% until 7.5 min, then returned to initial conditions over 0.2 min. Afterward, the system was re-equilibrated for 1.3 min before the following injection. Eluting conditions for pazopanib were a linear gradient of A and B as follows: the percentage of B, initially set at 5%, increased to reach 15% (<i>t</i> = 0.5 min), 45% (<i>t</i> = 2 min), 85% (<i>t</i> = 2.5 min), 95% (<i>t</i> = 3 min), stayed at 95% until 3.5 min, then returned to initial conditions over 0.2 min. Afterward, the system was re-equilibrated for 2.3 min before the following injection. The mass spectrometer was operated in positive ionization mode (ESI<sup>+</sup>), using cone voltages of 60 or 80 V and collision energy of 30 eV. The spectra were acquired in full scan (<i>m</i>/<i>z</i> range 200–500 amu for sunitinib, 200–520 amu for pazopanib), and multiple reaction monitoring (MRM) modes. MS/MS MRM transitions were as follows: for sunitinib <b>1</b>: <i>m</i>/<i>z</i> 399 → 326, 283; for <b>1</b>-CH<sub>2</sub>OH: <i>m</i>/<i>z</i> 415 → 342, 299; for <b>1</b>-CHO: <i>m</i>/<i>z</i> 413 → 340, 297, 268; for <b>1</b>-CH═N–OCH<sub>3</sub>: <i>m</i>/<i>z</i> 442 → 369, 326; for <b>1</b>-NHEt: <i>m</i>/<i>z</i> 371 → 326, 283; for pazopanib <b>2</b>: <i>m</i>/<i>z</i> 438 → 357, 341; for <b>2</b>-Cl: <i>m</i>/<i>z</i> 472 → 436, 391, 355; for <b>2</b>-CH<sub>2</sub>OH, R = H: <i>m</i>/<i>z</i> 454 → 436, 373; for <b>2</b>-CHO, R = H: <i>m</i>/<i>z</i> 452 → 371, 343, 328; for <b>2</b>-CH<sub>2</sub>OH, R = Cl: <i>m</i>/<i>z</i> 488 → 434, 407; for <b>2</b>-CHO, R = Cl: <i>m</i>/<i>z</i> 486 → 405, 371; for <b>2</b>-CH═N–OCH<sub>3</sub>: <i>m</i>/<i>z</i> 481 → 449, 368.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemical Studies</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Neutralization of Sunitinib <span class="smallcaps smallerCapital">l</span>-malate</h4><div class="NLM_p last">Sunitinib as a free base (<b>1</b>) was prepared by neutralization of the sunitinib salt form. Sunitinib <span class="smallcaps smallerCapital">l</span>-malate (100 mg, 188 μmol) was dissolved in 40 mL of a NaOH aqueous solution (1 M) and extracted three times by 40 mL of CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated <i>in vacuo</i> to yield the sunitinib free base (<b>1</b>, 74.8 mg, 99.6% recovery). The product is a mixture of isomers having <i>Z</i> and <i>E</i> configurations at C3–C8. For the sake of clarity, the NMR spectra of <i>Z</i> and <i>E</i> isomers are described separately. TLC (neutral Al<sub>2</sub>O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 95/5, v/v): <i>R</i><sub><i>f</i></sub> = 0.75. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = 7.60 (s, 1H, H8), 7.44 (m, 1H, H4), 6.88 (m, 2H, H6 and H7), 3.54 (t, 2H, <i>H</i><sub>2</sub>C16), 2.83 (t, 2H, <i>H</i><sub>2</sub>C17), 2.77 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.52 (s, 3H, <i>H</i><sub>3</sub>C–C11), 2.48 (s, 3H, <i>H</i><sub>3</sub>C–C13), 1.16 (t, 6H, 2 × <i>H</i><sub>3</sub>C20); for <i>E</i> isomer: δ (ppm) = 7.60 (s, 1H, H8), 7.43 (m, 1H, H4), 6.90 (m, 1H, H6), 6.88 (m, 1H, H7), 3.54 (t, 2H, <i>H</i><sub>2</sub>C16), 2.83 (t, 2H, <i>H</i><sub>2</sub>C17), 2.77 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.52 (s, 3H, <i>H</i><sub>3</sub>C–C11), 2.33 (s, 3H, <i>H</i><sub>3</sub>C–C13), 1.16 (t, 6H, 2 × <i>H</i><sub>3</sub>C20). <sup>1</sup>H NMR (500 MHz, pyridine-<i>d5</i>) for <i>Z</i> isomer: δ (ppm) = 15.41 (1H, <i>H</i>N10), 13.41 (1H, <i>H</i>N1), 8.92 (1H, H8), 8.80 (1H, H7), 8.61 (1H, <i>H</i>N15), 8.16 (1H, H6), 8.11 (1H, H4), 4.81 (2H, <i>H</i><sub>2</sub>C16), 3.78 (2H, <i>H</i><sub>2</sub>C17), 3.78 (3H, <i>H</i><sub>3</sub>C–C13), 3.74 (3H, <i>H</i><sub>3</sub>C–C11), 3.61 (4H, 2 × <i>H</i><sub>2</sub>C19), 2.09 (6H, 2 × <i>H</i><sub>3</sub>C20). <sup>13</sup>C NMR (125.72 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = 170.20 (C2), 167.27 (C14), 159.18 (C5), 136.70 (C11), 134.50 (C7a), 130.16 (C9), 127.20 (C3a), 126.13 (C13), 123.90 (C8), 119.45 (C12), 115.50 (C3), 112.40 (C6), 109.80 (C7), 104.87 (C4), 51.52 (C17), 48.73 (2 × C19), 36.52 (C16), 11.98 (H<sub>3</sub><i>C</i>–C11), 10.00 (2 × C20), 9.27 (H<sub>3</sub><i>C</i>–C13); for <i>E</i> isomer: δ (ppm) = 171.33 (C2), 134.50 (C7a), 128.16 (C9), 125.05 (C8), 123.90 (C13), 119.57 (C3), 119.19 (C12), 112.48 (C6), 109.80 (C7), 108.70 (C4), 51.60 (C17), 46.89 (2 × C19), 36.44 (C16), 12.00 (H<sub>3</sub><i>C</i>–C11), 10.01 (2 × C20), 9.89 (H<sub>3</sub><i>C</i>–C13). <sup>13</sup>C NMR (125.72 MHz, pyridine-<i>d</i><sub>5</sub>) for <i>Z</i> isomer: δ (ppm) = 172.00 (C2), 166.50 (C14), 160.26 (C5), 138.45 (C11), 136.70 (C7a), 131.21 (C9), 129.22 (C3a), 127.97 (C13), 125.62 (C8), 122.10 (C12), 116.96 (C3), 113.76 (C6), 111.35 (C4), 106.99 (C7), 53.34 (C17), 47.92 (2 × C19), 38.65 (C16), 14.71 (H<sub>3</sub><i>C</i>–C11), 13.04 (2 × C20), 12.10 (H<sub>3</sub><i>C</i>–C13). <sup>15</sup>N NMR (50.66 MHz, methanol-<i>d</i><sub>4</sub>): δ (ppm) = −338.6 (N18), −218.0 (N10). <sup>19</sup>F NMR (376.31 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = −124.11 (m); for <i>E</i> isomer: δ (ppm) = −124.00 (m). MS (ESI<sup>+</sup>/CH<sub>3</sub>OH): <i>m</i>/<i>z</i> = 399.2 (MH<sup>+</sup>); MS/MS fragments (30 eV): <i>m</i>/<i>z</i> = 326.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NH], <i>m</i>/<i>z</i> = 283.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>].</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Standard Conditions for Noncatalytic Oxidations. Homogeneous Conditions</h4><div class="NLM_p last">Sunitinib (<b>1</b>, 4.0 mg, 10 μmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL). <i>meta</i>-Chloroperbenzoic acid (<i>m</i>CPBA, 15 μmol) was then added. The solution was stirred at room temperature for 10 min, and the reaction was quenched by addition of acetone (1 mL). The reaction mixture was then purified by column chromatography (neutral Al<sub>2</sub>O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 100/0 to 90/10, v/v) to afford an orange solid. Quantitative yield.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Biphasic Conditions</h4><div class="NLM_p">In 1.15 mL of CH<sub>2</sub>Cl<sub>2</sub> containing 4 mg of sunitinib (<b>1</b>, 10 μmol), benzyldimethyltetradecylammonium chloride (BDTAC, 4 μmol) was added. Magnesium monoperphthalate (MMPP, 15 μmol in 0.4 mL of water, i.e., 30 μmol of monoperphthalate) or potassium hydrogen persulfate (KHSO<sub>5</sub>, 30 μmol in 0.4 mL of water) was then added, and the reaction mixture was magnetically stirred for 30 min. The reaction mixture was purified by column chromatography (neutral Al<sub>2</sub>O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 100/0 to 98/2, v/v).</div><div class="NLM_p last">TLC (neutral Al<sub>2</sub>O<sub>3,</sub> CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 95/5, v/v): <i>R</i><sub><i>f</i></sub> = 0.43. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = 7.58 (s, 1H, H8), 7.43 (m, 1H, H4), 6.88 (m, 1H, H6), 6.86 (m, 1H, H7), 3.82 (t, 2H, <i>H</i><sub>2</sub>C16), 3.46 (t, 2H, <i>H</i><sub>2</sub>C17), 3.38 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.52 (s, 3H, <i>H</i><sub>3</sub>C–C11), 2.48 (s, 3H, <i>H</i><sub>3</sub>C–C13), 1.37 (t, 6H, 2 × <i>H</i><sub>3</sub>C20); for <i>E</i> isomer: δ (ppm) = 7.60 (s, 1H, H8), 7.41 (m, 1H, H4), 6.96 (m, 1H, H6), 6.88 (m, 1H, H7), 3.82 (t, 2H, <i>H</i><sub>2</sub>C16), 3.46 (t, 2H, <i>H</i><sub>2</sub>C17), 3.38 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.53 (s, 3H, <i>H</i><sub>3</sub>C–C11), 2.33 (s, 3H, <i>H</i><sub>3</sub>C–C13), 1.37 (t, 6H, 2 × <i>H</i><sub>3</sub>C20). <sup>13</sup>C NMR (125.72 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = 170.26 (C2), 167.23 (C14), 159.08 (C5), 136.93 (C11), 134.30 (C7a), 130.24 (C9), 127.21 (C3a), 126.16 (C13), 123.89 (C8), 118.79 (C12), 115.54 (C3), 112.42 (C6), 109.84 (C7), 105.00 (C4), 61.97 (C17), 59.93 (2 × C19), 33.80 (C16), 12.16 (H<sub>3</sub><i>C</i>–C11), 9.49 (H<sub>3</sub><i>C</i>–C13), 7.26 (2 × C20); for <i>E</i> isomer: δ (ppm) = 171.13 (C2), 137.50 (C11), 127.97 (C3a), 127.88 (C9), 124.99 (C8), 123.55 (C13), 119.80 (C3), 118.79 (C12), 113.89 (C6), 109.80 (C7), 108.60 (C4), 61.97 (C17), 59.93 (2 × C19), 33.80 (C16), 11.65 (H<sub>3</sub><i>C</i>–C11), 10.00 (H<sub>3</sub><i>C</i>–C13), 7.26 (2 × C20). <sup>15</sup>N NMR (50.66 MHz, methanol-<i>d</i><sub>4</sub>): δ (ppm) = −258.3 (N18 → O), −213.3 (N10). <sup>19</sup>F NMR (376.31 MHz, methanol-<i>d</i><sub>4</sub>) for <i>Z</i> isomer: δ (ppm) = −124.07 (m); for <i>E</i> isomer: δ (ppm) = −123.98 (m). MS (ESI<sup>+</sup>/CH<sub>3</sub>OH): <i>m</i>/<i>z</i> = 415.2 (MH<sup>+</sup>); MS/MS fragments (30 eV): <i>m</i>/<i>z</i> = 326.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NH(→O)], <i>m</i>/<i>z</i> = 283.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>N → O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>].</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Standard Conditions for Catalytic Oxidations. Sunitinib</h4><div class="NLM_p last">Sunitinib (<b>1</b>, 12.0 mg, 30 μmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL). Mn<sup>III</sup>(TDCPP)Cl (0.6 μmol in 0.3 mL of CH<sub>2</sub>Cl<sub>2</sub>), 4-<i>t</i>-butylpyridine (15 μmol in 0.15 mL of CH<sub>2</sub>Cl<sub>2</sub>), BDTAC (4.5 mg, 12 μmol), and then KHSO<sub>5</sub> (90 μmol in 0.4 mL of water) were added. The reaction mixture was stirred at room temperature. After 60 or 180 min, the reaction was stopped by addition of acetone (1 mL). The aqueous phase was then purified by column chromatography (reverse phase C18, H<sub>2</sub>O/CH<sub>3</sub>OH/0.5% NH<sub>4</sub>OH, 50/50 to 0/100, v/v). <sup>1</sup>H NMR (500 MHz, pyridine-<i>d</i><sub>5</sub>) for <b>1</b>-CH<sub>2</sub>OH: δ (ppm) = 8.94 (s, 1H, <i>H</i>N15), 8.94 (s, 1H, H8), 8.83 (m, 1H, H7), 8.21 (m, 1H, H6), 8.10 (m, 1H, H4), 6.52 (s, 2H, HO-<i>H</i><sub>2</sub>C–C11), 4.81 (t, 2H, <i>H</i><sub>2</sub>C16), 3.87 (t, 2H, <i>H</i><sub>2</sub>C17), 3.83 (s, 3H, <i>H</i><sub>3</sub>C–C13), 3.61 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.09 (t, 6H, 2 × <i>H</i><sub>3</sub>C20); for <b>1</b>-CHO: δ (ppm) = 11.70 (s, 1H, O<i>H</i>C–C11), 9.86 (s, 1H, <i>H</i>N15), 4.90 (t, 2H, <i>H</i><sub>2</sub>C16), 3.86 (t, 2H, <i>H</i><sub>2</sub>C17), 3.61 (q, 4H, 2 × <i>H</i><sub>2</sub>C19), 2.09 (t, 6H, 2 × <i>H</i><sub>3</sub>C20); for <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>: δ (ppm) = 8.87 (s, 1H, H8), 6.09 (s, 2H, H<sub>3</sub>CO-<i>H</i><sub>2</sub>C–C11), 4.52 (s, 3H, <i>H</i><sub>3</sub>CO-H<sub>2</sub>C–C11), 3.75 (s, 3H, <i>H</i><sub>3</sub>C–C13). <sup>13</sup>C NMR (125.72 MHz, pyridine-<i>d</i><sub>5</sub>) for <b>1</b>-CH<sub>2</sub>OH: δ (ppm) = 171.95 (C2), 160.20 (C5), 143.49 (C11), 138.52 (C7a), 131.69 (C9), 127.73 (C13), 120.56 (C12), 117.88 (C3), 116.32 (C6), 111.39 (C4), 108.53 (C7), 59.11 (HO-H<sub>2</sub><i>C</i>–C11), 53.43 (C17), 48.00 (2 × C19), 38.80 (C16), 13.00 (2 × C20), 12.33 (H<sub>3</sub><i>C</i>–C13); for <b>1</b>-CHO: δ (ppm) = 182.40 (OH<i>C</i>–C11), 133.78 (C11), 53.43 (C17), 48.00 (2 × C19), 39.29 (C16), 13.00 (2 × C20); for <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>: δ (ppm) = 171.37 (C2), 137.34 (C11), 132.74 (C9), 129.73 (C13), 120.06 (C12), 68.50 (H<sub>3</sub>CO-H<sub>2</sub><i>C</i>–C11), 59.40 (H<sub>3</sub><i>C</i>O–H<sub>2</sub>C–C11), 11.45 (H3<i>C</i>–C13). MS (ESI<sup>+</sup>/CH<sub>3</sub>OH): <i>m</i>/<i>z</i> = 399.2 (MH<sup>+</sup> for <b>1</b>), 413.2 (MH<sup>+</sup> for <b>1</b>-CHO), 415.2 (MH<sup>+</sup> for <b>1</b>-CH<sub>2</sub>OH), 429.2 (MH<sup>+</sup> for <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>), 432.2, 675.4. MS/MS fragments of the parent ion <i>m</i>/<i>z</i> = 413.2 (30 eV): <i>m</i>/<i>z</i> = 340.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NH], 297.1 [MH<sup>+</sup> – CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>], 296.1, 268.1, 240.1; MS/MS fragments of the parent ion <i>m</i>/<i>z</i> = 415.2 (30 eV): <i>m</i>/<i>z</i> = 342.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NH], 299.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>]. Contaminated with a minor product oxidized on the side chain (hydroxylation or N-oxidation) giving rise to fragments <i>m</i>/<i>z</i> = 326.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NH + O], 283.1 [MH<sup>+</sup> – (CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub> + O].</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Pazopanib</h4><div class="NLM_p last">Pazopanib hydrochloride (<b>2</b>, 4.7 mg, 10 μmol) was dissolved in acetic acid (the solvent was incrementally added under gentle heating until complete dissolution). Mn<sup>III</sup>(TDCPP)Cl (0.2 μmol in 0.1 mL of acetic acid), 4-<i>t</i>-butylpyridine (5 μmol in 0.05 mL of acetic acid), and then MMPP (15 μmol, i.e., 30 μmol of monoperphthalate) were added. The reaction mixture was stirred at room temperature. After 90 min, the reaction was stopped by addition of acetone (1 mL). The crude mixture was then analyzed by mass spectrometry, NMR, and LC-MS without further purification. <sup>1</sup>H NMR (500 MHz, pyridine-<i>d</i><sub>5</sub>) for <b>2</b>: δ (ppm) = 11.61 (1H, <i>H</i>N15), 10.48 (1H, H17), 9.42 (1H, H21), 9.15 (1H, H13), 8.84 (1H, H3), 8.78 (1H, H6), 8.43 (1H, H20), 8.04 (1H, H5), 7.09 (1H, H14), 5.12 (3H, <i>H</i><sub>3</sub>C–N1), 4.69 (3H, <i>H</i><sub>3</sub>C–N8), 4.05 (3H, <i>H</i><sub>3</sub>C–C19), 3.56 (3H, <i>H</i><sub>3</sub>C–C7); for <b>2</b>-Cl: δ (ppm) = 11.84 (1H, <i>H</i>N15), 10.40 (1H, H17), 9.32 (1H, H21), 9.26 (1H, H13), 8.68 (1H, H6), 8.46 (1H, H20), 8.13 (1H, H5), 5.07 (3H, <i>H</i><sub>3</sub>C–N1), 4.73 (3H, <i>H</i><sub>3</sub>C–N8), 4.06 (3H, <i>H</i><sub>3</sub>C–C19), 3.48 (3H, <i>H</i><sub>3</sub>C–C7); for <b>2</b>-CH<sub>2</sub>OH, R14 = H or Cl: δ (ppm) = 6.33/6.39 (2H, HO-<i>H</i><sub>2</sub>C–C7), 5.40/5.45 (3H, <i>H</i><sub>3</sub>C–N1); for <b>2</b>-CHO, R14 = H or Cl: δ (ppm) = 11.56/11.62 (1H, O<i>H</i>C–C7), 5.56/5.64 (3H, <i>H</i><sub>3</sub>C–N1); for <b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>, R14 = H or Cl: δ (ppm) = 6.73/6.80 (2H, H<sub>3</sub>C-OC-O-<i>H</i><sub>2</sub>C–C7), 5.34/5.38 (3H, <i>H</i><sub>3</sub>C–N1), 3.11/3.11 (3H, <i>H</i><sub>3</sub>C-OC-O-H<sub>2</sub>C–C7). <sup>13</sup>C NMR (125.72 MHz, pyridine-<i>d</i><sub>5</sub>) for <b>2</b>: δ (ppm) = 164.23 (C9), 156.46 (C13), 149.18 (C2a), 144.27 (C18), 143.64 (C4), 141.50 (C16), 133.92 (C20), 133.05 (C7), 129.36 (C19), 123.13 (C21), 121.80 (C6), 121.30 (C6a), 121.25 (C5), 119.72 (C17), 116.00 (C3), 98.59 (C14), 39.46 (H<sub>3</sub><i>C</i>–N8), 38.30 (H<sub>3</sub><i>C</i>–N1), 20.73 (H<sub>3</sub><i>C</i>–C19), 10.39 (H<sub>3</sub><i>C</i>–C7); for <b>2</b>-Cl: δ (ppm) = 159.62 (C9), 158.45 (C13), 146.37 (C2a), 144.37 (C18), 141.02 (C4), 134.65 (C7), 134.00 (C20), 129.98 (C19), 123.27 (C21), 122.92 (C5), 122.38 (C6a), 120.77 (C6), 119.84 (C17), 107.83 (C14), 41.64 (H<sub>3</sub><i>C</i>–N8), 38.50 (H<sub>3</sub><i>C</i>–N1), 20.73 (H<sub>3</sub><i>C</i>–C19), 10.48 (H<sub>3</sub><i>C</i>–C7); for <b>2</b>-CH<sub>2</sub>OH, R14 = H or Cl: δ (ppm) = 136.80/136.84 (C7), 121.30/122.20 (C6a), 54.44/54.50 (HO-H<sub>2</sub><i>C</i>–C7), 39.10/39.19 (H<sub>3</sub><i>C</i>–N1); for <b>2</b>-CHO, R14 = H or Cl: δ (ppm) = 180.00/180.00 (OH<i>C</i>–C7), 132.60/132.60 (C7), 123.50/124.00 (C6a), 41.39/41.49 (H<sub>3</sub><i>C</i>–N1); for <b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>, R14 = H or Cl: δ (ppm) = 171.20/171.20 (H<sub>3</sub>C–O<i>C</i>–O-H<sub>2</sub>C–C7), 131.40/131.40 (C7), 55.70/55.71 (H<sub>3</sub>C-OC–O-H<sub>2</sub><i>C</i>–C7), 39.10/39.10 (H<sub>3</sub><i>C</i>–N1), 21.27/21.27 (H<sub>3</sub><i>C</i>-OC-O-H<sub>2</sub>C–C7). MS (ESI<sup>+</sup>/acetic acid): <i>m</i>/<i>z</i> = 438.50 (MH<sup>+</sup>), 452.50 (MH<sup>+</sup> for <b>2</b>-CHO), 454.40 (MH<sup>+</sup> for <b>2</b>-CH<sub>2</sub>OH), 472.40 (MH<sup>+</sup> for <b>2</b>-Cl), 486.30 (MH<sup>+</sup> for <b>2</b>-CHO, R = Cl), 488.30 (MH<sup>+</sup> for <b>2</b>-CH<sub>2</sub>OH, R = Cl), 496.40 (MH<sup>+</sup> for <b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>) 506.40 (MH<sup>+</sup> for a dichlorinated derivative of <b>2</b>-CH<sub>2</sub>OH).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Standard Conditions for Derivatization Reactions</h4><div class="NLM_p last">An aliquot of an aldehyde-containing medium (ca. 4 or 2 μmol of aldehyde derivative for sunitinib or pazopanib, respectively) was dissolved in H<sub>2</sub>O/CH<sub>3</sub>OH (0.5 mL, 80/20 v/v for sunitinib; 1.1 mL, 10/90 v/v for pazopanib). Sodium acetate (160 μmol in 0.05 or 0.2 mL of water for sunitinib or pazopanib, respectively) and methoxylamine (80 μmol in 0.05 or 0.2 mL of water for sunitinib or pazopanib, respectively) were then added. In both cases, the coupling reaction was accelerated by warming the mixture at +37 °C for 120 min. The crude reaction media were then analyzed by UHPLC-MS.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Biological Studies</h3><div class="NLM_p last">Microsomal incubations were performed according to supplier protocol. An aliquot of human liver microsomes (final protein concentration = 0.5 mg/mL) was added in a mixture of NADPH regenerating solutions A (12.5 μL), B (2.5 μL), and 0.1 M phosphate buffer (pH = 7.4, final volume = 250 μL). After pre-incubation at 37 °C for 5 min, microsomal incubations were started by the addition of sunitinib or pazopanib solutions (final substrate concentration 10 or 50 μM in DMF/DMSO, final solvent concentration below 0.2%). Incubations were performed at 37 °C during 90–120 min and stopped by the addition of 250 μL of acetonitrile for protein precipitation. The incubation mixture was then centrifuged 20 min at 4000 <i>g</i>, at room temperature. After filtration (0.2 μm syringe filters), supernatants were analyzed by UHPLC-MS. Negative control incubations were performed in the absence of NADPH regenerating solutions. Positive control incubations were performed with another TKI, imatinib mesylate (final concentration 10 μM): the generation of the main imatinib metabolite, <i>N</i>-desmethylimatinib, upon HLM incubation was monitored by UHPLC-MS (data not shown).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Derivatization of the aldehyde function was carried out by incubating human liver microsomes at 37 °C for 90 min with sunitinib or pazopanib (final substrate concentration 50 μM, final solvent concentration below 0.2%) in the presence of methoxylamine (final methoxylamine concentration 1 mM).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00812" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The proposed structures of the products are depicted. The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00812" class="ext-link">10.1021/acs.jmedchem.8b00812</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figure S1. Mass spectrometry of sunitinib oxidation products. Assignment of <i>m</i>/<i>z</i> values detected in MRM MS/MS mode. Figure S2. UHPLC-MS of <b>1</b>-CH═N-OCH<sub>3</sub>, the oxime derivatives of <b>1</b>-CHO detected after oxidation of <b>1</b> by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub> or by human liver microsomes and derivatization of the aldehyde function by CH<sub>3</sub>ONH<sub>2</sub>. Oxidation by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>: (a) XIC for <i>m</i>/<i>z</i> = 442, Inserts: mass spectra of the products eluted at 4.77 and 5.09 min; (b) MRM MS/MS 442 → 369 transition; (c) MRM MS/MS 442 → 326 transition. Oxidation by human liver microsomes: (d) XIC for <i>m</i>/<i>z</i> = 442; (e) MRM MS/MS 442 → 326 transition. The structures of the products are depicted. Figure S3. UHPLC-MS of <b>2</b>-CH═N-OCH<sub>3</sub>, the oxime derivatives of <b>2</b>-CHO (R14 = H) detected after oxidation of <b>2</b> by Mn<sup>III</sup>(TDCPP)Cl/MMPP or by human liver microsomes and derivatization of the aldehyde function by CH<sub>3</sub>ONH<sub>2</sub>. Oxidation by Mn<sup>III</sup>(TDCPP)Cl/MMPP: (a) XIC for <i>m</i>/<i>z</i> = 481, inserts: mass spectra of the products eluted at 2.96 and 3.11 min; (b) MRM MS/MS 481 → 449 transition; (c) MRM MS/MS 481 → 368 transition. Oxidation by human liver microsomes: (d) MRM MS/MS 481 → 368 transition (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf">jm8b00812_si_001.pdf (345.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_002.csv">jm8b00812_si_002.csv (0.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00812" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cécile Arellano</span> - <span class="hlFld-Affiliation affiliation">Centre
de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse,  Cedex
1, France</span>; 
    <span class="hlFld-Affiliation affiliation">Université
Paul Sabatier, 31400 Toulouse, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e1d1b1d17121b501f0c1b12121f10113e0b101708530a120d1b4d50180c"><span class="__cf_email__" data-cfemail="375452545e5b52195645525b5b5659587742595e411a435b445204195145">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne Robert</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9092-6776" title="Orcid link">http://orcid.org/0000-0002-9092-6776</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa9b94949fd48895989f888eba969999d78e958f96958f899fd49c88"><span class="__cf_email__" data-cfemail="d0b1bebeb5fea2bfb2b5a2a490bcb3b3fda4bfa5bcbfa5a3b5feb6a2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie-Noëlle Paludetto</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse,  Cedex
1, France</span>; 
    <span class="hlFld-Affiliation affiliation">Université
Paul Sabatier, 31400 Toulouse, France</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacie, Institut Claudius Regaud, IUCT-O, 31037 Toulouse, Cedex 1, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Bijani</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florent Puisset</span> - <span class="hlFld-Affiliation affiliation">Centre
de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, 31037 Toulouse,  Cedex
1, France</span>; 
    <span class="hlFld-Affiliation affiliation">Université
Paul Sabatier, 31400 Toulouse, France</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacie, Institut Claudius Regaud, IUCT-O, 31037 Toulouse, Cedex 1, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vania Bernardes-Génisson</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
de Chimie de Coordination du CNRS (LCC−CNRS), Université de Toulouse, 205 route de Narbonne, BP 44099, 31077 Toulouse, Cedex 4, France</span>; 
    <span class="hlFld-Affiliation affiliation">Université
Paul Sabatier, 31400 Toulouse, France</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3499-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the CNRS, INSERM, and Institut Claudius Regaud, IUCT-O, Toulouse. Prof. Bernard Meunier, LCC-CNRS, Toulouse, is gratefully acknowledged for discussion about the manuscript. The Mass Spectrometry Core Facility of Institut de chimie de Toulouse (ICT) is gratefully acknowledged for direct introduction mass spectrometry analyses.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BDTAC</td><td class="NLM_def"><p class="first last">benzyldimethyltetradecylammonium chloride</p></td></tr><tr><td class="NLM_term">CYP or P450</td><td class="NLM_def"><p class="first last">cytochrome(s) P450</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term"><i>m</i>CPBA</td><td class="NLM_def"><p class="first last"><i>meta-</i>chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">MMPP</td><td class="NLM_def"><p class="first last">magnesium monoperphthalate</p></td></tr><tr><td class="NLM_term">MRM</td><td class="NLM_def"><p class="first last">multiple reaction monitoring</p></td></tr><tr><td class="NLM_term">MS/MS</td><td class="NLM_def"><p class="first last">tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">peracetic acid</p></td></tr><tr><td class="NLM_term">RECC</td><td class="NLM_def"><p class="first last">renal cell cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lara, P. N.,  Jr</span></span> <span> </span><span class="NLM_article-title">Renal cell carcinoma: current status and emerging therapies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2006.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.ctrv.2006.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17329029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVyhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=299-313&author=E.+C.+Nelsonauthor=C.+P.+Evansauthor=P.+N.+Lara&title=Renal+cell+carcinoma%3A+current+status+and+emerging+therapies&doi=10.1016%2Fj.ctrv.2006.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Renal cell carcinoma: Current status and emerging therapies</span></div><div class="casAuthors">Nelson, Eric C.; Evans, Christopher P.; Lara, Primo N., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies and its incidence is increasing.  Smoking, obesity, and end-stage renal disease are important risk factors.  Localized RCC may be cured with surgical excision.  However, over one-third of patients eventually develop metastatic disease.  While chemotherapy and radiation therapy are relatively ineffective for RCC, immunotherapy modestly extends survival and may lead to tumor regression and long-term survival in a small minority of patients.  Recently, research into the pathol. of genetic syndromes assocd. with RCC has led to remarkable advances in our understanding of the pathogenesis of sporadic RCC.  Rational therapeutic agents developed from this understanding have established new treatment paradigms for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo36UZbI-Wx9rVg90H21EOLACvtfcHk0li1zpRmGMABYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVyhtrk%253D&md5=4b3d88e944299661e06aebdf37bc1f8f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BC.%26aulast%3DEvans%26aufirst%3DC.%2BP.%26aulast%3DLara%26aufirst%3DP.%2BN.%26atitle%3DRenal%2520cell%2520carcinoma%253A%2520current%2520status%2520and%2520emerging%2520therapies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D299%26epage%3D313%26doi%3D10.1016%2Fj.ctrv.2006.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bycott, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span> <span> </span><span class="NLM_article-title">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa065044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1056%2FNEJMoa065044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17215529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=115-124&author=R.+J.+Motzerauthor=T.+E.+Hutsonauthor=P.+Tomczakauthor=M.+D.+Michaelsonauthor=R.+M.+Bukowskiauthor=O.+Rixeauthor=S.+Oudardauthor=S.+Negrierauthor=C.+Szczylikauthor=S.+T.+Kimauthor=I.+Chenauthor=P.+W.+Bycottauthor=C.+M.+Baumauthor=R.+A.+Figlin&title=Sunitinib+versus+interferon+alfa+in+metastatic+renal-cell+carcinoma&doi=10.1056%2FNEJMoa065044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</span></div><div class="casAuthors">Motzer, J. Robert; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, M. Dror; Bukowski, Ronald M.; Rixe, Olivier; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Kim, Sindy T.; Chen, Isan; Bycott, Paul W.; Baum, Charles M.; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon α in a phase 3 trial is warranted.  We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-wk cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 wk, followed by 2 wk without treatment) or interferon α (at a dose of 9 MU given s.c. 3 times weekly).  The primary end point was progression-free survival.  Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety.  The median progression-free survival was significantly longer in the sunitinib group (11 mo) than in the interferon α group (5 mo), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54).  Sunitinib was also assocd. with a higher objective response rate than was interferon α (31 vs. 6%).  The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon α, whereas diarrhea was more frequent in the sunitinib group.  Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon α group.  Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who receiver sunitinib than in those receiving interferon α (ClinicalTrials.gov nos., NCT00098657 and NCT00083889).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQV3Ir65c7ZrVg90H21EOLACvtfcHk0li1zpRmGMABYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVGqsw%253D%253D&md5=233a6ec74994e3636c6beb2090b94a18</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa065044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa065044%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DRixe%26aufirst%3DO.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBycott%26aufirst%3DP.%2BW.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DSunitinib%2520versus%2520interferon%2520alfa%2520in%2520metastatic%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D115%26epage%3D124%26doi%3D10.1056%2FNEJMoa065044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladkov, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarbá, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R. E.</span></span> <span> </span><span class="NLM_article-title">Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.23.9764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1200%2FJCO.2009.23.9764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=20100962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1061-1068&author=C.+N.+Sternbergauthor=I.+D.+Davisauthor=J.+Mardiakauthor=C.+Szczylikauthor=E.+Leeauthor=J.+Wagstaffauthor=C.+H.+Barriosauthor=P.+Salmanauthor=O.+A.+Gladkovauthor=A.+Kavinaauthor=J.+J.+Zarb%C3%A1author=M.+Chenauthor=L.+McCannauthor=L.+Panditeauthor=D.+F.+Roychowdhuryauthor=R.+E.+Hawkins&title=Pazopanib+in+locally+advanced+or+metastatic+renal+cell+carcinoma%3A+results+of+a+randomized+phase+III+trial&doi=10.1200%2FJCO.2009.23.9764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</span></div><div class="casAuthors">Sternberg, Cora N.; Davis, Ian D.; Mardiak, Jozef; Szczylik, Cezary; Lee, Eunsik; Wagstaff, John; Barrios, Carlos H.; Salman, Pamela; Gladkov, Oleg A.; Kavina, Alexander; Zarba, Juan J.; Chen, Mei; McCann, Lauren; Pandite, Lini; Roychowdhury, Debasish F.; Hawkins, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1061-1068</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit.  This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).  Patients and Methods: Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo.  The primary end point was progression-free survival (PFS).  Secondary end points included overall survival, tumor response rate (Response Evaluation Criteria in Solid Tumors), and safety.  Radiog. assessments of tumors were independently reviewed.  Results: Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%).  PFS was significantly prolonged with pazopanib compared with placebo in the overall study population (median, PFS 9.2 v 4.2 mo; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 mo; HR, 0.40; 95% CI, 0.27 to 0.60; P < .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 mo; HR, 0.54; 95% CI, 0.35 to 0.84; P < .001).  The objective response rate was 30% with pazopanib compared with 3% with placebo (P < .001).  The median duration of response was longer than 1 yr.  The most common adverse events were diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting.  There was no evidence of clin. important differences in quality of life for pazopanib vs. placebo.  Conclusion: Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtrsHw15sJrVg90H21EOLACvtfcHk0liEvjD083x-Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt78%253D&md5=897c2b69e044628115f9d432a5865406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.9764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.9764%26sid%3Dliteratum%253Aachs%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DDavis%26aufirst%3DI.%2BD.%26aulast%3DMardiak%26aufirst%3DJ.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DSalman%26aufirst%3DP.%26aulast%3DGladkov%26aufirst%3DO.%2BA.%26aulast%3DKavina%26aufirst%3DA.%26aulast%3DZarb%25C3%25A1%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DMcCann%26aufirst%3DL.%26aulast%3DPandite%26aufirst%3DL.%26aulast%3DRoychowdhury%26aufirst%3DD.%2BF.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26atitle%3DPazopanib%2520in%2520locally%2520advanced%2520or%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520results%2520of%2520a%2520randomized%2520phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1061%26epage%3D1068%26doi%3D10.1200%2FJCO.2009.23.9764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Pazopanib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1038/nrd3073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1038%2Fnrd3073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=20043026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib&doi=10.1038%2Fnrd3073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib</span></div><div class="casAuthors">Bukowski, Ronald M.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-18</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Oct. 2009, pazopanib (Votrient; GlaxoSmithKline) - a multikinase inhibitor with targets that include vascular endothelial growth factor receptors- was approved by the US FDA for the treatment of advanced renal cell carcinoma.  Pazopanib is an interesting new agent that expands the available therapeutic options for patients with metastatic RCC.  The cooperative groups in the United States and Europe have had limited involvement in the development of this agent, but in the future should be involved in conducting trials such as those mentioned above, not only in the adjuvant setting, but also in patients with advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwntQHZo2xZrVg90H21EOLACvtfcHk0liEvjD083x-Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtbfE&md5=5f62da41556e474cead8e1877f34adc2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3073%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18%26doi%3D10.1038%2Fnrd3073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Négrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehmud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span> <span> </span><span class="NLM_article-title">Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.50.8267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1200%2FJCO.2013.50.8267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=24687826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1412-1418&author=B.+Escudierauthor=C.+Portaauthor=P.+Bonoauthor=T.+Powlesauthor=T.+Eisenauthor=C.+N.+Sternbergauthor=J.+E.+Gschwendauthor=U.+De+Giorgiauthor=O.+Parikhauthor=R.+Hawkinsauthor=E.+Sevinauthor=S.+N%C3%A9grierauthor=S.+Khanauthor=J.+Diazauthor=S.+Redhuauthor=F.+Mehmudauthor=D.+Cella&title=Randomized%2C+controlled%2C+double-blind%2C+cross-over+trial+assessing+treatment+preference+for+pazopanib+versus+sunitinib+in+patients+with+metastatic+renal+cell+carcinoma%3A+PISCES+study&doi=10.1200%2FJCO.2013.50.8267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study</span></div><div class="casAuthors">Escudier, Bernard; Porta, Camillo; Bono, Petri; Powles, Thomas; Eisen, Tim; Sternberg, Cora N.; Gschwend, Juergen E.; De Giorgi, Ugo; Parikh, Omi; Hawkins, Robert; Sevin, Emmanuel; Negrier, Sylvie; Khan, Sadya; Diaz, Jose; Redhu, Suman; Mehmud, Faisal; Cella, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1412-1418</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy.  This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.  Patients and Methods Patients with metastatic RCC were randomly assigned to pazopanib 800 mg per day for 10 wk, a 2-wk washout, and then sunitinib 50 mg per day (4 wk on, 2 wk off, 4 wk on) for 10 wk, or the reverse sequence.  The primary end point, patient preference for a specific treatment, was assessed by questionnaire at the end of the two treatment periods.  Other end points and analyses included reasons for preference, physician preference, safety, and HRQoL.  Results Of 169 randomly assigned patients, 114 met the following prespecified modified intent-to-treat criteria for the primary anal.: exposure to both treatments, no disease progression before cross over, and completion of the preference questionnaire.  Significantly more patients preferred pazopanib (70%) over sunitinib (22%); 8% expressed no preference (P < .001).  All preplanned sensitivity analyses, including the intent-to-treat population, statistically favored pazopanib.  Less fatigue and better overall quality of life were the main reasons for preferring pazopanib, with less diarrhea being the most cited reason for preferring sunitinib.  Physicians also preferred pazopanib (61%) over sunitinib (22%); 17% expressed no preference.  Adverse events were consistent with each drug's known profile.  Pazopanib was superior to sunitinib in HRQoL measures evaluating fatigue, hand/ft soreness, and mouth/throat soreness.  Conclusion This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHJKB0Uc6j-7Vg90H21EOLACvtfcHk0lhm9yB7-U7hoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsbvK&md5=1c272883dd8e81fa6b567f1a1bf2557a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.50.8267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.50.8267%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBono%26aufirst%3DP.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DDe%2BGiorgi%26aufirst%3DU.%26aulast%3DParikh%26aufirst%3DO.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DSevin%26aufirst%3DE.%26aulast%3DN%25C3%25A9grier%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DJ.%26aulast%3DRedhu%26aufirst%3DS.%26aulast%3DMehmud%26aufirst%3DF.%26aulast%3DCella%26aufirst%3DD.%26atitle%3DRandomized%252C%2520controlled%252C%2520double-blind%252C%2520cross-over%2520trial%2520assessing%2520treatment%2520preference%2520for%2520pazopanib%2520versus%2520sunitinib%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520PISCES%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D1412%26epage%3D1418%26doi%3D10.1200%2FJCO.2013.50.8267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span> <span> </span><span class="NLM_article-title">Risk of tyrosine kinase inhibitors induced hepatotoxicity in cancer patients: A meta-analysis</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.ctrv.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=23099278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=199-206&author=Y.+L.+Teoauthor=H.+K.+Hoauthor=A.+Chan&title=Risk+of+tyrosine+kinase+inhibitors+induced+hepatotoxicity+in+cancer+patients%3A+A+meta-analysis&doi=10.1016%2Fj.ctrv.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis</span></div><div class="casAuthors">Teo, Yi Ling; Ho, Han Kiat; Chan, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-206</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although existing evidence from clin. trials has demonstrated manifestation of hepatic adverse events (AEs) with the use of tyrosine kinase inhibitors (TKIs), overall risks have yet to be reported.  Thus we conducted a meta-anal. to det. the risk of hepatotoxicity assocd. with the use of TKIs, by comparing the occurrence of hepatotoxicity of the TKI arms against that of comparison arms.  A comprehensive literature search of randomized control trials involving TKIs was performed.  Only randomized, double-blind and placebo-controlled phase 2 or phase 3 human trials were included.  The included studies must involve the comparison of a TKI against placebo, or the comparison of TKI with chemotherapy agent against placebo with the same chemotherapy agent.  Twelve articles were included in the anal.  There was a significant overall increase in the odds of developing high-grade (grade 3 or above) hepatotoxicity with the use of TKIs compared to the control arms (Pooled OR 4.35, 95% CI 2.96-6.39).  The odds of developing all-types all-grades (Pooled OR 2.42, 95% CI 1.52-3.85) and high-grade hepatotoxicity due to elevation in alanine transaminase (Pooled OR 5.22, 95% CI 2.88-9.46), aspartate transaminase (Pooled OR 6.15, 95% CI 3.09-12.25) and total bilirubin (Pooled OR 1.76, 95% CI 0.59-5.24) was higher with the use of TKI than compared to the controls.  This is the first meta-anal. to demonstrate a significantly increased risk of hepatic AEs assocd. with TKIs use.  Clinicians should be aware of this risk and provide close monitoring in patients receiving these therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nrZOhsLGibVg90H21EOLACvtfcHk0lhm9yB7-U7hoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKns7jE&md5=08b21a0b9571df06b1af1f7ac2e44cf4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DY.%2BL.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DA.%26atitle%3DRisk%2520of%2520tyrosine%2520kinase%2520inhibitors%2520induced%2520hepatotoxicity%2520in%2520cancer%2520patients%253A%2520A%2520meta-analysis%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26spage%3D199%26epage%3D206%26doi%3D10.1016%2Fj.ctrv.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1007/s40264-013-0048-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1007%2Fs40264-013-0048-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=23620168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=491-503&author=R.+R.+Shahauthor=J.+Morganrothauthor=D.+R.+Shah&title=Hepatotoxicity+of+tyrosine+kinase+inhibitors%3A+clinical+and+regulatory+perspectives&doi=10.1007%2Fs40264-013-0048-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives</span></div><div class="casAuthors">Shah, Rashmi R.; Morganroth, Joel; Shah, Devron R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">491-503</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The introduction of small-mol. tyrosine kinase inhibitors (TKIs) in clin. oncol. has transformed the treatment of certain forms of cancers.  As of 31 March 2013, 18 such agents have been approved by the US Food and Drug Administration (FDA), 15 of these also by the European Medicines Agency (EMA), and a large no. of others are in development or under regulatory review.  Unexpectedly, however, their use has been found to be assocd. with serious toxic effects on a no. of vital organs including the liver.  Drug-induced hepatotoxicity has resulted in withdrawal from the market of many widely used drugs and is a major public health issue that continues to concern all the stakeholders.  This review focuses on hepatotoxic potential of TKIs.  The majority of TKIs approved to date are reported to induce hepatic injury.  Five of these (lapatinib, pazopanib, ponatinib, regorafenib and sunitinib) are sufficiently potent in this respect as to require a boxed label warning.  Onset of TKI-induced hepatotoxicity is usually within the first 2 mo of initiating treatment, but may be delayed, and is usually reversible.  Fatality from TKI-induced hepatotoxicity is uncommon compared to hepatotoxic drugs in other classes but may lead to long-term consequences such as cirrhosis.  Patients should be carefully monitored for TKI-induced hepatotoxicity, the management of which requires individually tailored reappraisal of the risk/benefit.  The risk is usually manageable by dose adjustment or a switch to a suitable alternative TKI.  Confirmation of TKI-induced hepatotoxicity can present challenges in the presence of hepatic metastasis and potential drug interactions.  Its diagnosis in a patient with TKI-sensitive cancer requires great care if therapy with the TKI suspected to be causal is to be modified or interrupted as a result.  Post-marketing experience with drugs such as imatinib, lapatinib and sorafenib suggests that the hepatotoxic safety of all the TKIs requires diligent surveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDb6HewTRrILVg90H21EOLACvtfcHk0lhm9yB7-U7hoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsLzO&md5=60d4c1d12c2085cdd88b984c56a18a0c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40264-013-0048-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-013-0048-4%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DMorganroth%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DD.%2BR.%26atitle%3DHepatotoxicity%2520of%2520tyrosine%2520kinase%2520inhibitors%253A%2520clinical%2520and%2520regulatory%2520perspectives%26jtitle%3DDrug%2520Saf.%26date%3D2013%26volume%3D36%26spage%3D491%26epage%3D503%26doi%3D10.1007%2Fs40264-013-0048-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramchandani, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbois, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidambaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahjoob, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1373</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-2328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1158%2F1078-0432.CCR-06-2328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17332278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1367-1373&author=V.+L.+Goodmanauthor=E.+P.+Rockauthor=R.+Dagherauthor=R.+P.+Ramchandaniauthor=S.+Abrahamauthor=J.+V.+S.+Gobburuauthor=B.+P.+Boothauthor=S.+L.+Verboisauthor=D.+E.+Morseauthor=C.+Y.+Liangauthor=N.+Chidambaramauthor=J.+X.+Jiangauthor=S.+Tangauthor=K.+Mahjoobauthor=R.+Justiceauthor=R.+Pazdur&title=Approval+summary%3A+sunitinib+for+the+treatment+of+imatinib+refractory+or+intolerant+gastrointestinal+stromal+tumors+and+advanced+renal+cell+carcinoma&doi=10.1158%2F1078-0432.CCR-06-2328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma</span></div><div class="casAuthors">Goodman, Vicki L.; Rock, Edwin P.; Dagher, Ramzi; Ramchandani, Roshni P.; Abraham, Sophia; Gobburu, Jogarao V. S.; Booth, Brian P.; Verbois, S. Leigh; Morse, David E.; Liang, Cheng Yi; Chidambaram, Nallaperumal; Jiang, Janet X.; Tang, Shenghui; Mahjoob, Kooros; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1367-1373</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent).  Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate (Gleevec).  Addnl., sunitinib received accelerated approval for the treatment of advanced renal cell carcinoma.  Exptl. Design: For the GIST indication, FDA reviewed data from a randomized, placebo-controlled trial with supportive evidence from a single-arm study.  For the advanced renal cell carcinoma indication, FDA reviewed data from two single-arm studies of patients with cytokine-refractory metastatic renal cell carcinoma.  Results: In patients with imatinib refractory or intolerant GIST, time-to-tumor progression of sunitinib-treated patients was superior to that of placebo-treated patients.  Median time-to-tumor progression of sunitinib-treated patients was 27.3 wk, compared with 6.4 wk for placebo-treated patients (P < 0.0001).  Partial responses were obsd. in 6.8% of sunitinib-treated patients.  In patients with metastatic renal cell carcinoma, partial responses were obsd. in 25.5% (95% confidence interval, 17.5, 34.9) and 36.5% (95% confidence interval, 24.7, 49.6) of patients treated with sunitinib. Median response durations were 27.1 and 54 wk.  The most common adverse events attributed to sunitinib included diarrhea, mucositis, skin abnormalities, and altered taste.  Redns. in left ventricular ejection fraction and severe hypertension were also more common in sunitinib-treated patients.  Conclusions: On Jan. 26, 2006, the FDA approved sunitinib for the treatment of patients with imatinib refractory or intolerant GIST.  Accelerated approval was granted for the treatment of advanced renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXuKPm_-9xrVg90H21EOLACvtfcHk0liA2bLm1wul5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjsbc%253D&md5=baa2be61674d19588b831222672f13f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2328%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DV.%2BL.%26aulast%3DRock%26aufirst%3DE.%2BP.%26aulast%3DDagher%26aufirst%3DR.%26aulast%3DRamchandani%26aufirst%3DR.%2BP.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DGobburu%26aufirst%3DJ.%2BV.%2BS.%26aulast%3DBooth%26aufirst%3DB.%2BP.%26aulast%3DVerbois%26aufirst%3DS.%2BL.%26aulast%3DMorse%26aufirst%3DD.%2BE.%26aulast%3DLiang%26aufirst%3DC.%2BY.%26aulast%3DChidambaram%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%2BX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DMahjoob%26aufirst%3DK.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520imatinib%2520refractory%2520or%2520intolerant%2520gastrointestinal%2520stromal%2520tumors%2520and%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1367%26epage%3D1373%26doi%3D10.1158%2F1078-0432.CCR-06-2328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sychterz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttle, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bershas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negash, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorycki, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. Y. K.</span></span> <span> </span><span class="NLM_article-title">Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.734642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.3109%2F00498254.2012.734642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=443-453&author=Y.+Dengauthor=C.+Sychterzauthor=A.+B.+Suttleauthor=M.+M.+Darauthor=D.+Bershasauthor=K.+Negashauthor=Y.+Qianauthor=E.+P.+Chenauthor=P.+D.+Goryckiauthor=M.+Y.+K.+Ho&title=Bioavailability%2C+metabolism+and+disposition+of+oral+pazopanib+in+patients+with+advanced+cancer&doi=10.3109%2F00498254.2012.734642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.734642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.734642%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DSychterz%26aufirst%3DC.%26aulast%3DSuttle%26aufirst%3DA.%2BB.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DBershas%26aufirst%3DD.%26aulast%3DNegash%26aufirst%3DK.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DE.%2BP.%26aulast%3DGorycki%26aufirst%3DP.%2BD.%26aulast%3DHo%26aufirst%3DM.%2BY.%2BK.%26atitle%3DBioavailability%252C%2520metabolism%2520and%2520disposition%2520of%2520oral%2520pazopanib%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26spage%3D443%26epage%3D453%26doi%3D10.3109%2F00498254.2012.734642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pool, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patyna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, distribution, and metabolism of [<sup>14</sup>C]sunitinib in rats, monkeys, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.042853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.111.042853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=539-555&author=B.+Speedauthor=H.-Z.+Buauthor=W.+F.+Poolauthor=G.+W.+Pengauthor=E.+Y.+Wuauthor=S.+Patynaauthor=C.+Belloauthor=P.+Kang&title=Pharmacokinetics%2C+distribution%2C+and+metabolism+of+%5B14C%5Dsunitinib+in+rats%2C+monkeys%2C+and+humans&doi=10.1124%2Fdmd.111.042853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.042853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.042853%26sid%3Dliteratum%253Aachs%26aulast%3DSpeed%26aufirst%3DB.%26aulast%3DBu%26aufirst%3DH.-Z.%26aulast%3DPool%26aufirst%3DW.%2BF.%26aulast%3DPeng%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DPatyna%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%26aulast%3DKang%26aufirst%3DP.%26atitle%3DPharmacokinetics%252C%2520distribution%252C%2520and%2520metabolism%2520of%2520%255B14C%255Dsunitinib%2520in%2520rats%252C%2520monkeys%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D539%26epage%3D555%26doi%3D10.1124%2Fdmd.111.042853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolites: current and emerging risk and hazard assessments</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00410</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00410" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=505-533&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=M.+O.+Ogeseauthor=J.+T.+Mettetalauthor=D.+P.+Williams&title=Reactive+metabolites%3A+current+and+emerging+risk+and+hazard+assessments&doi=10.1021%2Facs.chemrestox.5b00410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites: Current and Emerging Risk and Hazard Assessments</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Ogese, Monday O.; Mettetal, Jerome T.; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-533</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although idiosyncratic adverse drug reactions are rare, they are still a major concern to patient safety.  Reactive metabolites are widely accepted as playing a pivotal role in the pathogenesis of idiosyncratic adverse drug reactions.  While there are today well established strategies for the risk assessment of stable metabolites within the pharmaceutical industry, there is still no consensus on reactive metabolite risk assessment strategies.  This is due to the complexity of the mechanisms of these toxicities as well as the difficulty in identifying and quantifying short-lived reactive intermediates such as reactive metabolites.  In this review, reactive metabolite risk and hazard assessment approaches are discussed, and their pros and cons highlighted.  We also discuss the nature of idiosyncratic adverse drug reactions, using acetaminophen and nefazodone to exemplify the complexity of the underlying mechanisms of reactive metabolite mediated hepatotoxicity.  One of the key gaps moving forward is our understanding of and ability to predict the contribution of immune activation in idiosyncratic adverse drug reactions.  Sections are included on the clin. phenotypes of immune mediated idiosyncratic adverse drug reactions and on the present understanding of immune activation by reactive metabolites.  The advances being made in microphysiol. systems have a great potential to transform our ability to risk assess reactive metabolites, and an overview of the key components of these systems is presented.  Finally, the potential impact of systems pharmacol. approaches in reactive metabolite risk assessments is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplG7NDjykn-LVg90H21EOLACvtfcHk0liA2bLm1wul5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGnsro%253D&md5=36555d129e1c4667386d6ccced440e7f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00410%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DReactive%2520metabolites%253A%2520current%2520and%2520emerging%2520risk%2520and%2520hazard%2520assessments%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D505%26epage%3D533%26doi%3D10.1021%2Facs.chemrestox.5b00410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of ketene-reactive intermediate of erlotinib. Possibly responsible for inactivation of P450 enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&author=H.+Zhaoauthor=S.+Liauthor=Z.+Yangauthor=Y.+Pengauthor=X.+Chenauthor=J.+Zheng&title=Identification+of+ketene-reactive+intermediate+of+erlotinib.+Possibly+responsible+for+inactivation+of+P450+enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520ketene-reactive%2520intermediate%2520of%2520erlotinib.%2520Possibly%2520responsible%2520for%2520inactivation%2520of%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span>; <span class="NLM_string-name">Robert, A.</span>; <span class="NLM_string-name">Pratviel, G.</span>; <span class="NLM_string-name">Bernadou, J.</span></span> <span> </span><span class="NLM_article-title">Metalloporphyrins in catalytic oxidations and oxidative DNA cleavage</span>. In  <i>The Porphyrin Handbook</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Kadish, K. M.</span>, <span class="NLM_string-name">Smith, K. M.</span>, <span class="NLM_string-name">Guilard, R.</span></span>, Eds; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2000</span>, Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">187</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=119-187&author=B.+Meunier&author=A.+Robert&author=G.+Pratviel&author=J.+Bernadouauthor=K.+M.+Kadish&author=K.+M.+Smith&author=R.+Guilard&title=The+Porphyrin+Handbook"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DMetalloporphyrins%2520in%2520catalytic%2520oxidations%2520and%2520oxidative%2520DNA%2520cleavage%26btitle%3DThe%2520Porphyrin%2520Handbook%26aulast%3DKadish%26aufirst%3DK.%2BM.%26pub%3DAcademic%2520Press%26date%3D2000%26volume%3D4%26spage%3D119%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3980</span>, <span class="refDoi"> DOI: 10.1021/cr020443g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr020443g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=3947-3980&author=B.+Meunierauthor=S.+P.+de+Visserauthor=S.+Shaik&title=Mechanism+of+oxidation+reactions+catalyzed+by+cytochrome+P450+enzymes&doi=10.1021%2Fcr020443g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes</span></div><div class="casAuthors">Meunier, Bernard; de Visser, Samueel P.; Shaik, Sason</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3947-3980</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The exact nature of the active species in cytochrome P 450 enzymes (the putative high-valent iron-oxo intermediate) is still a matter of intensive debates.  Site-directed mutagenesis studies in conjunction with structural studies allowed different hypotheses to be checked.  Theor. calcns. became available and enabled various hypotheses to be tested and new solns. to be offered.  All these studies have enriched the knowledge on mol. enzymol. and the coordination chem. of metal-peroxo and high-valent metal-oxo species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR8qIfDs6uAbVg90H21EOLACvtfcHk0ljl-nWBHUsF4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVejtr8%253D&md5=d10f62537d0af7d3895217ee91a5119b</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fcr020443g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr020443g%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DB.%26aulast%3Dde%2BVisser%26aufirst%3DS.%2BP.%26aulast%3DShaik%26aufirst%3DS.%26atitle%3DMechanism%2520of%2520oxidation%2520reactions%2520catalyzed%2520by%2520cytochrome%2520P450%2520enzymes%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D3947%26epage%3D3980%26doi%3D10.1021%2Fcr020443g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Oxygen activation and radical transformations in heme proteins and metalloporphyrins</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2491</span>– <span class="NLM_lpage">2553</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC1cXk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=2491-2553&author=X.+Huangauthor=J.+T.+Groves&title=Oxygen+activation+and+radical+transformations+in+heme+proteins+and+metalloporphyrins&doi=10.1021%2Facs.chemrev.7b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen Activation and Radical Transformations in Heme Proteins and Metalloporphyrins</span></div><div class="casAuthors">Huang, Xiongyi; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2491-2553</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a result of the adaptation of life to an aerobic environment, nature has evolved a panoply of metalloproteins for oxidative metab. and protection against reactive oxygen species.  Despite the diverse structures and functions of these proteins, they share common mechanistic grounds.  An open-shell transition metal like iron or copper is employed to interact with O2 and its derived intermediates such as hydrogen peroxide to afford a variety of metal-oxygen intermediates.  These reactive intermediates, including metal-superoxo, -(hydro)peroxo, and high-valent metal-oxo species, are the basis for the various biol. functions of O2-utilizing metalloproteins.  Collectively, these processes are called oxygen activation.  Much of our understanding of the reactivity of these reactive intermediates has come from the study of heme-contg. proteins and related metalloporphyrin compds.  These studies have not only deepened our understanding of various functions of heme proteins such as O2 storage and transport, degrdn. of reactive oxygen species, redox signaling and biol. oxygenation, etc., but have also driven the development of bioinorg. chem. and biomimetic catalysis.  In this review, we survey the range of O2 activation processes mediated by heme proteins and model compds. with a focus on recent progress in the characterization and reactivity of important iron-oxygen intermediates.  Representative reactions initiated by these reactive intermediates as well as some context from prior decades will also be presented.  We will discuss the fundamental mechanistic features of these transformations and delineate the underlying structural and electronic factors that contribute to the spectrum of reactivities that has been obsd. in nature as well as those that have been invented using these paradigms.  Given the recent developments in biocatalysis for non-natural chemistries and the renaissance of radical chem. in org. synthesis, we envision that new enzymic and synthetic transformations will emerge based on the radical processes mediated by metalloproteins and their synthetic analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0oXolZg6abVg90H21EOLACvtfcHk0ljl-nWBHUsF4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXk&md5=284bf769bb4b83373ee7e10bb2f44bfa</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00373%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DOxygen%2520activation%2520and%2520radical%2520transformations%2520in%2520heme%2520proteins%2520and%2520metalloporphyrins%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26spage%3D2491%26epage%3D2553%26doi%3D10.1021%2Facs.chemrev.7b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Biomimetic chemical catalysts in the oxidative activation of drugs</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1002/adsc.200303191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1002%2Fadsc.200303191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ensb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2004&pages=171-184&author=J.+Bernadouauthor=B.+Meunier&title=Biomimetic+chemical+catalysts+in+the+oxidative+activation+of+drugs&doi=10.1002%2Fadsc.200303191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic chemical catalysts in the oxidative activation of drugs</span></div><div class="casAuthors">Bernadou, Jean; Meunier, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2+3</span>),
    <span class="NLM_cas:pages">171-184</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  An overview of the biomimetic catalysts used in the oxidative activation of drugs is given, with an emphasis on the use of synthetic metalloporphyrins as models of cytochrome P 450 to mimic the in vivo metab. of pharmaceuticals.  In addn., a special focus is directed towards the recent results from the authors' group on the oxidative activation of isoniazid, an antitubercular drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeyVJ-gPZePrVg90H21EOLACvtfcHk0ljl-nWBHUsF4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ensb0%253D&md5=f42510049c4ee8e0a498d9d2028cf6ed</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200303191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200303191%26sid%3Dliteratum%253Aachs%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DBiomimetic%2520chemical%2520catalysts%2520in%2520the%2520oxidative%2520activation%2520of%2520drugs%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2004%26volume%3D346%26spage%3D171%26epage%3D184%26doi%3D10.1002%2Fadsc.200303191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnafous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defrance, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Model systems for oxidative drug-metabolism studies - Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">817</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1993&pages=811-817&author=M.+Vidalauthor=M.+Bonnafousauthor=S.+Defranceauthor=P.+Loiseauauthor=J.+Bernadouauthor=B.+Meunier&title=Model+systems+for+oxidative+drug-metabolism+studies+-+Catalytic+behavior+of+water-soluble+metalloporphyrins+depends+on+both+the+intrinsic+robustness+of+the+catalyst+and+the+nature+of+substrates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVidal%26aufirst%3DM.%26aulast%3DBonnafous%26aufirst%3DM.%26aulast%3DDefrance%26aufirst%3DS.%26aulast%3DLoiseau%26aufirst%3DP.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DModel%2520systems%2520for%2520oxidative%2520drug-metabolism%2520studies%2520-%2520Catalytic%2520behavior%2520of%2520water-soluble%2520metalloporphyrins%2520depends%2520on%2520both%2520the%2520intrinsic%2520robustness%2520of%2520the%2520catalyst%2520and%2520the%2520nature%2520of%2520substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1993%26volume%3D21%26spage%3D811%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaggero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Oxidation of SR 48117, an antagonist of vasopressin V<sub>1a</sub> receptors, by biomimetic catalysts based on metalloporphyrin or Schiff-base complexes</span>. <i>Bull. Soc. Chim. Fr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1994&pages=706-712&author=N.+Gaggeroauthor=A.+Robertauthor=J.+Bernadouauthor=B.+Meunier&title=Oxidation+of+SR+48117%2C+an+antagonist+of+vasopressin+V1a+receptors%2C+by+biomimetic+catalysts+based+on+metalloporphyrin+or+Schiff-base+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaggero%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DOxidation%2520of%2520SR%252048117%252C%2520an%2520antagonist%2520of%2520vasopressin%2520V1a%2520receptors%252C%2520by%2520biomimetic%2520catalysts%2520based%2520on%2520metalloporphyrin%2520or%2520Schiff-base%2520complexes%26jtitle%3DBull.%2520Soc.%2520Chim.%2520Fr.%26date%3D1994%26volume%3D131%26spage%3D706%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasseur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratviel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span> <span> </span><span class="NLM_article-title">Metalloporphyrin-catalyzed hydroxylation of the <i>N,N</i>-dimethylamide function of the drug molecule SSR180575 to a stable <i>N</i>-methyl-<i>N</i>-carbinolamide</span>. <i>C. R. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1016/j.crci.2013.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.crci.2013.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1002-1007&author=I.+Nicolasauthor=C.+Bijaniauthor=D.+Brasseurauthor=G.+Pratvielauthor=J.+Bernadouauthor=A.+Robert&title=Metalloporphyrin-catalyzed+hydroxylation+of+the+N%2CN-dimethylamide+function+of+the+drug+molecule+SSR180575+to+a+stable+N-methyl-N-carbinolamide&doi=10.1016%2Fj.crci.2013.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Metalloporphyrin-catalyzed hydroxylation of the N,N-dimethylamide function of the drug molecule SSR180575 to a stable N-methyl-N-carbinolamide</span></div><div class="casAuthors">Nicolas, Irene; Bijani, Christian; Brasseur, Denis; Pratviel, Genevieve; Bernadou, Jean; Robert, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus Chimie</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1002-1007</span>CODEN:
                <span class="NLM_cas:coden">CRCOCR</span>;
        ISSN:<span class="NLM_cas:issn">1631-0748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The metalloporphyrin-catalyzed oxidn. of SSR180575, a ligand of the peripheral benzodiazepine receptor, that contains both N-methylindole and N,N-dimethylamide functions, produces a high yield of a stable carbinolamide deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo10tvMKPP947Vg90H21EOLACvtfcHk0lhyDlmKLRSVqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrur3N&md5=2476231a9f626996224aaea070ed7b84</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.crci.2013.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crci.2013.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas%26aufirst%3DI.%26aulast%3DBijani%26aufirst%3DC.%26aulast%3DBrasseur%26aufirst%3DD.%26aulast%3DPratviel%26aufirst%3DG.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DRobert%26aufirst%3DA.%26atitle%3DMetalloporphyrin-catalyzed%2520hydroxylation%2520of%2520the%2520N%252CN-dimethylamide%2520function%2520of%2520the%2520drug%2520molecule%2520SSR180575%2520to%2520a%2520stable%2520N-methyl-N-carbinolamide%26jtitle%3DC.%2520R.%2520Chim.%26date%3D2013%26volume%3D16%26spage%3D1002%26epage%3D1007%26doi%3D10.1016%2Fj.crci.2013.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolman, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, U. E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltier, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, A.</span></span> <span> </span><span class="NLM_article-title">Emerging technologies for metabolite generation and structural diversification</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5483</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.bmcl.2013.08.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5471-5483&author=K.+P.+Cusackauthor=H.+F.+Koolmanauthor=U.+E.+W.+Langeauthor=H.+M.+Peltierauthor=I.+Pielauthor=A.+Vasudevan&title=Emerging+technologies+for+metabolite+generation+and+structural+diversification&doi=10.1016%2Fj.bmcl.2013.08.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DKoolman%26aufirst%3DH.%2BF.%26aulast%3DLange%26aufirst%3DU.%2BE.%2BW.%26aulast%3DPeltier%26aufirst%3DH.%2BM.%26aulast%3DPiel%26aufirst%3DI.%26aulast%3DVasudevan%26aufirst%3DA.%26atitle%3DEmerging%2520technologies%2520for%2520metabolite%2520generation%2520and%2520structural%2520diversification%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5471%26epage%3D5483%26doi%3D10.1016%2Fj.bmcl.2013.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, N.</span></span> <span> </span><span class="NLM_article-title">High-performance liquid chromatographic method for determination of reversible isomers of SU5416</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1110</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2006.01.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.chroma.2006.01.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1110&publication_year=2006&pages=73-80&author=A.+Sistlaauthor=W.+L.+Yangauthor=N.+Shenoy&title=High-performance+liquid+chromatographic+method+for+determination+of+reversible+isomers+of+SU5416&doi=10.1016%2Fj.chroma.2006.01.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2006.01.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2006.01.079%26sid%3Dliteratum%253Aachs%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DW.%2BL.%26aulast%3DShenoy%26aufirst%3DN.%26atitle%3DHigh-performance%2520liquid%2520chromatographic%2520method%2520for%2520determination%2520of%2520reversible%2520isomers%2520of%2520SU5416%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2006%26volume%3D1110%26spage%3D73%26epage%3D80%26doi%3D10.1016%2Fj.chroma.2006.01.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalariya, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talluri, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gananadhamu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silicotoxicity prediction</span>. <i>J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1002/jms.3602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1002%2Fjms.3602" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2015&pages=918-928&author=P.+N.+Patelauthor=P.+D.+Kalariyaauthor=M.+Sharmaauthor=P.+Gargauthor=M.+V.+Talluriauthor=S.+Gananadhamuauthor=R.+Srinivas&title=Characterization+of+forced+degradation+products+of+pazopanib+hydrochloride+by+UHPLC-Q-TOF%2FMS+and+in+silicotoxicity+prediction&doi=10.1002%2Fjms.3602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjms.3602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjms.3602%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BN.%26aulast%3DKalariya%26aufirst%3DP.%2BD.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DTalluri%26aufirst%3DM.%2BV.%26aulast%3DGananadhamu%26aufirst%3DS.%26aulast%3DSrinivas%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520forced%2520degradation%2520products%2520of%2520pazopanib%2520hydrochloride%2520by%2520UHPLC-Q-TOF%252FMS%2520and%2520in%2520silicotoxicity%2520prediction%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2015%26volume%3D50%26spage%3D918%26epage%3D928%26doi%3D10.1002%2Fjms.3602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claparols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">The antimalarial drug artemisinin alkylates heme in infected mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">13676</span>– <span class="NLM_lpage">13680</span>, <span class="refDoi"> DOI: 10.1073/pnas.0500972102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1073%2Fpnas.0500972102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=16155128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=13676-13680&author=A.+Robertauthor=F.+Benoit-Vicalauthor=C.+Claparolsauthor=B.+Meunier&title=The+antimalarial+drug+artemisinin+alkylates+heme+in+infected+mice&doi=10.1073%2Fpnas.0500972102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The antimalarial drug artemisinin alkylates heme in infected mice</span></div><div class="casAuthors">Robert, Anne; Benoit-Vical, Francoise; Claparols, Catherine; Meunier, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13676-13680</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heme alkylation by the antimalarial drug artemisinin is reported in vivo, within infected mice that have been treated at pharmacol. relevant doses.  Adducts resulting from the alkylation of heme by the drug were characterized in the spleen of treated mice, and their glucuroconjugated derivs. were present in the urine.  Because these heme-artemisinin adducts were not obsd. in noninfected mice, this report confirms that the alkylating activity of this antimalarial drug is related to the presence of the parasite in infected animals.  The identification of heme-artemisinin adducts in mice should be considered as the signature of the alkylation capacity of artemisinin in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYd5mkEcJobVg90H21EOLACvtfcHk0lhsva66oqG6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrzJ&md5=e86b8627e9bc341cddce3de8a64e8614</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0500972102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0500972102%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DClaparols%26aufirst%3DC.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DThe%2520antimalarial%2520drug%2520artemisinin%2520alkylates%2520heme%2520in%2520infected%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D13676%26epage%3D13680%26doi%3D10.1073%2Fpnas.0500972102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.-K.</span></span> <span> </span><span class="NLM_article-title">Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s13318-015-0252-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1007%2Fs13318-015-0252-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=25737032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=465-468&author=X.-J.+Liuauthor=H.+Luauthor=J.-X.+Sunauthor=S.-R.+Wangauthor=Y.-S.+Moauthor=X.-S.+Yangauthor=B.-K.+Shi&title=Metabolic+behavior+prediction+of+pazopanib+by+cytochrome+P450+%28CYP%29+3A4+by+molecular+docking&doi=10.1007%2Fs13318-015-0252-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking</span></div><div class="casAuthors">Liu, Xing-Jie; Lu, Hua; Sun, Ju-Xiang; Wang, Su-Rong; Mo, Yan-Shuai; Yang, Xing-Sheng; Shi, Ben-Kang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Metab.-mediated drug adverse effects (e.g., drug-drug interaction, bioactivation, etc.) strongly limit the utilization of clin. drugs.  The present study aims to predict the metabolic capability of cytochrome P 450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers esp. for ovarian cancer.  Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was Me group located besides nitrogen in the five-membered ring.  The distance between the hydrogen atom in Me group and active center is 3.64 Å.  The interaction amino acid is Glu374.  Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential.  The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metab. of pazopanib.  All these data were helpful for the clin. application of pazopanib, and R&D of other tinib drug candidates as new anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yVM7aEyvKrVg90H21EOLACvtfcHk0lhsva66oqG6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCqtbo%253D&md5=b77a2066f132f458faf21b65aa8b2bf9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs13318-015-0252-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-015-0252-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.-J.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.-X.%26aulast%3DWang%26aufirst%3DS.-R.%26aulast%3DMo%26aufirst%3DY.-S.%26aulast%3DYang%26aufirst%3DX.-S.%26aulast%3DShi%26aufirst%3DB.-K.%26atitle%3DMetabolic%2520behavior%2520prediction%2520of%2520pazopanib%2520by%2520cytochrome%2520P450%2520%2528CYP%2529%25203A4%2520by%2520molecular%2520docking%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2016%26volume%3D41%26spage%3D465%26epage%3D468%26doi%3D10.1007%2Fs13318-015-0252-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.bcp.2015.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=26212543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=111-121&author=X.+Liuauthor=Y.+Luauthor=X.+Guanauthor=D.+Dongauthor=H.+Chavanauthor=J.+Wangauthor=Y.+Zhangauthor=P.+Krishnamurthyauthor=F.+Li&title=Metabolomics+reveals+the+formation+of+aldehydes+and+iminium+in+gefitinib+metabolism&doi=10.1016%2Fj.bcp.2015.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism</span></div><div class="casAuthors">Liu, Xing; Lu, Yuanfu; Guan, Xinfu; Dong, Bingning; Chavan, Hemantkumar; Wang, Jin; Zhang, Yiqing; Krishnamurthy, Partha; Li, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gefitinib (GEF), an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, is widely used for the treatment of cancers, particularly non-small cell lung cancer.  However, its clin. use is limited by multiple adverse effects assocd. with GEF, such as liver and lung injuries, severe nausea, and diarrhea.  Although, the exact mechanism of GEF adverse effects are still unknown, xenobiotic-induced bioactivation is thought to play a significant role in GEF induced toxicity.  Using a metabolomic approach, we investigated the metabolic pathways of GEF in human and mouse liver microsomes.  Thirty four GEF metabolites and adducts were identified and half of them are novel.  The potential reactive metabolites, two aldehydes and one iminium, were identified for the first time.  The previously reported GSH adducts and primary amines were obsd. as well.  The aldehyde and iminium pathways were further confirmed by using methoxylamine and potassium cyanide as trapping reagents.  Using recombinant CYP450 isoforms, CYP3A4 inhibitor, and S9 from Cyp3a-null mice, we confirmed CYP3A is the major enzyme contributing to the formation of aldehydes, GSH adducts, and primary amines in liver.  Multiple enzymes contribute to the formation of iminium.  This study provided us more knowledge of GEF bioactivation and enzymes involved in metabolic pathways, which can be utilized for understanding the mechanism of adverse effects assocd. with GEF and predicting possible drug-drug interactions.  Further studies are suggested to det. the roles of these bioactivation pathways in GEF toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrViZ82Ih6lArVg90H21EOLACvtfcHk0lhsva66oqG6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chsb7M&md5=f95cbe2470bb41319e9e0fd1b5c3e25c</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DD.%26aulast%3DChavan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DF.%26atitle%3DMetabolomics%2520reveals%2520the%2520formation%2520of%2520aldehydes%2520and%2520iminium%2520in%2520gefitinib%2520metabolism%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D97%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.bcp.2015.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Attwa, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrabiah, H.</span></span> <span> </span><span class="NLM_article-title">A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: application to metabolic stability investigation and excretion rate</span>. <i>Eur. J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">344</span>, <span class="refDoi"> DOI: 10.1177/1469066718768327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1177%2F1469066718768327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=29629565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A280%3ADC%252BC1MjgtFCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=344&author=M.+W.+Attwaauthor=A.+A.+Kadiauthor=H.+W.+Darwishauthor=S.+M.+Amerauthor=H.+Alrabiah&title=A+reliable+and+stable+method+for+the+determination+of+foretinib+in+human+plasma+by+LC-MS%2FMS%3A+application+to+metabolic+stability+investigation+and+excretion+rate&doi=10.1177%2F1469066718768327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate</span></div><div class="casAuthors">Attwa Mohamed W; Kadi Adnan A; Darwish Hany W; Alrabiah Haitham; Darwish Hany W; Amer Sawsan M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of mass spectrometry (Chichester, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">344-351</span>
        ISSN:<span class="NLM_cas:issn">1469-0667</span>.
    </div><div class="casAbstract">Foretinib (GSK1363089) is a multiple receptor tyrosine kinases inhibitor.  In this study, a reliable, fast liquid chromatography-tandem mass spectrometric method was described for assaying foretinib in plasma, urine, and rat liver microsome samples.  Simple extraction procedure by protein preciptation with acetonitrile was implemented for foretinib and brigatinib (internal standard) analysis.  Chromatographic resolution of analytes was achieved on C18 column with the help of isocratic mobile phase.  The binary mobile phase consisted of 60% ammonium formate (10 mM, pH 4.2) and 40% acetonitrile at a flow rate of 0.25 mL/min.  Run time was 3 min, and both foretinib and brigatinib were eluted within 0.74 and 1.95 min; they were detected in positive ion mode utilizing multiple reactions monitoring mode.  Linearity of the proposed method ranged from 5 to 500 ng/mL (r(2 )≥ 0.9993) in the human plasma.  Lower limit of quantification and detection were 6.0 and 1.8 ng/mL, respectively.  Intraday and interday precision and accuracy were 0.16 to 1.67 % and -2.39 to -0.52 %.  In vitro half-life and intrinsic clearance were 24.93 min and 6.56 mL/min/kg, respectively.  Literature review showed that no previous studies have been proposed for the analytical quantification of foretinib in human plasma or its metabolic stability.  The established method was also applied to estimate the rate of foretinib excretion in rat urine.  The developed method can be used for foretinib pharmacokinetic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR88i1cxfWsWIkFb3mqPUYDfW6udTcc2ea-6bjgppPfgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjgtFCisw%253D%253D&md5=7faf22bffbbcc3f53b09c41bc47092ec</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1177%2F1469066718768327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1469066718768327%26sid%3Dliteratum%253Aachs%26aulast%3DAttwa%26aufirst%3DM.%2BW.%26aulast%3DKadi%26aufirst%3DA.%2BA.%26aulast%3DDarwish%26aufirst%3DH.%2BW.%26aulast%3DAmer%26aufirst%3DS.%2BM.%26aulast%3DAlrabiah%26aufirst%3DH.%26atitle%3DA%2520reliable%2520and%2520stable%2520method%2520for%2520the%2520determination%2520of%2520foretinib%2520in%2520human%2520plasma%2520by%2520LC-MS%252FMS%253A%2520application%2520to%2520metabolic%2520stability%2520investigation%2520and%2520excretion%2520rate%26jtitle%3DEur.%2520J.%2520Mass%2520Spectrom.%26date%3D2018%26volume%3D24%26spage%3D344%26doi%3D10.1177%2F1469066718768327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Utermoehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollison, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span> <span> </span><span class="NLM_article-title">In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.110.033159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1688-1697&author=T.+Schulz-Utermoehlauthor=M.+Spearauthor=C.+R.+Pollardauthor=C.+Pattisonauthor=H.+Rollisonauthor=S.+Sardaauthor=M.+Wardauthor=N.+Bushbyauthor=A.+Jordanauthor=M.+Harrison&title=In+vitro+hepatic+metabolism+of+cediranib%2C+a+potent+vascular+endothelial+growth+factor+tyrosine+kinase+inhibitor%3A+interspecies+comparison+and+human+enzymology&doi=10.1124%2Fdmd.110.033159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033159%26sid%3Dliteratum%253Aachs%26aulast%3DSchulz-Utermoehl%26aufirst%3DT.%26aulast%3DSpear%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DC.%2BR.%26aulast%3DPattison%26aufirst%3DC.%26aulast%3DRollison%26aufirst%3DH.%26aulast%3DSarda%26aufirst%3DS.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DBushby%26aufirst%3DN.%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520hepatic%2520metabolism%2520of%2520cediranib%252C%2520a%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitor%253A%2520interspecies%2520comparison%2520and%2520human%2520enzymology%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1688%26epage%3D1697%26doi%3D10.1124%2Fdmd.110.033159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1′-hydroxylation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.110.037853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=757-762&author=M.+Sugiyamaauthor=K.-I.+Fujitaauthor=N.+Murayamaauthor=Y.+Akiyamaauthor=H.+Yamazakiauthor=Y.+Sasaki&title=Sorafenib+and+sunitinib%2C+two+anticancer+drugs%2C+inhibit+CYP3A4-mediated+and+activate+CY3A5-mediated+midazolam+1%E2%80%B2-hydroxylation&doi=10.1124%2Fdmd.110.037853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037853%26sid%3Dliteratum%253Aachs%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DK.-I.%26aulast%3DMurayama%26aufirst%3DN.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DY.%26atitle%3DSorafenib%2520and%2520sunitinib%252C%2520two%2520anticancer%2520drugs%252C%2520inhibit%2520CYP3A4-mediated%2520and%2520activate%2520CY3A5-mediated%2520midazolam%25201%25E2%2580%25B2-hydroxylation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D757%26epage%3D762%26doi%3D10.1124%2Fdmd.110.037853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keisner, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. R.</span></span> <span> </span><span class="NLM_article-title">Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.2165/11588960-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.2165%2F11588960-000000000-00000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=443-454&author=S.+V.+Keisnerauthor=S.+R.+Shah&title=Pazopanib%3A+the+newest+tyrosine+kinase+inhibitor+for+the+treatment+of+advanced+or+metastatic+renal+cell+carcinoma&doi=10.2165%2F11588960-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.2165%2F11588960-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11588960-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKeisner%26aufirst%3DS.%2BV.%26aulast%3DShah%26aufirst%3DS.%2BR.%26atitle%3DPazopanib%253A%2520the%2520newest%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520advanced%2520or%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D443%26epage%3D454%26doi%3D10.2165%2F11588960-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Filppula, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.057695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.114.057695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1202-1209&author=A.+M.+Filppulaauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=In+vitro+assessment+of+time-dependent+inhibitory+effects+on+CYP2C8+and+CYP3A+activity+by+fourteen+protein+kinase+inhibitors&doi=10.1124%2Fdmd.114.057695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.057695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.057695%26sid%3Dliteratum%253Aachs%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520time-dependent%2520inhibitory%2520effects%2520on%2520CYP2C8%2520and%2520CYP3A%2520activity%2520by%2520fourteen%2520protein%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D1202%26epage%3D1209%26doi%3D10.1124%2Fdmd.114.057695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperly, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudeman, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4632</span>– <span class="NLM_lpage">4640</span>, <span class="refDoi"> DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0liYkrsLuFPtsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">App, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2588</span>– <span class="NLM_lpage">2603</span>, <span class="refDoi"> DOI: 10.1021/jm980123i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases&doi=10.1021%2Fjm980123i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0liYkrsLuFPtsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603%26doi%3D10.1021%2Fjm980123i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirazian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-Fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lg1id1bcgHWbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-Fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated drug molecules: focus on FDA-approved deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+drug+molecules%3A+focus+on+FDA-approved+deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0lg1id1bcgHWbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520drug%2520molecules%253A%2520focus%2520on%2520FDA-approved%2520deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kihn-Botulinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of tetramesitylporphyrin</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/ic00274a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00274a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=209-210&author=M.+Kihn-Botulinskiauthor=B.+Meunier&title=Synthesis+of+tetramesitylporphyrin&doi=10.1021%2Fic00274a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fic00274a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00274a046%26sid%3Dliteratum%253Aachs%26aulast%3DKihn-Botulinski%26aufirst%3DM.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520tetramesitylporphyrin%26jtitle%3DInorg.%2520Chem.%26date%3D1988%26volume%3D27%26spage%3D209%26epage%3D210%26doi%3D10.1021%2Fic00274a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Preparation and catalytic activities of the manganese and iron derivatives of Br<sub>8</sub>TMP and Cl<sub>12</sub>TMP, two robust porphyrin ligands obtained by halogenation of tetramesitylporphyrin</span>. <i>Bull. Soc. Chim. Fr.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1992&pages=85-97&author=P.+Hoffmannauthor=A.+Robertauthor=B.+Meunier&title=Preparation+and+catalytic+activities+of+the+manganese+and+iron+derivatives+of+Br8TMP+and+Cl12TMP%2C+two+robust+porphyrin+ligands+obtained+by+halogenation+of+tetramesitylporphyrin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DPreparation%2520and%2520catalytic%2520activities%2520of%2520the%2520manganese%2520and%2520iron%2520derivatives%2520of%2520Br8TMP%2520and%2520Cl12TMP%252C%2520two%2520robust%2520porphyrin%2520ligands%2520obtained%2520by%2520halogenation%2520of%2520tetramesitylporphyrin%26jtitle%3DBull.%2520Soc.%2520Chim.%2520Fr.%26date%3D1992%26volume%3D129%26spage%3D85%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paludetto, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisset, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Louedec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, C.</span></span> <span> </span><span class="NLM_article-title">Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2018.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.jpba.2018.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=29571135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFGnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=373-383&author=M.-N.+Paludettoauthor=F.+Puissetauthor=F.+Le+Louedecauthor=B.+Allalauthor=T.+Lafontauthor=E.+Chatelutauthor=C.+Arellano&title=Simultaneous+monitoring+of+pazopanib+and+its+metabolites+by+UPLC%E2%80%93MS%2FMS&doi=10.1016%2Fj.jpba.2018.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS</span></div><div class="casAuthors">Paludetto, Marie-Noelle; Puisset, Florent; Le Louedec, Felicien; Allal, Ben; Lafont, Thierry; Chatelut, Etienne; Arellano, Cecile</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) approved as first-line treatment for patients with advanced renal cell carcinoma (RCC) and as second-line treatment for patients with advanced soft tissue sarcoma (STS) previously treated with chemotherapy.  The most common adverse events, obsd. during the RCC and STS trials, were gastrointestinal disorders, hypertension, fatigue, elevated ALAT and ASAT, but the mol. mechanisms explaining pazopanib toxicity remain unclear.  Therapeutic activity is considered to be mainly dependent on pazopanib exposure as the primary metabolites are inactive or display low plasma concns., but metabolites may be involved in toxicity as relationships between metabolite profiles and toxicity have not been evaluated.  The authors report, for the first time, the validation of a method for the simultaneous quantification of pazopanib and semi-quantification of its metabolites (relative detn.).  As there are no stds. available, pazopanib metabolites were generated with human liver microsomes (HLM) to provide controls in the development of an UPLC-MS/MS method for monitoring both pazopanib and metabolites.  The optimized method was validated for specificity, linearity, sensitivity, precision, accuracy, matrix effect and stability.  The coeff. of variation (CV%) for intra-day and inter-day precision varied from 2.1% to 7.9% and 5.6% to 13.1% resp.  The biases varied from -12% to 2.3% (intra-day) and 3.8% to 13.1% (inter-day) for accuracy evaluation.  Intra-day and inter-day precision CV were resp. 20.1% and 19.6% and accuracy biases were between 20.7% (intra-day) and 3.8% (inter-day) at the limit of quantification.  The recoveries from matrix samples spiked with pazopanib were resp. 102.6 ± 12.9% and 102.5 ± 1.2% at low and high levels of calibration range.  No matrix effect was evidenced as demonstrated by the normalized matrix factor values: 1.3 ± 0.1 and 1.2 ± 0.2 resp. measured at low and high part of calibration range.  A good stability of pazopanib was obsd. during short term, long term and in process storage conditions and after three freeze/thaw cycles.  The method was applied to clin. samples from three patients treated with pazopanib to establish the metabolite profiles (semi-quant. data) during treatment.  The assessment of metabolite profiles could be useful to improve the authors' understanding of the occurrence of adverse events and to improve pazopanib pharmacokinetic-pharmacodynamic relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdIuYV01fYArVg90H21EOLACvtfcHk0lg4QDYIvX83eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFGnsLw%253D&md5=754a0e2572ea00b8ff414f853c3414f9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2018.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2018.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DPaludetto%26aufirst%3DM.-N.%26aulast%3DPuisset%26aufirst%3DF.%26aulast%3DLe%2BLouedec%26aufirst%3DF.%26aulast%3DAllal%26aufirst%3DB.%26aulast%3DLafont%26aufirst%3DT.%26aulast%3DChatelut%26aufirst%3DE.%26aulast%3DArellano%26aufirst%3DC.%26atitle%3DSimultaneous%2520monitoring%2520of%2520pazopanib%2520and%2520its%2520metabolites%2520by%2520UPLC%25E2%2580%2593MS%252FMS%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2018%26volume%3D154%26spage%3D373%26epage%3D383%26doi%3D10.1016%2Fj.jpba.2018.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hongjian Liu, Chaorong Qi, Lu Wang, Yanhui Guo, Dan Li, <span class="NLM_string-name hlFld-ContribAuthor">Huanfeng Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Base-Promoted Three-Component Cascade Reaction of α-Hydroxy Ketones, Malonodinitrile, and Alcohols: Direct Access to Tetrasubstituted NH-Pyrroles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (14)
                                     , 9610-9620. <a href="https://doi.org/10.1021/acs.joc.1c00882" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00882%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DBase-Promoted%252BThree-Component%252BCascade%252BReaction%252Bof%252B%2525CE%2525B1-Hydroxy%252BKetones%25252C%252BMalonodinitrile%25252C%252Band%252BAlcohols%25253A%252BDirect%252BAccess%252Bto%252BTetrasubstituted%252BNH-Pyrroles%26aulast%3DLiu%26aufirst%3DHongjian%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16042021%26date%3D06072021%26volume%3D86%26issue%3D14%26spage%3D9610%26epage%3D9620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marie-Noëlle Paludetto, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, <span class="NLM_string-name hlFld-ContribAuthor">Cécile Arellano</span>. </span><span class="cited-content_cbyCitation_article-title">Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug–Drug Interactions in Vitro and in Patient Samples. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (1)
                                     , 181-190. <a href="https://doi.org/10.1021/acs.chemrestox.9b00205" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.9b00205</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.9b00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.9b00205%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DInvolvement%252Bof%252BPazopanib%252Band%252BSunitinib%252BAldehyde%252BReactive%252BMetabolites%252Bin%252BToxicity%252Band%252BDrug%2525E2%252580%252593Drug%252BInteractions%252Bin%252BVitro%252Band%252Bin%252BPatient%252BSamples%26aulast%3DPaludetto%26aufirst%3DMarie-No%25C3%25ABlle%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D16052019%26date%3D26092019%26date%3D19092019%26volume%3D33%26issue%3D1%26spage%3D181%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haochen  Jiang</span>, <span class="hlFld-ContribAuthor ">Ying  Jin</span>, <span class="hlFld-ContribAuthor ">Hao  Yan</span>, <span class="hlFld-ContribAuthor ">Zhifei  Xu</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Qiaojun  He</span>, <span class="hlFld-ContribAuthor ">Peihua  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatotoxicity of FDA-approved small molecule kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Safety</span><span> <strong>2021,</strong> <em>20 </em>
                                    (3)
                                     , 335-348. <a href="https://doi.org/10.1080/14740338.2021.1867104" title="DOI URL">https://doi.org/10.1080/14740338.2021.1867104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14740338.2021.1867104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14740338.2021.1867104%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Safety%26atitle%3DHepatotoxicity%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bkinase%252Binhibitors%26aulast%3DJiang%26aufirst%3DHaochen%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D3%26spage%3D335%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabriel  Tao</span>, <span class="hlFld-ContribAuthor ">Junqing  Huang</span>, <span class="hlFld-ContribAuthor ">Bhagavatula  Moorthy</span>, <span class="hlFld-ContribAuthor ">Cathryn  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Hu</span>, <span class="hlFld-ContribAuthor ">Song  Gao</span>, <span class="hlFld-ContribAuthor ">Romi  Ghose</span>. </span><span class="cited-content_cbyCitation_article-title">Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (11)
                                     , 1109-1124. <a href="https://doi.org/10.1080/17425255.2020.1815705" title="DOI URL">https://doi.org/10.1080/17425255.2020.1815705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2020.1815705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2020.1815705%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DPotential%252Brole%252Bof%252Bdrug%252Bmetabolizing%252Benzymes%252Bin%252Bchemotherapy-induced%252Bgastrointestinal%252Btoxicity%252Band%252Bhepatotoxicity%26aulast%3DTao%26aufirst%3DGabriel%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D11%26spage%3D1109%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiang  Shi</span>, <span class="hlFld-ContribAuthor ">Xi  Yang</span>, <span class="hlFld-ContribAuthor ">Lijun  Ren</span>, <span class="hlFld-ContribAuthor ">William B.  Mattes</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (3)
                                     , 217-226. <a href="https://doi.org/10.1080/17425255.2020.1727886" title="DOI URL">https://doi.org/10.1080/17425255.2020.1727886</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2020.1727886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2020.1727886%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DRecent%252Badvances%252Bin%252Bunderstanding%252Bthe%252Bhepatotoxicity%252Bassociated%252Bwith%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DShi%26aufirst%3DQiang%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D217%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie‐Noëlle  Paludetto</span>, <span class="hlFld-ContribAuthor ">Florent  Puisset</span>, <span class="hlFld-ContribAuthor ">Etienne  Chatelut</span>, <span class="hlFld-ContribAuthor ">Cécile  Arellano</span>. </span><span class="cited-content_cbyCitation_article-title">Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2105-2152. <a href="https://doi.org/10.1002/med.21577" title="DOI URL">https://doi.org/10.1002/med.21577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21577%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DIdentifying%252Bthe%252Breactive%252Bmetabolites%252Bof%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Ba%252Bcomprehensive%252Bapproach%25253A%252BImplications%252Bfor%252Bdrug%2525E2%252580%252590drug%252Binteractions%252Band%252Bhepatotoxicity%26aulast%3DPaludetto%26aufirst%3DMarie%25E2%2580%2590No%25C3%25ABlle%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2105%26epage%3D2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengning  Ma</span>, <span class="hlFld-ContribAuthor ">Zicheng  Ma</span>, <span class="hlFld-ContribAuthor ">Dawei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Multi-Substituted Pyrrole Derivatives Through [3+2] Cycloaddition with Tosylmethyl Isocyanides (TosMICs) and Electron-Deficient Compounds. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 2666. <a href="https://doi.org/10.3390/molecules23102666" title="DOI URL">https://doi.org/10.3390/molecules23102666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23102666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23102666%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Bof%252BMulti-Substituted%252BPyrrole%252BDerivatives%252BThrough%252B%25255B3%25252B2%25255D%252BCycloaddition%252Bwith%252BTosylmethyl%252BIsocyanides%252B%252528TosMICs%252529%252Band%252BElectron-Deficient%252BCompounds%26aulast%3DMa%26aufirst%3DZhengning%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the tyrosine kinase inhibitors (TKIs) sunitinib <b>1</b> and pazopanib <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General scheme of catalytic oxidations and metalloporphyrins used as catalysts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Catalytic oxidation of <b>1</b> in the presence of Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>, resulting in oxidation at methyl-C11 (<b>1</b>-CH<sub>2</sub>OH, <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>, and <b>1</b>-CHO were characterized by NMR and mass spectrometry, partial NMR data in pyridine-<i>d</i><sub>5</sub> are reported on the structures) and in N18-desethylation (<b>1</b>-NHEt was detected by UHPLC-MS). Noncatalytic oxidation of <b>1</b> provided <b>1</b>-<i>N</i>-oxide (given as comparison).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Catalytic oxidation of <b>1</b> by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>: UHPLC-MS of the reaction mixture. (a) Total ionic current (TIC, scanning mode). (b) XIC for <i>m</i>/<i>z</i> = 399, insert: mass spectrum at 4.62 min, assigned to <b>1</b>; (c) XIC for <i>m</i>/<i>z</i> = 415; (d) XIC for <i>m</i>/<i>z</i> = 413, insert: mass spectrum at 4.36 min, assigned to <b>1</b>-CHO; (e) XIC for <i>m</i>/<i>z</i> = 429, insert: mass spectrum at 4.56 min, assigned to <b>1</b>-CH<sub>2</sub>OCH<sub>3</sub>; (f) XIC for <i>m</i>/<i>z</i> = 371, insert: mass spectrum at 4.28 min, assigned to <b>1</b>-NHEt.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Oxidation of <b>1</b> catalyzed by human liver microsomes: UHPLC-MS of the reaction mixture. (a) XIC for <i>m</i>/<i>z</i> = 399, assigned to <b>1</b>; (b) XIC for <i>m</i>/<i>z</i> = 371, assigned to <b>1</b>-NHEt; (c) XIC for <i>m</i>/<i>z</i> = 413, assigned to <b>1</b>-CHO, insert: mass spectrum at 4.36 min, assigned to the mixture of <b>1</b>-CHO + <b>1</b>-CH<sub>2</sub>OH; (d) 413 → 340 MRM MS/MS transition; (e) 413 → 268 MRM MS/MS transition; (f) XIC for <i>m</i>/<i>z</i> = 415, assigned to <b>1</b>-CH<sub>2</sub>OH, insert: mass spectrum at 4.36 min, assigned to the mixture of <b>1</b>-CH<sub>2</sub>OH + <b>1</b>-CHO; (g) 415 → 342 MRM MS/MS transition; (h) 415 → 299 MRM MS/MS transition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Catalytic oxidation of <b>2</b> in the presence of Mn<sup>III</sup>(TDCPP)Cl/MMPP, resulting in chlorination at C14 providing <b>2</b>-Cl, and oxidation at methyl-C7 providing <b>2</b>-CH<sub>2</sub>OH, <b>2</b>- CH<sub>2</sub>OCOCH<sub>3</sub> and <b>2</b>-CHO. These metabolites were characterized by NMR and mass spectrometry. The chlorinated derivatives of <b>2</b>-CH<sub>2</sub>OH, <b>2</b>-CH<sub>2</sub>OCOCH<sub>3</sub>, and <b>2</b>-CHO were also characterized by NMR (partial NMR data in pyridine-<i>d</i><sub>5</sub> are reported on the structures). The “a” denotes detected only in NMR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Catalytic oxidation of <b>2</b> by Mn<sup>III</sup>(TDCPP)Cl/MMPP: UHPLC-MS of the reaction mixture. Traces a–c: XIC for pazopanib <b>2</b>, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, respectively (R = H). Traces d–f: XIC for the chlorinated derivatives <b>2</b>-Cl, <b>2</b>-CH<sub>2</sub>OH, and <b>2</b>-CHO, with R = Cl (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> for the structures). Inserts contain the mass spectra of the assigned chromatographic peaks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/medium/jm-2018-00812r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of specific MS/MS transitions (MRM mode) of <b>2</b>-CHO (traces a–c) and <b>2</b>-Cl (traces d–f) in the mixture of oxidation products of pazopanib <b>2</b>, after oxidation by Mn<sup>III</sup>(TDCPP)Cl/MMPP or by human liver microsomes. R stands for the substituent at C14 (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-17/acs.jmedchem.8b00812/20180907/images/large/jm-2018-00812r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00812&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lara, P. N.,  Jr</span></span> <span> </span><span class="NLM_article-title">Renal cell carcinoma: current status and emerging therapies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2006.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.ctrv.2006.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17329029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVyhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=299-313&author=E.+C.+Nelsonauthor=C.+P.+Evansauthor=P.+N.+Lara&title=Renal+cell+carcinoma%3A+current+status+and+emerging+therapies&doi=10.1016%2Fj.ctrv.2006.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Renal cell carcinoma: Current status and emerging therapies</span></div><div class="casAuthors">Nelson, Eric C.; Evans, Christopher P.; Lara, Primo N., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies and its incidence is increasing.  Smoking, obesity, and end-stage renal disease are important risk factors.  Localized RCC may be cured with surgical excision.  However, over one-third of patients eventually develop metastatic disease.  While chemotherapy and radiation therapy are relatively ineffective for RCC, immunotherapy modestly extends survival and may lead to tumor regression and long-term survival in a small minority of patients.  Recently, research into the pathol. of genetic syndromes assocd. with RCC has led to remarkable advances in our understanding of the pathogenesis of sporadic RCC.  Rational therapeutic agents developed from this understanding have established new treatment paradigms for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo36UZbI-Wx9rVg90H21EOLACvtfcHk0lhW7QgCqVWJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVyhtrk%253D&md5=4b3d88e944299661e06aebdf37bc1f8f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BC.%26aulast%3DEvans%26aufirst%3DC.%2BP.%26aulast%3DLara%26aufirst%3DP.%2BN.%26atitle%3DRenal%2520cell%2520carcinoma%253A%2520current%2520status%2520and%2520emerging%2520therapies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D299%26epage%3D313%26doi%3D10.1016%2Fj.ctrv.2006.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bycott, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span> <span> </span><span class="NLM_article-title">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa065044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1056%2FNEJMoa065044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17215529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=115-124&author=R.+J.+Motzerauthor=T.+E.+Hutsonauthor=P.+Tomczakauthor=M.+D.+Michaelsonauthor=R.+M.+Bukowskiauthor=O.+Rixeauthor=S.+Oudardauthor=S.+Negrierauthor=C.+Szczylikauthor=S.+T.+Kimauthor=I.+Chenauthor=P.+W.+Bycottauthor=C.+M.+Baumauthor=R.+A.+Figlin&title=Sunitinib+versus+interferon+alfa+in+metastatic+renal-cell+carcinoma&doi=10.1056%2FNEJMoa065044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</span></div><div class="casAuthors">Motzer, J. Robert; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, M. Dror; Bukowski, Ronald M.; Rixe, Olivier; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Kim, Sindy T.; Chen, Isan; Bycott, Paul W.; Baum, Charles M.; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon α in a phase 3 trial is warranted.  We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-wk cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 wk, followed by 2 wk without treatment) or interferon α (at a dose of 9 MU given s.c. 3 times weekly).  The primary end point was progression-free survival.  Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety.  The median progression-free survival was significantly longer in the sunitinib group (11 mo) than in the interferon α group (5 mo), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54).  Sunitinib was also assocd. with a higher objective response rate than was interferon α (31 vs. 6%).  The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon α, whereas diarrhea was more frequent in the sunitinib group.  Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon α group.  Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who receiver sunitinib than in those receiving interferon α (ClinicalTrials.gov nos., NCT00098657 and NCT00083889).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQV3Ir65c7ZrVg90H21EOLACvtfcHk0lhW7QgCqVWJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVGqsw%253D%253D&md5=233a6ec74994e3636c6beb2090b94a18</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa065044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa065044%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DRixe%26aufirst%3DO.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBycott%26aufirst%3DP.%2BW.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DSunitinib%2520versus%2520interferon%2520alfa%2520in%2520metastatic%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D115%26epage%3D124%26doi%3D10.1056%2FNEJMoa065044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczylik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladkov, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarbá, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R. E.</span></span> <span> </span><span class="NLM_article-title">Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1068</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.23.9764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1200%2FJCO.2009.23.9764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=20100962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1061-1068&author=C.+N.+Sternbergauthor=I.+D.+Davisauthor=J.+Mardiakauthor=C.+Szczylikauthor=E.+Leeauthor=J.+Wagstaffauthor=C.+H.+Barriosauthor=P.+Salmanauthor=O.+A.+Gladkovauthor=A.+Kavinaauthor=J.+J.+Zarb%C3%A1author=M.+Chenauthor=L.+McCannauthor=L.+Panditeauthor=D.+F.+Roychowdhuryauthor=R.+E.+Hawkins&title=Pazopanib+in+locally+advanced+or+metastatic+renal+cell+carcinoma%3A+results+of+a+randomized+phase+III+trial&doi=10.1200%2FJCO.2009.23.9764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</span></div><div class="casAuthors">Sternberg, Cora N.; Davis, Ian D.; Mardiak, Jozef; Szczylik, Cezary; Lee, Eunsik; Wagstaff, John; Barrios, Carlos H.; Salman, Pamela; Gladkov, Oleg A.; Kavina, Alexander; Zarba, Juan J.; Chen, Mei; McCann, Lauren; Pandite, Lini; Roychowdhury, Debasish F.; Hawkins, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1061-1068</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit.  This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).  Patients and Methods: Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo.  The primary end point was progression-free survival (PFS).  Secondary end points included overall survival, tumor response rate (Response Evaluation Criteria in Solid Tumors), and safety.  Radiog. assessments of tumors were independently reviewed.  Results: Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%).  PFS was significantly prolonged with pazopanib compared with placebo in the overall study population (median, PFS 9.2 v 4.2 mo; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 mo; HR, 0.40; 95% CI, 0.27 to 0.60; P < .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 mo; HR, 0.54; 95% CI, 0.35 to 0.84; P < .001).  The objective response rate was 30% with pazopanib compared with 3% with placebo (P < .001).  The median duration of response was longer than 1 yr.  The most common adverse events were diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting.  There was no evidence of clin. important differences in quality of life for pazopanib vs. placebo.  Conclusion: Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtrsHw15sJrVg90H21EOLACvtfcHk0lhW7QgCqVWJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt78%253D&md5=897c2b69e044628115f9d432a5865406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.9764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.9764%26sid%3Dliteratum%253Aachs%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DDavis%26aufirst%3DI.%2BD.%26aulast%3DMardiak%26aufirst%3DJ.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DSalman%26aufirst%3DP.%26aulast%3DGladkov%26aufirst%3DO.%2BA.%26aulast%3DKavina%26aufirst%3DA.%26aulast%3DZarb%25C3%25A1%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DMcCann%26aufirst%3DL.%26aulast%3DPandite%26aufirst%3DL.%26aulast%3DRoychowdhury%26aufirst%3DD.%2BF.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26atitle%3DPazopanib%2520in%2520locally%2520advanced%2520or%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520results%2520of%2520a%2520randomized%2520phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1061%26epage%3D1068%26doi%3D10.1200%2FJCO.2009.23.9764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Pazopanib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1038/nrd3073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1038%2Fnrd3073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=20043026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib&doi=10.1038%2Fnrd3073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib</span></div><div class="casAuthors">Bukowski, Ronald M.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-18</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Oct. 2009, pazopanib (Votrient; GlaxoSmithKline) - a multikinase inhibitor with targets that include vascular endothelial growth factor receptors- was approved by the US FDA for the treatment of advanced renal cell carcinoma.  Pazopanib is an interesting new agent that expands the available therapeutic options for patients with metastatic RCC.  The cooperative groups in the United States and Europe have had limited involvement in the development of this agent, but in the future should be involved in conducting trials such as those mentioned above, not only in the adjuvant setting, but also in patients with advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwntQHZo2xZrVg90H21EOLACvtfcHk0lhWVq3Hf75ilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqtbfE&md5=5f62da41556e474cead8e1877f34adc2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3073%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18%26doi%3D10.1038%2Fnrd3073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Négrier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehmud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span> <span> </span><span class="NLM_article-title">Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.50.8267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1200%2FJCO.2013.50.8267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=24687826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1412-1418&author=B.+Escudierauthor=C.+Portaauthor=P.+Bonoauthor=T.+Powlesauthor=T.+Eisenauthor=C.+N.+Sternbergauthor=J.+E.+Gschwendauthor=U.+De+Giorgiauthor=O.+Parikhauthor=R.+Hawkinsauthor=E.+Sevinauthor=S.+N%C3%A9grierauthor=S.+Khanauthor=J.+Diazauthor=S.+Redhuauthor=F.+Mehmudauthor=D.+Cella&title=Randomized%2C+controlled%2C+double-blind%2C+cross-over+trial+assessing+treatment+preference+for+pazopanib+versus+sunitinib+in+patients+with+metastatic+renal+cell+carcinoma%3A+PISCES+study&doi=10.1200%2FJCO.2013.50.8267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study</span></div><div class="casAuthors">Escudier, Bernard; Porta, Camillo; Bono, Petri; Powles, Thomas; Eisen, Tim; Sternberg, Cora N.; Gschwend, Juergen E.; De Giorgi, Ugo; Parikh, Omi; Hawkins, Robert; Sevin, Emmanuel; Negrier, Sylvie; Khan, Sadya; Diaz, Jose; Redhu, Suman; Mehmud, Faisal; Cella, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1412-1418</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy.  This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.  Patients and Methods Patients with metastatic RCC were randomly assigned to pazopanib 800 mg per day for 10 wk, a 2-wk washout, and then sunitinib 50 mg per day (4 wk on, 2 wk off, 4 wk on) for 10 wk, or the reverse sequence.  The primary end point, patient preference for a specific treatment, was assessed by questionnaire at the end of the two treatment periods.  Other end points and analyses included reasons for preference, physician preference, safety, and HRQoL.  Results Of 169 randomly assigned patients, 114 met the following prespecified modified intent-to-treat criteria for the primary anal.: exposure to both treatments, no disease progression before cross over, and completion of the preference questionnaire.  Significantly more patients preferred pazopanib (70%) over sunitinib (22%); 8% expressed no preference (P < .001).  All preplanned sensitivity analyses, including the intent-to-treat population, statistically favored pazopanib.  Less fatigue and better overall quality of life were the main reasons for preferring pazopanib, with less diarrhea being the most cited reason for preferring sunitinib.  Physicians also preferred pazopanib (61%) over sunitinib (22%); 17% expressed no preference.  Adverse events were consistent with each drug's known profile.  Pazopanib was superior to sunitinib in HRQoL measures evaluating fatigue, hand/ft soreness, and mouth/throat soreness.  Conclusion This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHJKB0Uc6j-7Vg90H21EOLACvtfcHk0lhWVq3Hf75ilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsbvK&md5=1c272883dd8e81fa6b567f1a1bf2557a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.50.8267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.50.8267%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBono%26aufirst%3DP.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DSternberg%26aufirst%3DC.%2BN.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DDe%2BGiorgi%26aufirst%3DU.%26aulast%3DParikh%26aufirst%3DO.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DSevin%26aufirst%3DE.%26aulast%3DN%25C3%25A9grier%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DJ.%26aulast%3DRedhu%26aufirst%3DS.%26aulast%3DMehmud%26aufirst%3DF.%26aulast%3DCella%26aufirst%3DD.%26atitle%3DRandomized%252C%2520controlled%252C%2520double-blind%252C%2520cross-over%2520trial%2520assessing%2520treatment%2520preference%2520for%2520pazopanib%2520versus%2520sunitinib%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520PISCES%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D1412%26epage%3D1418%26doi%3D10.1200%2FJCO.2013.50.8267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span> <span> </span><span class="NLM_article-title">Risk of tyrosine kinase inhibitors induced hepatotoxicity in cancer patients: A meta-analysis</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2012.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.ctrv.2012.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=23099278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKns7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=199-206&author=Y.+L.+Teoauthor=H.+K.+Hoauthor=A.+Chan&title=Risk+of+tyrosine+kinase+inhibitors+induced+hepatotoxicity+in+cancer+patients%3A+A+meta-analysis&doi=10.1016%2Fj.ctrv.2012.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis</span></div><div class="casAuthors">Teo, Yi Ling; Ho, Han Kiat; Chan, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-206</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Although existing evidence from clin. trials has demonstrated manifestation of hepatic adverse events (AEs) with the use of tyrosine kinase inhibitors (TKIs), overall risks have yet to be reported.  Thus we conducted a meta-anal. to det. the risk of hepatotoxicity assocd. with the use of TKIs, by comparing the occurrence of hepatotoxicity of the TKI arms against that of comparison arms.  A comprehensive literature search of randomized control trials involving TKIs was performed.  Only randomized, double-blind and placebo-controlled phase 2 or phase 3 human trials were included.  The included studies must involve the comparison of a TKI against placebo, or the comparison of TKI with chemotherapy agent against placebo with the same chemotherapy agent.  Twelve articles were included in the anal.  There was a significant overall increase in the odds of developing high-grade (grade 3 or above) hepatotoxicity with the use of TKIs compared to the control arms (Pooled OR 4.35, 95% CI 2.96-6.39).  The odds of developing all-types all-grades (Pooled OR 2.42, 95% CI 1.52-3.85) and high-grade hepatotoxicity due to elevation in alanine transaminase (Pooled OR 5.22, 95% CI 2.88-9.46), aspartate transaminase (Pooled OR 6.15, 95% CI 3.09-12.25) and total bilirubin (Pooled OR 1.76, 95% CI 0.59-5.24) was higher with the use of TKI than compared to the controls.  This is the first meta-anal. to demonstrate a significantly increased risk of hepatic AEs assocd. with TKIs use.  Clinicians should be aware of this risk and provide close monitoring in patients receiving these therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nrZOhsLGibVg90H21EOLACvtfcHk0lhWVq3Hf75ilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKns7jE&md5=08b21a0b9571df06b1af1f7ac2e44cf4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DY.%2BL.%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DChan%26aufirst%3DA.%26atitle%3DRisk%2520of%2520tyrosine%2520kinase%2520inhibitors%2520induced%2520hepatotoxicity%2520in%2520cancer%2520patients%253A%2520A%2520meta-analysis%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26spage%3D199%26epage%3D206%26doi%3D10.1016%2Fj.ctrv.2012.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1007/s40264-013-0048-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1007%2Fs40264-013-0048-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=23620168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=491-503&author=R.+R.+Shahauthor=J.+Morganrothauthor=D.+R.+Shah&title=Hepatotoxicity+of+tyrosine+kinase+inhibitors%3A+clinical+and+regulatory+perspectives&doi=10.1007%2Fs40264-013-0048-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives</span></div><div class="casAuthors">Shah, Rashmi R.; Morganroth, Joel; Shah, Devron R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">491-503</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The introduction of small-mol. tyrosine kinase inhibitors (TKIs) in clin. oncol. has transformed the treatment of certain forms of cancers.  As of 31 March 2013, 18 such agents have been approved by the US Food and Drug Administration (FDA), 15 of these also by the European Medicines Agency (EMA), and a large no. of others are in development or under regulatory review.  Unexpectedly, however, their use has been found to be assocd. with serious toxic effects on a no. of vital organs including the liver.  Drug-induced hepatotoxicity has resulted in withdrawal from the market of many widely used drugs and is a major public health issue that continues to concern all the stakeholders.  This review focuses on hepatotoxic potential of TKIs.  The majority of TKIs approved to date are reported to induce hepatic injury.  Five of these (lapatinib, pazopanib, ponatinib, regorafenib and sunitinib) are sufficiently potent in this respect as to require a boxed label warning.  Onset of TKI-induced hepatotoxicity is usually within the first 2 mo of initiating treatment, but may be delayed, and is usually reversible.  Fatality from TKI-induced hepatotoxicity is uncommon compared to hepatotoxic drugs in other classes but may lead to long-term consequences such as cirrhosis.  Patients should be carefully monitored for TKI-induced hepatotoxicity, the management of which requires individually tailored reappraisal of the risk/benefit.  The risk is usually manageable by dose adjustment or a switch to a suitable alternative TKI.  Confirmation of TKI-induced hepatotoxicity can present challenges in the presence of hepatic metastasis and potential drug interactions.  Its diagnosis in a patient with TKI-sensitive cancer requires great care if therapy with the TKI suspected to be causal is to be modified or interrupted as a result.  Post-marketing experience with drugs such as imatinib, lapatinib and sorafenib suggests that the hepatotoxic safety of all the TKIs requires diligent surveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDb6HewTRrILVg90H21EOLACvtfcHk0lhxu34BvhJeJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsLzO&md5=60d4c1d12c2085cdd88b984c56a18a0c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40264-013-0048-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-013-0048-4%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DMorganroth%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DD.%2BR.%26atitle%3DHepatotoxicity%2520of%2520tyrosine%2520kinase%2520inhibitors%253A%2520clinical%2520and%2520regulatory%2520perspectives%26jtitle%3DDrug%2520Saf.%26date%3D2013%26volume%3D36%26spage%3D491%26epage%3D503%26doi%3D10.1007%2Fs40264-013-0048-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramchandani, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobburu, J. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbois, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidambaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahjoob, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1373</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-2328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1158%2F1078-0432.CCR-06-2328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=17332278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1367-1373&author=V.+L.+Goodmanauthor=E.+P.+Rockauthor=R.+Dagherauthor=R.+P.+Ramchandaniauthor=S.+Abrahamauthor=J.+V.+S.+Gobburuauthor=B.+P.+Boothauthor=S.+L.+Verboisauthor=D.+E.+Morseauthor=C.+Y.+Liangauthor=N.+Chidambaramauthor=J.+X.+Jiangauthor=S.+Tangauthor=K.+Mahjoobauthor=R.+Justiceauthor=R.+Pazdur&title=Approval+summary%3A+sunitinib+for+the+treatment+of+imatinib+refractory+or+intolerant+gastrointestinal+stromal+tumors+and+advanced+renal+cell+carcinoma&doi=10.1158%2F1078-0432.CCR-06-2328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma</span></div><div class="casAuthors">Goodman, Vicki L.; Rock, Edwin P.; Dagher, Ramzi; Ramchandani, Roshni P.; Abraham, Sophia; Gobburu, Jogarao V. S.; Booth, Brian P.; Verbois, S. Leigh; Morse, David E.; Liang, Cheng Yi; Chidambaram, Nallaperumal; Jiang, Janet X.; Tang, Shenghui; Mahjoob, Kooros; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1367-1373</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent).  Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate (Gleevec).  Addnl., sunitinib received accelerated approval for the treatment of advanced renal cell carcinoma.  Exptl. Design: For the GIST indication, FDA reviewed data from a randomized, placebo-controlled trial with supportive evidence from a single-arm study.  For the advanced renal cell carcinoma indication, FDA reviewed data from two single-arm studies of patients with cytokine-refractory metastatic renal cell carcinoma.  Results: In patients with imatinib refractory or intolerant GIST, time-to-tumor progression of sunitinib-treated patients was superior to that of placebo-treated patients.  Median time-to-tumor progression of sunitinib-treated patients was 27.3 wk, compared with 6.4 wk for placebo-treated patients (P < 0.0001).  Partial responses were obsd. in 6.8% of sunitinib-treated patients.  In patients with metastatic renal cell carcinoma, partial responses were obsd. in 25.5% (95% confidence interval, 17.5, 34.9) and 36.5% (95% confidence interval, 24.7, 49.6) of patients treated with sunitinib. Median response durations were 27.1 and 54 wk.  The most common adverse events attributed to sunitinib included diarrhea, mucositis, skin abnormalities, and altered taste.  Redns. in left ventricular ejection fraction and severe hypertension were also more common in sunitinib-treated patients.  Conclusions: On Jan. 26, 2006, the FDA approved sunitinib for the treatment of patients with imatinib refractory or intolerant GIST.  Accelerated approval was granted for the treatment of advanced renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXuKPm_-9xrVg90H21EOLACvtfcHk0lhxu34BvhJeJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjsbc%253D&md5=baa2be61674d19588b831222672f13f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2328%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DV.%2BL.%26aulast%3DRock%26aufirst%3DE.%2BP.%26aulast%3DDagher%26aufirst%3DR.%26aulast%3DRamchandani%26aufirst%3DR.%2BP.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DGobburu%26aufirst%3DJ.%2BV.%2BS.%26aulast%3DBooth%26aufirst%3DB.%2BP.%26aulast%3DVerbois%26aufirst%3DS.%2BL.%26aulast%3DMorse%26aufirst%3DD.%2BE.%26aulast%3DLiang%26aufirst%3DC.%2BY.%26aulast%3DChidambaram%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%2BX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DMahjoob%26aufirst%3DK.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520imatinib%2520refractory%2520or%2520intolerant%2520gastrointestinal%2520stromal%2520tumors%2520and%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1367%26epage%3D1373%26doi%3D10.1158%2F1078-0432.CCR-06-2328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sychterz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttle, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bershas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negash, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorycki, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. Y. K.</span></span> <span> </span><span class="NLM_article-title">Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.3109/00498254.2012.734642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.3109%2F00498254.2012.734642" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=443-453&author=Y.+Dengauthor=C.+Sychterzauthor=A.+B.+Suttleauthor=M.+M.+Darauthor=D.+Bershasauthor=K.+Negashauthor=Y.+Qianauthor=E.+P.+Chenauthor=P.+D.+Goryckiauthor=M.+Y.+K.+Ho&title=Bioavailability%2C+metabolism+and+disposition+of+oral+pazopanib+in+patients+with+advanced+cancer&doi=10.3109%2F00498254.2012.734642"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.734642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.734642%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DSychterz%26aufirst%3DC.%26aulast%3DSuttle%26aufirst%3DA.%2BB.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DBershas%26aufirst%3DD.%26aulast%3DNegash%26aufirst%3DK.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DE.%2BP.%26aulast%3DGorycki%26aufirst%3DP.%2BD.%26aulast%3DHo%26aufirst%3DM.%2BY.%2BK.%26atitle%3DBioavailability%252C%2520metabolism%2520and%2520disposition%2520of%2520oral%2520pazopanib%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DXenobiotica%26date%3D2013%26volume%3D43%26spage%3D443%26epage%3D453%26doi%3D10.3109%2F00498254.2012.734642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pool, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patyna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, distribution, and metabolism of [<sup>14</sup>C]sunitinib in rats, monkeys, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.042853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.111.042853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=539-555&author=B.+Speedauthor=H.-Z.+Buauthor=W.+F.+Poolauthor=G.+W.+Pengauthor=E.+Y.+Wuauthor=S.+Patynaauthor=C.+Belloauthor=P.+Kang&title=Pharmacokinetics%2C+distribution%2C+and+metabolism+of+%5B14C%5Dsunitinib+in+rats%2C+monkeys%2C+and+humans&doi=10.1124%2Fdmd.111.042853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.042853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.042853%26sid%3Dliteratum%253Aachs%26aulast%3DSpeed%26aufirst%3DB.%26aulast%3DBu%26aufirst%3DH.-Z.%26aulast%3DPool%26aufirst%3DW.%2BF.%26aulast%3DPeng%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DPatyna%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%26aulast%3DKang%26aufirst%3DP.%26atitle%3DPharmacokinetics%252C%2520distribution%252C%2520and%2520metabolism%2520of%2520%255B14C%255Dsunitinib%2520in%2520rats%252C%2520monkeys%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D539%26epage%3D555%26doi%3D10.1124%2Fdmd.111.042853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolites: current and emerging risk and hazard assessments</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00410</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00410" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=505-533&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=M.+O.+Ogeseauthor=J.+T.+Mettetalauthor=D.+P.+Williams&title=Reactive+metabolites%3A+current+and+emerging+risk+and+hazard+assessments&doi=10.1021%2Facs.chemrestox.5b00410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites: Current and Emerging Risk and Hazard Assessments</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Ogese, Monday O.; Mettetal, Jerome T.; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-533</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although idiosyncratic adverse drug reactions are rare, they are still a major concern to patient safety.  Reactive metabolites are widely accepted as playing a pivotal role in the pathogenesis of idiosyncratic adverse drug reactions.  While there are today well established strategies for the risk assessment of stable metabolites within the pharmaceutical industry, there is still no consensus on reactive metabolite risk assessment strategies.  This is due to the complexity of the mechanisms of these toxicities as well as the difficulty in identifying and quantifying short-lived reactive intermediates such as reactive metabolites.  In this review, reactive metabolite risk and hazard assessment approaches are discussed, and their pros and cons highlighted.  We also discuss the nature of idiosyncratic adverse drug reactions, using acetaminophen and nefazodone to exemplify the complexity of the underlying mechanisms of reactive metabolite mediated hepatotoxicity.  One of the key gaps moving forward is our understanding of and ability to predict the contribution of immune activation in idiosyncratic adverse drug reactions.  Sections are included on the clin. phenotypes of immune mediated idiosyncratic adverse drug reactions and on the present understanding of immune activation by reactive metabolites.  The advances being made in microphysiol. systems have a great potential to transform our ability to risk assess reactive metabolites, and an overview of the key components of these systems is presented.  Finally, the potential impact of systems pharmacol. approaches in reactive metabolite risk assessments is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplG7NDjykn-LVg90H21EOLACvtfcHk0lgGQlu_z1RTcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGnsro%253D&md5=36555d129e1c4667386d6ccced440e7f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00410%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DReactive%2520metabolites%253A%2520current%2520and%2520emerging%2520risk%2520and%2520hazard%2520assessments%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D505%26epage%3D533%26doi%3D10.1021%2Facs.chemrestox.5b00410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of ketene-reactive intermediate of erlotinib. Possibly responsible for inactivation of P450 enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&author=H.+Zhaoauthor=S.+Liauthor=Z.+Yangauthor=Y.+Pengauthor=X.+Chenauthor=J.+Zheng&title=Identification+of+ketene-reactive+intermediate+of+erlotinib.+Possibly+responsible+for+inactivation+of+P450+enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520ketene-reactive%2520intermediate%2520of%2520erlotinib.%2520Possibly%2520responsible%2520for%2520inactivation%2520of%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span>; <span class="NLM_string-name">Robert, A.</span>; <span class="NLM_string-name">Pratviel, G.</span>; <span class="NLM_string-name">Bernadou, J.</span></span> <span> </span><span class="NLM_article-title">Metalloporphyrins in catalytic oxidations and oxidative DNA cleavage</span>. In  <i>The Porphyrin Handbook</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Kadish, K. M.</span>, <span class="NLM_string-name">Smith, K. M.</span>, <span class="NLM_string-name">Guilard, R.</span></span>, Eds; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2000</span>, Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">187</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=119-187&author=B.+Meunier&author=A.+Robert&author=G.+Pratviel&author=J.+Bernadouauthor=K.+M.+Kadish&author=K.+M.+Smith&author=R.+Guilard&title=The+Porphyrin+Handbook"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DMetalloporphyrins%2520in%2520catalytic%2520oxidations%2520and%2520oxidative%2520DNA%2520cleavage%26btitle%3DThe%2520Porphyrin%2520Handbook%26aulast%3DKadish%26aufirst%3DK.%2BM.%26pub%3DAcademic%2520Press%26date%3D2000%26volume%3D4%26spage%3D119%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3980</span>, <span class="refDoi"> DOI: 10.1021/cr020443g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr020443g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=3947-3980&author=B.+Meunierauthor=S.+P.+de+Visserauthor=S.+Shaik&title=Mechanism+of+oxidation+reactions+catalyzed+by+cytochrome+P450+enzymes&doi=10.1021%2Fcr020443g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes</span></div><div class="casAuthors">Meunier, Bernard; de Visser, Samueel P.; Shaik, Sason</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3947-3980</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The exact nature of the active species in cytochrome P 450 enzymes (the putative high-valent iron-oxo intermediate) is still a matter of intensive debates.  Site-directed mutagenesis studies in conjunction with structural studies allowed different hypotheses to be checked.  Theor. calcns. became available and enabled various hypotheses to be tested and new solns. to be offered.  All these studies have enriched the knowledge on mol. enzymol. and the coordination chem. of metal-peroxo and high-valent metal-oxo species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR8qIfDs6uAbVg90H21EOLACvtfcHk0lgGQlu_z1RTcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVejtr8%253D&md5=d10f62537d0af7d3895217ee91a5119b</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fcr020443g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr020443g%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DB.%26aulast%3Dde%2BVisser%26aufirst%3DS.%2BP.%26aulast%3DShaik%26aufirst%3DS.%26atitle%3DMechanism%2520of%2520oxidation%2520reactions%2520catalyzed%2520by%2520cytochrome%2520P450%2520enzymes%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D3947%26epage%3D3980%26doi%3D10.1021%2Fcr020443g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Oxygen activation and radical transformations in heme proteins and metalloporphyrins</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2491</span>– <span class="NLM_lpage">2553</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC1cXk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=2491-2553&author=X.+Huangauthor=J.+T.+Groves&title=Oxygen+activation+and+radical+transformations+in+heme+proteins+and+metalloporphyrins&doi=10.1021%2Facs.chemrev.7b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen Activation and Radical Transformations in Heme Proteins and Metalloporphyrins</span></div><div class="casAuthors">Huang, Xiongyi; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2491-2553</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  As a result of the adaptation of life to an aerobic environment, nature has evolved a panoply of metalloproteins for oxidative metab. and protection against reactive oxygen species.  Despite the diverse structures and functions of these proteins, they share common mechanistic grounds.  An open-shell transition metal like iron or copper is employed to interact with O2 and its derived intermediates such as hydrogen peroxide to afford a variety of metal-oxygen intermediates.  These reactive intermediates, including metal-superoxo, -(hydro)peroxo, and high-valent metal-oxo species, are the basis for the various biol. functions of O2-utilizing metalloproteins.  Collectively, these processes are called oxygen activation.  Much of our understanding of the reactivity of these reactive intermediates has come from the study of heme-contg. proteins and related metalloporphyrin compds.  These studies have not only deepened our understanding of various functions of heme proteins such as O2 storage and transport, degrdn. of reactive oxygen species, redox signaling and biol. oxygenation, etc., but have also driven the development of bioinorg. chem. and biomimetic catalysis.  In this review, we survey the range of O2 activation processes mediated by heme proteins and model compds. with a focus on recent progress in the characterization and reactivity of important iron-oxygen intermediates.  Representative reactions initiated by these reactive intermediates as well as some context from prior decades will also be presented.  We will discuss the fundamental mechanistic features of these transformations and delineate the underlying structural and electronic factors that contribute to the spectrum of reactivities that has been obsd. in nature as well as those that have been invented using these paradigms.  Given the recent developments in biocatalysis for non-natural chemistries and the renaissance of radical chem. in org. synthesis, we envision that new enzymic and synthetic transformations will emerge based on the radical processes mediated by metalloproteins and their synthetic analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0oXolZg6abVg90H21EOLACvtfcHk0ljJJtGvXZS5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXk&md5=284bf769bb4b83373ee7e10bb2f44bfa</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00373%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DOxygen%2520activation%2520and%2520radical%2520transformations%2520in%2520heme%2520proteins%2520and%2520metalloporphyrins%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26spage%3D2491%26epage%3D2553%26doi%3D10.1021%2Facs.chemrev.7b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Biomimetic chemical catalysts in the oxidative activation of drugs</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1002/adsc.200303191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1002%2Fadsc.200303191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ensb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2004&pages=171-184&author=J.+Bernadouauthor=B.+Meunier&title=Biomimetic+chemical+catalysts+in+the+oxidative+activation+of+drugs&doi=10.1002%2Fadsc.200303191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic chemical catalysts in the oxidative activation of drugs</span></div><div class="casAuthors">Bernadou, Jean; Meunier, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2+3</span>),
    <span class="NLM_cas:pages">171-184</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  An overview of the biomimetic catalysts used in the oxidative activation of drugs is given, with an emphasis on the use of synthetic metalloporphyrins as models of cytochrome P 450 to mimic the in vivo metab. of pharmaceuticals.  In addn., a special focus is directed towards the recent results from the authors' group on the oxidative activation of isoniazid, an antitubercular drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeyVJ-gPZePrVg90H21EOLACvtfcHk0ljJJtGvXZS5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ensb0%253D&md5=f42510049c4ee8e0a498d9d2028cf6ed</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200303191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200303191%26sid%3Dliteratum%253Aachs%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DBiomimetic%2520chemical%2520catalysts%2520in%2520the%2520oxidative%2520activation%2520of%2520drugs%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2004%26volume%3D346%26spage%3D171%26epage%3D184%26doi%3D10.1002%2Fadsc.200303191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnafous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defrance, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiseau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Model systems for oxidative drug-metabolism studies - Catalytic behavior of water-soluble metalloporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">817</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1993&pages=811-817&author=M.+Vidalauthor=M.+Bonnafousauthor=S.+Defranceauthor=P.+Loiseauauthor=J.+Bernadouauthor=B.+Meunier&title=Model+systems+for+oxidative+drug-metabolism+studies+-+Catalytic+behavior+of+water-soluble+metalloporphyrins+depends+on+both+the+intrinsic+robustness+of+the+catalyst+and+the+nature+of+substrates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVidal%26aufirst%3DM.%26aulast%3DBonnafous%26aufirst%3DM.%26aulast%3DDefrance%26aufirst%3DS.%26aulast%3DLoiseau%26aufirst%3DP.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DModel%2520systems%2520for%2520oxidative%2520drug-metabolism%2520studies%2520-%2520Catalytic%2520behavior%2520of%2520water-soluble%2520metalloporphyrins%2520depends%2520on%2520both%2520the%2520intrinsic%2520robustness%2520of%2520the%2520catalyst%2520and%2520the%2520nature%2520of%2520substrates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1993%26volume%3D21%26spage%3D811%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaggero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Oxidation of SR 48117, an antagonist of vasopressin V<sub>1a</sub> receptors, by biomimetic catalysts based on metalloporphyrin or Schiff-base complexes</span>. <i>Bull. Soc. Chim. Fr.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1994&pages=706-712&author=N.+Gaggeroauthor=A.+Robertauthor=J.+Bernadouauthor=B.+Meunier&title=Oxidation+of+SR+48117%2C+an+antagonist+of+vasopressin+V1a+receptors%2C+by+biomimetic+catalysts+based+on+metalloporphyrin+or+Schiff-base+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaggero%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DOxidation%2520of%2520SR%252048117%252C%2520an%2520antagonist%2520of%2520vasopressin%2520V1a%2520receptors%252C%2520by%2520biomimetic%2520catalysts%2520based%2520on%2520metalloporphyrin%2520or%2520Schiff-base%2520complexes%26jtitle%3DBull.%2520Soc.%2520Chim.%2520Fr.%26date%3D1994%26volume%3D131%26spage%3D706%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasseur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratviel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernadou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span> <span> </span><span class="NLM_article-title">Metalloporphyrin-catalyzed hydroxylation of the <i>N,N</i>-dimethylamide function of the drug molecule SSR180575 to a stable <i>N</i>-methyl-<i>N</i>-carbinolamide</span>. <i>C. R. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1016/j.crci.2013.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.crci.2013.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1002-1007&author=I.+Nicolasauthor=C.+Bijaniauthor=D.+Brasseurauthor=G.+Pratvielauthor=J.+Bernadouauthor=A.+Robert&title=Metalloporphyrin-catalyzed+hydroxylation+of+the+N%2CN-dimethylamide+function+of+the+drug+molecule+SSR180575+to+a+stable+N-methyl-N-carbinolamide&doi=10.1016%2Fj.crci.2013.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Metalloporphyrin-catalyzed hydroxylation of the N,N-dimethylamide function of the drug molecule SSR180575 to a stable N-methyl-N-carbinolamide</span></div><div class="casAuthors">Nicolas, Irene; Bijani, Christian; Brasseur, Denis; Pratviel, Genevieve; Bernadou, Jean; Robert, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus Chimie</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1002-1007</span>CODEN:
                <span class="NLM_cas:coden">CRCOCR</span>;
        ISSN:<span class="NLM_cas:issn">1631-0748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The metalloporphyrin-catalyzed oxidn. of SSR180575, a ligand of the peripheral benzodiazepine receptor, that contains both N-methylindole and N,N-dimethylamide functions, produces a high yield of a stable carbinolamide deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo10tvMKPP947Vg90H21EOLACvtfcHk0ljND95TnVr76A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrur3N&md5=2476231a9f626996224aaea070ed7b84</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.crci.2013.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crci.2013.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas%26aufirst%3DI.%26aulast%3DBijani%26aufirst%3DC.%26aulast%3DBrasseur%26aufirst%3DD.%26aulast%3DPratviel%26aufirst%3DG.%26aulast%3DBernadou%26aufirst%3DJ.%26aulast%3DRobert%26aufirst%3DA.%26atitle%3DMetalloporphyrin-catalyzed%2520hydroxylation%2520of%2520the%2520N%252CN-dimethylamide%2520function%2520of%2520the%2520drug%2520molecule%2520SSR180575%2520to%2520a%2520stable%2520N-methyl-N-carbinolamide%26jtitle%3DC.%2520R.%2520Chim.%26date%3D2013%26volume%3D16%26spage%3D1002%26epage%3D1007%26doi%3D10.1016%2Fj.crci.2013.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolman, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, U. E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltier, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, A.</span></span> <span> </span><span class="NLM_article-title">Emerging technologies for metabolite generation and structural diversification</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5483</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.bmcl.2013.08.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5471-5483&author=K.+P.+Cusackauthor=H.+F.+Koolmanauthor=U.+E.+W.+Langeauthor=H.+M.+Peltierauthor=I.+Pielauthor=A.+Vasudevan&title=Emerging+technologies+for+metabolite+generation+and+structural+diversification&doi=10.1016%2Fj.bmcl.2013.08.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DKoolman%26aufirst%3DH.%2BF.%26aulast%3DLange%26aufirst%3DU.%2BE.%2BW.%26aulast%3DPeltier%26aufirst%3DH.%2BM.%26aulast%3DPiel%26aufirst%3DI.%26aulast%3DVasudevan%26aufirst%3DA.%26atitle%3DEmerging%2520technologies%2520for%2520metabolite%2520generation%2520and%2520structural%2520diversification%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5471%26epage%3D5483%26doi%3D10.1016%2Fj.bmcl.2013.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, N.</span></span> <span> </span><span class="NLM_article-title">High-performance liquid chromatographic method for determination of reversible isomers of SU5416</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1110</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2006.01.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.chroma.2006.01.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1110&publication_year=2006&pages=73-80&author=A.+Sistlaauthor=W.+L.+Yangauthor=N.+Shenoy&title=High-performance+liquid+chromatographic+method+for+determination+of+reversible+isomers+of+SU5416&doi=10.1016%2Fj.chroma.2006.01.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2006.01.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2006.01.079%26sid%3Dliteratum%253Aachs%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DW.%2BL.%26aulast%3DShenoy%26aufirst%3DN.%26atitle%3DHigh-performance%2520liquid%2520chromatographic%2520method%2520for%2520determination%2520of%2520reversible%2520isomers%2520of%2520SU5416%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2006%26volume%3D1110%26spage%3D73%26epage%3D80%26doi%3D10.1016%2Fj.chroma.2006.01.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalariya, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talluri, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gananadhamu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silicotoxicity prediction</span>. <i>J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1002/jms.3602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1002%2Fjms.3602" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2015&pages=918-928&author=P.+N.+Patelauthor=P.+D.+Kalariyaauthor=M.+Sharmaauthor=P.+Gargauthor=M.+V.+Talluriauthor=S.+Gananadhamuauthor=R.+Srinivas&title=Characterization+of+forced+degradation+products+of+pazopanib+hydrochloride+by+UHPLC-Q-TOF%2FMS+and+in+silicotoxicity+prediction&doi=10.1002%2Fjms.3602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjms.3602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjms.3602%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BN.%26aulast%3DKalariya%26aufirst%3DP.%2BD.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DGarg%26aufirst%3DP.%26aulast%3DTalluri%26aufirst%3DM.%2BV.%26aulast%3DGananadhamu%26aufirst%3DS.%26aulast%3DSrinivas%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520forced%2520degradation%2520products%2520of%2520pazopanib%2520hydrochloride%2520by%2520UHPLC-Q-TOF%252FMS%2520and%2520in%2520silicotoxicity%2520prediction%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2015%26volume%3D50%26spage%3D918%26epage%3D928%26doi%3D10.1002%2Fjms.3602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claparols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">The antimalarial drug artemisinin alkylates heme in infected mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">13676</span>– <span class="NLM_lpage">13680</span>, <span class="refDoi"> DOI: 10.1073/pnas.0500972102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1073%2Fpnas.0500972102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=16155128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=13676-13680&author=A.+Robertauthor=F.+Benoit-Vicalauthor=C.+Claparolsauthor=B.+Meunier&title=The+antimalarial+drug+artemisinin+alkylates+heme+in+infected+mice&doi=10.1073%2Fpnas.0500972102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The antimalarial drug artemisinin alkylates heme in infected mice</span></div><div class="casAuthors">Robert, Anne; Benoit-Vical, Francoise; Claparols, Catherine; Meunier, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13676-13680</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heme alkylation by the antimalarial drug artemisinin is reported in vivo, within infected mice that have been treated at pharmacol. relevant doses.  Adducts resulting from the alkylation of heme by the drug were characterized in the spleen of treated mice, and their glucuroconjugated derivs. were present in the urine.  Because these heme-artemisinin adducts were not obsd. in noninfected mice, this report confirms that the alkylating activity of this antimalarial drug is related to the presence of the parasite in infected animals.  The identification of heme-artemisinin adducts in mice should be considered as the signature of the alkylation capacity of artemisinin in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYd5mkEcJobVg90H21EOLACvtfcHk0ljND95TnVr76A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrzJ&md5=e86b8627e9bc341cddce3de8a64e8614</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0500972102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0500972102%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DClaparols%26aufirst%3DC.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DThe%2520antimalarial%2520drug%2520artemisinin%2520alkylates%2520heme%2520in%2520infected%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D13676%26epage%3D13680%26doi%3D10.1073%2Fpnas.0500972102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.-K.</span></span> <span> </span><span class="NLM_article-title">Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s13318-015-0252-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1007%2Fs13318-015-0252-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=25737032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=465-468&author=X.-J.+Liuauthor=H.+Luauthor=J.-X.+Sunauthor=S.-R.+Wangauthor=Y.-S.+Moauthor=X.-S.+Yangauthor=B.-K.+Shi&title=Metabolic+behavior+prediction+of+pazopanib+by+cytochrome+P450+%28CYP%29+3A4+by+molecular+docking&doi=10.1007%2Fs13318-015-0252-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking</span></div><div class="casAuthors">Liu, Xing-Jie; Lu, Hua; Sun, Ju-Xiang; Wang, Su-Rong; Mo, Yan-Shuai; Yang, Xing-Sheng; Shi, Ben-Kang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Metab.-mediated drug adverse effects (e.g., drug-drug interaction, bioactivation, etc.) strongly limit the utilization of clin. drugs.  The present study aims to predict the metabolic capability of cytochrome P 450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers esp. for ovarian cancer.  Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was Me group located besides nitrogen in the five-membered ring.  The distance between the hydrogen atom in Me group and active center is 3.64 Å.  The interaction amino acid is Glu374.  Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential.  The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metab. of pazopanib.  All these data were helpful for the clin. application of pazopanib, and R&D of other tinib drug candidates as new anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yVM7aEyvKrVg90H21EOLACvtfcHk0lgWXYrVu90gBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCqtbo%253D&md5=b77a2066f132f458faf21b65aa8b2bf9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs13318-015-0252-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-015-0252-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.-J.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.-X.%26aulast%3DWang%26aufirst%3DS.-R.%26aulast%3DMo%26aufirst%3DY.-S.%26aulast%3DYang%26aufirst%3DX.-S.%26aulast%3DShi%26aufirst%3DB.-K.%26atitle%3DMetabolic%2520behavior%2520prediction%2520of%2520pazopanib%2520by%2520cytochrome%2520P450%2520%2528CYP%2529%25203A4%2520by%2520molecular%2520docking%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2016%26volume%3D41%26spage%3D465%26epage%3D468%26doi%3D10.1007%2Fs13318-015-0252-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.bcp.2015.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=26212543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=111-121&author=X.+Liuauthor=Y.+Luauthor=X.+Guanauthor=D.+Dongauthor=H.+Chavanauthor=J.+Wangauthor=Y.+Zhangauthor=P.+Krishnamurthyauthor=F.+Li&title=Metabolomics+reveals+the+formation+of+aldehydes+and+iminium+in+gefitinib+metabolism&doi=10.1016%2Fj.bcp.2015.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism</span></div><div class="casAuthors">Liu, Xing; Lu, Yuanfu; Guan, Xinfu; Dong, Bingning; Chavan, Hemantkumar; Wang, Jin; Zhang, Yiqing; Krishnamurthy, Partha; Li, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gefitinib (GEF), an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, is widely used for the treatment of cancers, particularly non-small cell lung cancer.  However, its clin. use is limited by multiple adverse effects assocd. with GEF, such as liver and lung injuries, severe nausea, and diarrhea.  Although, the exact mechanism of GEF adverse effects are still unknown, xenobiotic-induced bioactivation is thought to play a significant role in GEF induced toxicity.  Using a metabolomic approach, we investigated the metabolic pathways of GEF in human and mouse liver microsomes.  Thirty four GEF metabolites and adducts were identified and half of them are novel.  The potential reactive metabolites, two aldehydes and one iminium, were identified for the first time.  The previously reported GSH adducts and primary amines were obsd. as well.  The aldehyde and iminium pathways were further confirmed by using methoxylamine and potassium cyanide as trapping reagents.  Using recombinant CYP450 isoforms, CYP3A4 inhibitor, and S9 from Cyp3a-null mice, we confirmed CYP3A is the major enzyme contributing to the formation of aldehydes, GSH adducts, and primary amines in liver.  Multiple enzymes contribute to the formation of iminium.  This study provided us more knowledge of GEF bioactivation and enzymes involved in metabolic pathways, which can be utilized for understanding the mechanism of adverse effects assocd. with GEF and predicting possible drug-drug interactions.  Further studies are suggested to det. the roles of these bioactivation pathways in GEF toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrViZ82Ih6lArVg90H21EOLACvtfcHk0lgWXYrVu90gBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chsb7M&md5=f95cbe2470bb41319e9e0fd1b5c3e25c</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DD.%26aulast%3DChavan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DF.%26atitle%3DMetabolomics%2520reveals%2520the%2520formation%2520of%2520aldehydes%2520and%2520iminium%2520in%2520gefitinib%2520metabolism%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D97%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.bcp.2015.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Attwa, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrabiah, H.</span></span> <span> </span><span class="NLM_article-title">A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: application to metabolic stability investigation and excretion rate</span>. <i>Eur. J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">344</span>, <span class="refDoi"> DOI: 10.1177/1469066718768327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1177%2F1469066718768327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=29629565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A280%3ADC%252BC1MjgtFCisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=344&author=M.+W.+Attwaauthor=A.+A.+Kadiauthor=H.+W.+Darwishauthor=S.+M.+Amerauthor=H.+Alrabiah&title=A+reliable+and+stable+method+for+the+determination+of+foretinib+in+human+plasma+by+LC-MS%2FMS%3A+application+to+metabolic+stability+investigation+and+excretion+rate&doi=10.1177%2F1469066718768327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate</span></div><div class="casAuthors">Attwa Mohamed W; Kadi Adnan A; Darwish Hany W; Alrabiah Haitham; Darwish Hany W; Amer Sawsan M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of mass spectrometry (Chichester, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">344-351</span>
        ISSN:<span class="NLM_cas:issn">1469-0667</span>.
    </div><div class="casAbstract">Foretinib (GSK1363089) is a multiple receptor tyrosine kinases inhibitor.  In this study, a reliable, fast liquid chromatography-tandem mass spectrometric method was described for assaying foretinib in plasma, urine, and rat liver microsome samples.  Simple extraction procedure by protein preciptation with acetonitrile was implemented for foretinib and brigatinib (internal standard) analysis.  Chromatographic resolution of analytes was achieved on C18 column with the help of isocratic mobile phase.  The binary mobile phase consisted of 60% ammonium formate (10 mM, pH 4.2) and 40% acetonitrile at a flow rate of 0.25 mL/min.  Run time was 3 min, and both foretinib and brigatinib were eluted within 0.74 and 1.95 min; they were detected in positive ion mode utilizing multiple reactions monitoring mode.  Linearity of the proposed method ranged from 5 to 500 ng/mL (r(2 )≥ 0.9993) in the human plasma.  Lower limit of quantification and detection were 6.0 and 1.8 ng/mL, respectively.  Intraday and interday precision and accuracy were 0.16 to 1.67 % and -2.39 to -0.52 %.  In vitro half-life and intrinsic clearance were 24.93 min and 6.56 mL/min/kg, respectively.  Literature review showed that no previous studies have been proposed for the analytical quantification of foretinib in human plasma or its metabolic stability.  The established method was also applied to estimate the rate of foretinib excretion in rat urine.  The developed method can be used for foretinib pharmacokinetic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR88i1cxfWsWIkFb3mqPUYDfW6udTcc2eZ8KVa-wQLav7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjgtFCisw%253D%253D&md5=7faf22bffbbcc3f53b09c41bc47092ec</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1177%2F1469066718768327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1469066718768327%26sid%3Dliteratum%253Aachs%26aulast%3DAttwa%26aufirst%3DM.%2BW.%26aulast%3DKadi%26aufirst%3DA.%2BA.%26aulast%3DDarwish%26aufirst%3DH.%2BW.%26aulast%3DAmer%26aufirst%3DS.%2BM.%26aulast%3DAlrabiah%26aufirst%3DH.%26atitle%3DA%2520reliable%2520and%2520stable%2520method%2520for%2520the%2520determination%2520of%2520foretinib%2520in%2520human%2520plasma%2520by%2520LC-MS%252FMS%253A%2520application%2520to%2520metabolic%2520stability%2520investigation%2520and%2520excretion%2520rate%26jtitle%3DEur.%2520J.%2520Mass%2520Spectrom.%26date%3D2018%26volume%3D24%26spage%3D344%26doi%3D10.1177%2F1469066718768327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Utermoehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollison, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span> <span> </span><span class="NLM_article-title">In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.110.033159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1688-1697&author=T.+Schulz-Utermoehlauthor=M.+Spearauthor=C.+R.+Pollardauthor=C.+Pattisonauthor=H.+Rollisonauthor=S.+Sardaauthor=M.+Wardauthor=N.+Bushbyauthor=A.+Jordanauthor=M.+Harrison&title=In+vitro+hepatic+metabolism+of+cediranib%2C+a+potent+vascular+endothelial+growth+factor+tyrosine+kinase+inhibitor%3A+interspecies+comparison+and+human+enzymology&doi=10.1124%2Fdmd.110.033159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033159%26sid%3Dliteratum%253Aachs%26aulast%3DSchulz-Utermoehl%26aufirst%3DT.%26aulast%3DSpear%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DC.%2BR.%26aulast%3DPattison%26aufirst%3DC.%26aulast%3DRollison%26aufirst%3DH.%26aulast%3DSarda%26aufirst%3DS.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DBushby%26aufirst%3DN.%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520hepatic%2520metabolism%2520of%2520cediranib%252C%2520a%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitor%253A%2520interspecies%2520comparison%2520and%2520human%2520enzymology%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1688%26epage%3D1697%26doi%3D10.1124%2Fdmd.110.033159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1′-hydroxylation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.110.037853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=757-762&author=M.+Sugiyamaauthor=K.-I.+Fujitaauthor=N.+Murayamaauthor=Y.+Akiyamaauthor=H.+Yamazakiauthor=Y.+Sasaki&title=Sorafenib+and+sunitinib%2C+two+anticancer+drugs%2C+inhibit+CYP3A4-mediated+and+activate+CY3A5-mediated+midazolam+1%E2%80%B2-hydroxylation&doi=10.1124%2Fdmd.110.037853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037853%26sid%3Dliteratum%253Aachs%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DK.-I.%26aulast%3DMurayama%26aufirst%3DN.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DY.%26atitle%3DSorafenib%2520and%2520sunitinib%252C%2520two%2520anticancer%2520drugs%252C%2520inhibit%2520CYP3A4-mediated%2520and%2520activate%2520CY3A5-mediated%2520midazolam%25201%25E2%2580%25B2-hydroxylation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D757%26epage%3D762%26doi%3D10.1124%2Fdmd.110.037853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keisner, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. R.</span></span> <span> </span><span class="NLM_article-title">Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.2165/11588960-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.2165%2F11588960-000000000-00000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=443-454&author=S.+V.+Keisnerauthor=S.+R.+Shah&title=Pazopanib%3A+the+newest+tyrosine+kinase+inhibitor+for+the+treatment+of+advanced+or+metastatic+renal+cell+carcinoma&doi=10.2165%2F11588960-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.2165%2F11588960-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11588960-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DKeisner%26aufirst%3DS.%2BV.%26aulast%3DShah%26aufirst%3DS.%2BR.%26atitle%3DPazopanib%253A%2520the%2520newest%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520advanced%2520or%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D443%26epage%3D454%26doi%3D10.2165%2F11588960-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Filppula, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backman, J. T.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.057695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1124%2Fdmd.114.057695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1202-1209&author=A.+M.+Filppulaauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=In+vitro+assessment+of+time-dependent+inhibitory+effects+on+CYP2C8+and+CYP3A+activity+by+fourteen+protein+kinase+inhibitors&doi=10.1124%2Fdmd.114.057695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.057695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.057695%26sid%3Dliteratum%253Aachs%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520time-dependent%2520inhibitory%2520effects%2520on%2520CYP2C8%2520and%2520CYP3A%2520activity%2520by%2520fourteen%2520protein%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D1202%26epage%3D1209%26doi%3D10.1124%2Fdmd.114.057695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperly, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudeman, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4632</span>– <span class="NLM_lpage">4640</span>, <span class="refDoi"> DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28Pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0lhkYGonvaQONw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">App, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2588</span>– <span class="NLM_lpage">2603</span>, <span class="refDoi"> DOI: 10.1021/jm980123i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases&doi=10.1021%2Fjm980123i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0lj2BLSeNPXIxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603%26doi%3D10.1021%2Fjm980123i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirazian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1021/jm0204183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-Fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase&doi=10.1021%2Fjm0204183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lj2BLSeNPXIxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-Fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119%26doi%3D10.1021%2Fjm0204183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated drug molecules: focus on FDA-approved deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+drug+molecules%3A+focus+on+FDA-approved+deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0lj2BLSeNPXIxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520drug%2520molecules%253A%2520focus%2520on%2520FDA-approved%2520deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kihn-Botulinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of tetramesitylporphyrin</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/ic00274a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00274a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=209-210&author=M.+Kihn-Botulinskiauthor=B.+Meunier&title=Synthesis+of+tetramesitylporphyrin&doi=10.1021%2Fic00274a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fic00274a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00274a046%26sid%3Dliteratum%253Aachs%26aulast%3DKihn-Botulinski%26aufirst%3DM.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520tetramesitylporphyrin%26jtitle%3DInorg.%2520Chem.%26date%3D1988%26volume%3D27%26spage%3D209%26epage%3D210%26doi%3D10.1021%2Fic00274a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, B.</span></span> <span> </span><span class="NLM_article-title">Preparation and catalytic activities of the manganese and iron derivatives of Br<sub>8</sub>TMP and Cl<sub>12</sub>TMP, two robust porphyrin ligands obtained by halogenation of tetramesitylporphyrin</span>. <i>Bull. Soc. Chim. Fr.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1992&pages=85-97&author=P.+Hoffmannauthor=A.+Robertauthor=B.+Meunier&title=Preparation+and+catalytic+activities+of+the+manganese+and+iron+derivatives+of+Br8TMP+and+Cl12TMP%2C+two+robust+porphyrin+ligands+obtained+by+halogenation+of+tetramesitylporphyrin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DA.%26aulast%3DMeunier%26aufirst%3DB.%26atitle%3DPreparation%2520and%2520catalytic%2520activities%2520of%2520the%2520manganese%2520and%2520iron%2520derivatives%2520of%2520Br8TMP%2520and%2520Cl12TMP%252C%2520two%2520robust%2520porphyrin%2520ligands%2520obtained%2520by%2520halogenation%2520of%2520tetramesitylporphyrin%26jtitle%3DBull.%2520Soc.%2520Chim.%2520Fr.%26date%3D1992%26volume%3D129%26spage%3D85%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paludetto, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisset, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Louedec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, C.</span></span> <span> </span><span class="NLM_article-title">Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2018.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=10.1016%2Fj.jpba.2018.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=29571135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFGnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=373-383&author=M.-N.+Paludettoauthor=F.+Puissetauthor=F.+Le+Louedecauthor=B.+Allalauthor=T.+Lafontauthor=E.+Chatelutauthor=C.+Arellano&title=Simultaneous+monitoring+of+pazopanib+and+its+metabolites+by+UPLC%E2%80%93MS%2FMS&doi=10.1016%2Fj.jpba.2018.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS</span></div><div class="casAuthors">Paludetto, Marie-Noelle; Puisset, Florent; Le Louedec, Felicien; Allal, Ben; Lafont, Thierry; Chatelut, Etienne; Arellano, Cecile</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) approved as first-line treatment for patients with advanced renal cell carcinoma (RCC) and as second-line treatment for patients with advanced soft tissue sarcoma (STS) previously treated with chemotherapy.  The most common adverse events, obsd. during the RCC and STS trials, were gastrointestinal disorders, hypertension, fatigue, elevated ALAT and ASAT, but the mol. mechanisms explaining pazopanib toxicity remain unclear.  Therapeutic activity is considered to be mainly dependent on pazopanib exposure as the primary metabolites are inactive or display low plasma concns., but metabolites may be involved in toxicity as relationships between metabolite profiles and toxicity have not been evaluated.  The authors report, for the first time, the validation of a method for the simultaneous quantification of pazopanib and semi-quantification of its metabolites (relative detn.).  As there are no stds. available, pazopanib metabolites were generated with human liver microsomes (HLM) to provide controls in the development of an UPLC-MS/MS method for monitoring both pazopanib and metabolites.  The optimized method was validated for specificity, linearity, sensitivity, precision, accuracy, matrix effect and stability.  The coeff. of variation (CV%) for intra-day and inter-day precision varied from 2.1% to 7.9% and 5.6% to 13.1% resp.  The biases varied from -12% to 2.3% (intra-day) and 3.8% to 13.1% (inter-day) for accuracy evaluation.  Intra-day and inter-day precision CV were resp. 20.1% and 19.6% and accuracy biases were between 20.7% (intra-day) and 3.8% (inter-day) at the limit of quantification.  The recoveries from matrix samples spiked with pazopanib were resp. 102.6 ± 12.9% and 102.5 ± 1.2% at low and high levels of calibration range.  No matrix effect was evidenced as demonstrated by the normalized matrix factor values: 1.3 ± 0.1 and 1.2 ± 0.2 resp. measured at low and high part of calibration range.  A good stability of pazopanib was obsd. during short term, long term and in process storage conditions and after three freeze/thaw cycles.  The method was applied to clin. samples from three patients treated with pazopanib to establish the metabolite profiles (semi-quant. data) during treatment.  The assessment of metabolite profiles could be useful to improve the authors' understanding of the occurrence of adverse events and to improve pazopanib pharmacokinetic-pharmacodynamic relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdIuYV01fYArVg90H21EOLACvtfcHk0ligCYnqEa2_aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFGnsLw%253D&md5=754a0e2572ea00b8ff414f853c3414f9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2018.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2018.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DPaludetto%26aufirst%3DM.-N.%26aulast%3DPuisset%26aufirst%3DF.%26aulast%3DLe%2BLouedec%26aufirst%3DF.%26aulast%3DAllal%26aufirst%3DB.%26aulast%3DLafont%26aufirst%3DT.%26aulast%3DChatelut%26aufirst%3DE.%26aulast%3DArellano%26aufirst%3DC.%26atitle%3DSimultaneous%2520monitoring%2520of%2520pazopanib%2520and%2520its%2520metabolites%2520by%2520UPLC%25E2%2580%2593MS%252FMS%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2018%26volume%3D154%26spage%3D373%26epage%3D383%26doi%3D10.1016%2Fj.jpba.2018.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i22"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00812">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35283"></div></div></div></div></div><hr /></hr><p class="last">The proposed structures of the products are depicted. The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00812">10.1021/acs.jmedchem.8b00812</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figure S1. Mass spectrometry of sunitinib oxidation products. Assignment of <i>m</i>/<i>z</i> values detected in MRM MS/MS mode. Figure S2. UHPLC-MS of <b>1</b>-CH═N-OCH<sub>3</sub>, the oxime derivatives of <b>1</b>-CHO detected after oxidation of <b>1</b> by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub> or by human liver microsomes and derivatization of the aldehyde function by CH<sub>3</sub>ONH<sub>2</sub>. Oxidation by Mn<sup>III</sup>(TDCPP)Cl/KHSO<sub>5</sub>: (a) XIC for <i>m</i>/<i>z</i> = 442, Inserts: mass spectra of the products eluted at 4.77 and 5.09 min; (b) MRM MS/MS 442 → 369 transition; (c) MRM MS/MS 442 → 326 transition. Oxidation by human liver microsomes: (d) XIC for <i>m</i>/<i>z</i> = 442; (e) MRM MS/MS 442 → 326 transition. The structures of the products are depicted. Figure S3. UHPLC-MS of <b>2</b>-CH═N-OCH<sub>3</sub>, the oxime derivatives of <b>2</b>-CHO (R14 = H) detected after oxidation of <b>2</b> by Mn<sup>III</sup>(TDCPP)Cl/MMPP or by human liver microsomes and derivatization of the aldehyde function by CH<sub>3</sub>ONH<sub>2</sub>. Oxidation by Mn<sup>III</sup>(TDCPP)Cl/MMPP: (a) XIC for <i>m</i>/<i>z</i> = 481, inserts: mass spectra of the products eluted at 2.96 and 3.11 min; (b) MRM MS/MS 481 → 449 transition; (c) MRM MS/MS 481 → 368 transition. Oxidation by human liver microsomes: (d) MRM MS/MS 481 → 368 transition (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_001.pdf">jm8b00812_si_001.pdf (345.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00812/suppl_file/jm8b00812_si_002.csv">jm8b00812_si_002.csv (0.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00812&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00812%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00812" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e5655fd03c76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
